[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the synonym for Acrokeratosis paraneoplastica is:\nBazex syndrome\nAcrokeratosis paraneoplastica and Bazex syndrome are used interchangeably to refer to the same condition, which is a rare acral psoriasiform dermatosis associated with internal malignancies, most frequently squamous cell carcinoma of the upper aerodigestive tract.",
    "llama-2-7b-chat-hf_fact_raw": "1. Acrokeratosis paraneoplastica is also known as Bazex syndrome.\n2. Acrokeratosis paraneoplastica is a rare acral psoriasiform dermatosis.\n3. Acrokeratosis paraneoplastica is associated with internal malignancies.\n4. The most frequent internal malignancy associated with Acrokeratosis paraneoplastica is squamous cell carcinoma of the upper aerodigestive tract.",
    "llama-2-7b-chat-hf_fact": [
      "Acrokeratosis paraneoplastica is also known as Bazex syndrome.",
      "Acrokeratosis paraneoplastica is a rare acral psoriasiform dermatosis.",
      "Acrokeratosis paraneoplastica is associated with internal malignancies.",
      "The most frequent internal malignancy associated with Acrokeratosis paraneoplastica is squamous cell carcinoma of the upper aerodigestive tract."
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Weaver syndrome and Sotos syndrome do share some similarities, but they are distinct conditions. Weaver syndrome is caused by pathogenic variants in the DNA methyltransferase 3A (DNMT3A) gene, while Sotos syndrome is caused by mutations in the USP90 gene.\nOne of the main differences between the two syndromes is the facial appearance. Weaver syndrome is characterized by a broad forehead, ocular hypertelorism, prominent wide philtrum, micrognathia, deep horizontal chin groove, and deep-set nails, while Sotos syndrome has a distinctive facial appearance with a flat nasal bridge, widely spaced eyes, and a small lower jaw.\nAnother difference is the degree of overgrowth. Weaver syndrome is characterized by prenatal-onset overgrowth with accelerated osseous maturation, widened distal long bones, and camptodactyly, while Sotos syndrome is characterized by tall stature and macrocephaly.\nIn terms of intellectual disability, both syndromes can have varying degrees of learning disability, but Sotos syndrome is generally more severe.\nIn summary, while Weaver syndrome and Sotos syndrome share some similarities, they are distinct conditions with different genetic causes and clinical features. It is important to consider the specific clinical features and genetic causes when differentiating between these two syndromes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Weaver syndrome is caused by pathogenic variants in the DNA methyltransferase 3A (DNMT3A) gene.\n2. Sotos syndrome is caused by mutations in the USP90 gene.\n3. Weaver syndrome is characterized by features such as a broad forehead, ocular hypertelorism, prominent wide philtrum, micrognathia, deep horizontal chin groove, and deep-set nails.\n4. Sotos syndrome is characterized by a distinctive facial appearance with a flat nasal bridge, widely spaced eyes, and a small lower jaw.\n5. Weaver syndrome is associated with prenatal-onset overgrowth with accelerated osseous maturation, while Sotos syndrome is characterized by tall stature and macrocephaly.",
    "llama-2-7b-chat-hf_fact": [
      "Weaver syndrome is caused by pathogenic variants in the DNA methyltransferase 3A (DNMT3A) gene.",
      "Sotos syndrome is caused by mutations in the USP90 gene.",
      "Weaver syndrome is characterized by features such as a broad forehead, ocular hypertelorism, prominent wide philtrum, micrognathia, deep horizontal chin groove, and deep-set nails.",
      "Sotos syndrome is characterized by a distinctive facial appearance with a flat nasal bridge, widely spaced eyes, and a small lower jaw.",
      "Weaver syndrome is associated with prenatal-onset overgrowth with accelerated osseous maturation, while Sotos syndrome is characterized by tall stature and macrocephaly."
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the following are the releases of the JASPAR database:\n1. JASPAR 2014\n2. JASPAR 2016\n3. JASPAR 2018\n4. JASPAR 2020\n5. JASPAR 2022 (9th release)\nEach release contains updated and expanded data on transcription factor binding profiles, including new taxonomic groups and improved quality control. The most recent release, JASPAR 2022, includes data from over 18,000 ChIP-seq datasets and provides a new tool for performing JASPAR TFBS enrichment analysis in user-provided genomic regions.",
    "llama-2-7b-chat-hf_fact_raw": "1. JASPAR 2014 is a release of the JASPAR database.\n2. JASPAR 2016 is a release of the JASPAR database.\n3. JASPAR 2018 is a release of the JASPAR database.\n4. JASPAR 2020 is a release of the JASPAR database.\n5. JASPAR 2022 is the 9th release of the JASPAR database.",
    "llama-2-7b-chat-hf_fact": [
      "JASPAR 2014 is a release of the JASPAR database.",
      "JASPAR 2016 is a release of the JASPAR database.",
      "JASPAR 2018 is a release of the JASPAR database.",
      "JASPAR 2020 is a release of the JASPAR database.",
      "JASPAR 2022 is the 9th release of the JASPAR database."
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the function of the viral KP4 protein is to kill sensitive Ustilago strains and inhibit Fusarium and plant root growth by inhibiting calcium uptake. The protein is secreted by the maize smut fungus Ustilago maydis and has been shown to play a critical role in fungal-plant-bacterial associations. The toxicity of the KP4 protein has been associated with the inhibition of cell growth and division by blocking voltage-gated calcium channels and other components in calcium-regulated signal transduction pathways. Additionally, KP4-like proteins (KP4L) in the genus Fusarium may contribute to fungal virulence in wheat seedling rot and are expressed during Fusarium head blight development.",
    "llama-2-7b-chat-hf_fact_raw": "1. The viral KP4 protein functions to kill sensitive Ustilago strains.\n2. KP4 protein inhibits Fusarium and plant root growth by inhibiting calcium uptake.\n3. The KP4 protein is secreted by the maize smut fungus Ustilago maydis.\n4. The toxicity of the KP4 protein is associated with the inhibition of cell growth and division by blocking voltage-gated calcium channels.\n5. KP4-like proteins in the genus Fusarium may contribute to fungal virulence in wheat seedling rot and are expressed during Fusarium head blight development.",
    "llama-2-7b-chat-hf_fact": [
      "The viral KP4 protein functions to kill sensitive Ustilago strains.",
      "KP4 protein inhibits Fusarium and plant root growth by inhibiting calcium uptake.",
      "The KP4 protein is secreted by the maize smut fungus Ustilago maydis.",
      "The toxicity of the KP4 protein is associated with the inhibition of cell growth and division by blocking voltage-gated calcium channels.",
      "KP4-like proteins in the genus Fusarium may contribute to fungal virulence in wheat seedling rot and are expressed during Fusarium head blight development."
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it appears that DITPA (3,5-diiodothyroproprionic acid) is a thyroid hormone analog that has been studied in experimental and clinical settings for its potential benefits in treating various conditions, including congestive heart failure.\nDocument 0 suggests that DITPA has beneficial hemodynamic effects in animal studies and a pilot trial in patients with congestive heart failure. Document 1 provides additional information on the positive inotropic effects of DITPA, which means it can increase the force of contraction of the heart muscle, without affecting the heart rate.\nDocument 2 also confirms the positive hemodynamic effects of DITPA in animal studies and a pilot trial in patients with congestive heart failure. Document 3 mentions that DITPA improved some hemodynamic and metabolic parameters in these patients, but there was no evidence for symptomatic benefit.\nDocument 4 highlights the potential of DITPA as a treatment for metabolic disorders, as it ameliorates metabolic parameters in male mice with MCT8 deficiency. Document 5 mentions that DITPA is an analogue with inotropic selectivity and low metabolic activity, which suggests that it may have a more targeted effect on the heart muscle compared to other thyroid hormone analogs.\nDocument 6 provides an overview of the potential benefits and limitations of thyroid hormone analogs, including DITPA, in the treatment of various conditions. Document 7 notes that thyroid-stimulating hormone was suppressed in patients given DITPA, which suggests that it has a thyromimetic effect.\nDocument 8 provides a summary of the results of a study on the use of DITPA in patients with congestive heart failure, including the finding that it improved some hemodynamic and metabolic parameters, but there was no evidence for symptomatic benefit.\nOverall, the information provided in the documents suggests that DITPA is a thyroid hormone analog with potential benefits in treating congestive heart failure and other conditions, but more research is needed to fully understand its effects and potential side effects.",
    "llama-2-7b-chat-hf_fact_raw": "1. DITPA (3,5-diiodothyroproprionic acid) is a thyroid hormone analog that has been studied in experimental and clinical settings.\n2. DITPA has shown beneficial hemodynamic effects in animal studies and a pilot trial in patients with congestive heart failure.\n3. DITPA can increase the force of contraction of the heart muscle without affecting the heart rate, known as positive inotropic effects.\n4. DITPA improved some hemodynamic and metabolic parameters in patients with congestive heart failure, but there was no evidence for symptomatic benefit.\n5. DITPA has the potential as a treatment for metabolic disorders and has been shown to ameliorate metabolic parameters in male mice with MCT8 deficiency.",
    "llama-2-7b-chat-hf_fact": [
      "DITPA (3,5-diiodothyroproprionic acid) is a thyroid hormone analog that has been studied in experimental and clinical settings.",
      "DITPA has shown beneficial hemodynamic effects in animal studies and a pilot trial in patients with congestive heart failure.",
      "DITPA can increase the force of contraction of the heart muscle without affecting the heart rate, known as positive inotropic effects.",
      "DITPA improved some hemodynamic and metabolic parameters in patients with congestive heart failure, but there was no evidence for symptomatic benefit.",
      "DITPA has the potential as a treatment for metabolic disorders and has been shown to ameliorate metabolic parameters in male mice with MCT8 deficiency."
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that \"COUGER\" is a term used in various contexts:\n1. In document 0, \"COUGER\" is mentioned as an acronym for \"Cougar Cutting Tools Inc,\" a manufacturer of custom solid carbide cutting tools.\n2. In document 8, \"COUGER\" is used as a common name for the cougar, a large cat species also known as the mountain lion or panther.\n3. In document 9, \"COUGER\" is used as the scientific name for the cougar, with the scientific name being \"Puma concolor.\"\nTherefore, the answer to the user's question \"What is the COUGER tool?\" depends on the context in which the term is used. If the user is referring to the manufacturer of cutting tools, then the answer is \"Cougar Cutting Tools Inc.\" If the user is referring to the cougar cat species, then the answer is \"Puma concolor.\"",
    "llama-2-7b-chat-hf_fact_raw": "1. \"COUGER\" is an acronym for \"Cougar Cutting Tools Inc,\" a manufacturer of custom solid carbide cutting tools.\n2. \"COUGER\" is used as a common name for the cougar, a large cat species.\n3. The cougar is also known as the mountain lion or panther.\n4. The scientific name for the cougar is \"Puma concolor.\"",
    "llama-2-7b-chat-hf_fact": [
      "\"COUGER\" is an acronym for \"Cougar Cutting Tools Inc,\" a manufacturer of custom solid carbide cutting tools.",
      "\"COUGER\" is used as a common name for the cougar, a large cat species.",
      "The cougar is also known as the mountain lion or panther.",
      "The scientific name for the cougar is \"Puma concolor.\""
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there is no specific medication or antiviral drug available to treat tick-borne encephalitis (TBE). The treatment for TBE is primarily focused on relieving symptoms and supporting the body's immune system.\nRest, fluids, and over-the-counter pain medications may help to alleviate headaches and other symptoms associated with TBE. In severe cases, patients may require hospitalization for intravenous fluids, oxygen therapy, and other supportive care.\nIt is important to note that TBE is a severe viral infection that can have a long-term impact on a person's health. In some cases, TBE can lead to long-term neurological problems, such as memory loss, difficulty with concentration, and mood changes.\nThe TBE vaccine is available for prevention, and it is recommended for people who live in or visit areas where TBE is common, such as parts of Europe and Asia. The vaccine is not 100% effective, but it can reduce the risk of infection and the severity of symptoms.\nIn summary, there is no specific medication or antiviral drug available to treat TBE, and treatment is primarily focused on relieving symptoms and supporting the body's immune system. The TBE vaccine is available for prevention, and it is recommended for people who are at risk of infection.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no specific medication or antiviral drug available to treat tick-borne encephalitis (TBE).\n2. Treatment for TBE is primarily focused on relieving symptoms and supporting the body's immune system.\n3. In severe cases of TBE, patients may require hospitalization for supportive care such as intravenous fluids and oxygen therapy.\n4. Tick-borne encephalitis can lead to long-term neurological problems in some cases.\n5. A vaccine for TBE is available and recommended for people who live in or visit areas where TBE is common.",
    "llama-2-7b-chat-hf_fact": [
      "There is no specific medication or antiviral drug available to treat tick-borne encephalitis (TBE).",
      "Treatment for TBE is primarily focused on relieving symptoms and supporting the body's immune system.",
      "In severe cases of TBE, patients may require hospitalization for supportive care such as intravenous fluids and oxygen therapy.",
      "Tick-borne encephalitis can lead to long-term neurological problems in some cases.",
      "A vaccine for TBE is available and recommended for people who live in or visit areas where TBE is common."
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the genome browser database for DNA shape annotations that is available is GBshape. According to Document 1, GBshape provides DNA shape annotations of entire genomes, and Document 2 states that the database currently contains annotations for minor groove width, propeller twist, roll, helix twist, and hydroxyl radical cleavage for 94 organisms. Additionally, Document 3 mentions that GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution.\nTherefore, based on the information provided, the answer to the user's question is that GBshape is the genome browser database for DNA shape annotations that is available.",
    "llama-2-7b-chat-hf_fact_raw": "1. GBshape is a genome browser database for DNA shape annotations.\n2. GBshape provides DNA shape annotations of entire genomes.\n3. The database contains annotations for minor groove width, propeller twist, roll, helix twist, and hydroxyl radical cleavage.\n4. GBshape includes DNA shape annotations for 94 organisms.\n5. GBshape allows users to visualize DNA shape annotations in a genome browser track format and to download quantitative values of DNA shape features.",
    "llama-2-7b-chat-hf_fact": [
      "GBshape is a genome browser database for DNA shape annotations.",
      "GBshape provides DNA shape annotations of entire genomes.",
      "The database contains annotations for minor groove width, propeller twist, roll, helix twist, and hydroxyl radical cleavage.",
      "GBshape includes DNA shape annotations for 94 organisms.",
      "GBshape allows users to visualize DNA shape annotations in a genome browser track format and to download quantitative values of DNA shape features."
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the syndromes associated with mutations in the EZH2 gene are:\n1. Weaver Syndrome: The p.Glu745Lys mutation in the EZH2 gene has been associated with acute lymphoblastic leukemia and lymphoma in Weaver Syndrome patients.\n2. Myelodysplastic syndromes (MDS): EZH2 mutations are frequently detected in MDS, a heterogeneous pre-malignant disorder of hematopoietic stem cells.\n3. Myeloproliferative neoplasms (MPN): The EZH2 gene is located on chromosome 7q36.1, a region frequently deleted in acute myeloid leukemia (AML), MDS, and MPN.\n4. Chronic myeloid leukemia (CML): While loss-of-function mutations of EZH2 frequently affect patients with MDS and myelofibrosis, cases of CML seem to be largely characterized by EZH2 overexpression.\n5. Acute myeloid leukemia (AML): EZH2 mutations are associated with a poorer prognosis in AML, and tumors harboring mutations in other epigenetic genes such as ARID1A, KDM6, and BAP1 are highly sensitive to EZH2 inhibition.\nIt is important to note that these associations are based on the information provided in the documents and may not be comprehensive or up-to-date. Further research and clinical studies may provide additional insights into the relationship between EZH2 mutations and various syndromes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The p.Glu745Lys mutation in the EZH2 gene has been associated with acute lymphoblastic leukemia and lymphoma in Weaver Syndrome patients.\n2. EZH2 mutations are frequently detected in Myelodysplastic syndromes (MDS).\n3. The EZH2 gene is located on chromosome 7q36.1, which is a region frequently deleted in acute myeloid leukemia (AML), MDS, and Myeloproliferative neoplasms (MPN).\n4. Loss-of-function mutations of EZH2 frequently affect patients with MDS and myelofibrosis, and cases of Chronic myeloid leukemia (CML) are characterized by EZH2 overexpression.\n5. EZH2 mutations are associated with a poorer prognosis in Acute myeloid leukemia (AML).",
    "llama-2-7b-chat-hf_fact": [
      "The p.Glu745Lys mutation in the EZH2 gene has been associated with acute lymphoblastic leukemia and lymphoma in Weaver Syndrome patients.",
      "EZH2 mutations are frequently detected in Myelodysplastic syndromes (MDS).",
      "The EZH2 gene is located on chromosome 7q36.1, which is a region frequently deleted in acute myeloid leukemia (AML), MDS, and Myeloproliferative neoplasms (MPN).",
      "Loss-of-function mutations of EZH2 frequently affect patients with MDS and myelofibrosis, and cases of Chronic myeloid leukemia (CML) are characterized by EZH2 overexpression.",
      "EZH2 mutations are associated with a poorer prognosis in Acute myeloid leukemia (AML)."
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0-9, the following human proteins are known to undergo a dimer-to-tetramer transition:\n1. Inositol-Requiring enzyme 1α (IRE1): Document 0 mentions that the accumulation of misfolded proteins drives the activation of IRE1, which undergoes a dimer-to-tetramer transition.\n2. Protein kinase R (PKR)-like ER kinase (PERK): Document 0 also mentions that PERK undergoes a dimer-to-tetramer transition in response to misfolded proteins.\n3. Pyruvate kinase M2 (PKM2): Document 1 and 2 mention that PKM2 can exist as a dimer or a tetramer, and that the tetrameric form has higher kinase activity. The transition from a dimer to a tetramer is thought to be regulated by posttranslational modifications.\n4. Streptavidin: Document 6 mentions that streptavidin, a tetrameric protein, is an excellent model for studying subunit-subunit interactions in multimeric proteins.\n5. Mammalian Prdx6: Document 7 mentions that Prdx6, a cytosolic protein, can translocate to acidic organelles and undergo a dimer-to-tetramer transition.\nIt is worth noting that the information provided in the documents is focused on the structural and functional aspects of these proteins, and not all of them provide direct evidence for a dimer-to-tetramer transition. However, based on the available data, it is clear that these proteins can exist in both dimer and tetramer forms, and that the transition between these forms may play a role in their function and regulation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Inositol-Requiring enzyme 1α (IRE1) is known to undergo a dimer-to-tetramer transition.\n2. Protein kinase R (PKR)-like ER kinase (PERK) undergoes a dimer-to-tetramer transition in response to misfolded proteins.\n3. Pyruvate kinase M2 (PKM2) can exist as a dimer or a tetramer, with the tetrameric form having higher kinase activity.\n4. Streptavidin is a tetrameric protein that can be used as a model for studying subunit-subunit interactions in multimeric proteins.\n5. Mammalian Prdx6 is a cytosolic protein that can undergo a dimer-to-tetramer transition when it translocates to acidic organelles.",
    "llama-2-7b-chat-hf_fact": [
      "Inositol-Requiring enzyme 1α (IRE1) is known to undergo a dimer-to-tetramer transition.",
      "Protein kinase R (PKR)-like ER kinase (PERK) undergoes a dimer-to-tetramer transition in response to misfolded proteins.",
      "Pyruvate kinase M2 (PKM2) can exist as a dimer or a tetramer, with the tetrameric form having higher kinase activity.",
      "Streptavidin is a tetrameric protein that can be used as a model for studying subunit-subunit interactions in multimeric proteins.",
      "Mammalian Prdx6 is a cytosolic protein that can undergo a dimer-to-tetramer transition when it translocates to acidic organelles."
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the protein that has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein is HAX-1.\nDocument 1 mentions that HAX-1 is a mitochondrial protein that has been shown to interact with PLN and modulate its inhibitory function on the sarcoendoplasmic reticulum calcium ATPase (SERCA). This interaction is thought to play a role in regulating cardiac contractility and survival.\nDocument 2 also highlights the anti-apoptotic function of HAX-1, suggesting that it may play a role in protecting cardiac cells from apoptosis under conditions of impaired Ca2+ cycling.\nDocument 5 provides further evidence of the interaction between PLN and HAX-1, showing that dephosphorylated PLN inhibits SERCA2a and that PLN phosphorylation, at either Ser16 by PKA or Thr17 by Ca2+-calmodulin-dependent protein kinase, enhances its inhibitory function on SERCA2a.\nOverall, the information provided in the documents suggests that HAX-1 is a key player in the regulation of Ca2+ handling in cardiac muscle and that its interaction with PLN is an important aspect of this regulation.",
    "llama-2-7b-chat-hf_fact_raw": "1. HAX-1 has been found to interact with phospholamban (PLN).\n2. HAX-1 modulates the inhibitory function of PLN on the sarcoendoplasmic reticulum calcium ATPase (SERCA).\n3. The interaction between HAX-1 and PLN is thought to play a role in regulating cardiac contractility and survival.\n4. HAX-1 has an anti-apoptotic function that may protect cardiac cells from apoptosis under conditions of impaired Ca2+ cycling.\n5. Dephosphorylated PLN inhibits SERCA2a, and PLN phosphorylation enhances its inhibitory function on SERCA2a.",
    "llama-2-7b-chat-hf_fact": [
      "HAX-1 has been found to interact with phospholamban (PLN).",
      "HAX-1 modulates the inhibitory function of PLN on the sarcoendoplasmic reticulum calcium ATPase (SERCA).",
      "The interaction between HAX-1 and PLN is thought to play a role in regulating cardiac contractility and survival.",
      "HAX-1 has an anti-apoptotic function that may protect cardiac cells from apoptosis under conditions of impaired Ca2+ cycling.",
      "Dephosphorylated PLN inhibits SERCA2a, and PLN phosphorylation enhances its inhibitory function on SERCA2a."
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, there is some evidence to suggest that vitamin D supplementation may reduce the incidence of falls in older people.\nDocument 0 mentions that vitamin D has been shown to have a positive effect on postural adaptations, which may explain the decreased fall and bone fracture rates in older adults. Additionally, Document 1 highlights the importance of addressing risk factors for falls, such as vitamin D deficiency, in older adults.\nDocument 4, an update of a Cochrane review first published in 2009, found that interventions designed to reduce the incidence of falls in older people living in the community were effective. The review included 17 randomized controlled trials (RCTs) and found a 21% reduction in falls with substantial heterogeneity. However, the review did not find a statistically significant effect on people experiencing a fall.\nDocument 7 mentions that after falling, a quarter of older adults restrict their activity for at least a day or seek medical attention, and that more serious injuries, such as fractures, joint dislocations, sprains or strains, can occur.\nDocument 8, a meta-analysis of multifactorial intervention trials, found a 21% reduction in falls with substantial heterogeneity, but no statistically significant effect on people experiencing a fall.\nDocument 9, a systematic review of the literature on the effectiveness and harms of fall prevention interventions in community-dwelling older adults, found that falls are the most common cause of injury-related morbidity and mortality among older adults, and that fall prevention interventions can be effective in reducing falls.\nBased on the evidence provided in these documents, it appears that vitamin D supplementation may have a positive effect on reducing the incidence of falls in older people, although the evidence is not conclusive and more research is needed to confirm these findings.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vitamin D supplementation may reduce the incidence of falls in older people according to some evidence.\n2. Document 0 suggests that vitamin D has a positive effect on postural adaptations, which may lead to decreased fall and bone fracture rates in older adults.\n3. A Cochrane review update, which included 17 randomized controlled trials, found a 21% reduction in falls among older people living in the community.\n4. Document 7 states that a quarter of older adults restrict their activity for at least a day or seek medical attention after falling.\n5. Document 9 indicates that fall prevention interventions can be effective in reducing falls among community-dwelling older adults.",
    "llama-2-7b-chat-hf_fact": [
      "Vitamin D supplementation may reduce the incidence of falls in older people according to some evidence.",
      "Document 0 suggests that vitamin D has a positive effect on postural adaptations, which may lead to decreased fall and bone fracture rates in older adults.",
      "A Cochrane review update, which included 17 randomized controlled trials, found a 21% reduction in falls among older people living in the community.",
      "Document 7 states that a quarter of older adults restrict their activity for at least a day or seek medical attention after falling.",
      "Document 9 indicates that fall prevention interventions can be effective in reducing falls among community-dwelling older adults."
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, there is a clear association between Jarid2 and miR-155 in Th17 cells.\nDocument 1 states that Jarid2 associates with the polycomb repressive complex 2 (PRC2) in a range of different cell types, including ESCs and thymocytes. Document 2 shows that PRC2 binding to chromatin and H3K27 histone methylation is increased in miR-155-deficient cells, coinciding with failure to express Il22, Il10, Il9, and Atf3. These findings suggest that Jarid2 may play a role in regulating the expression of these genes in Th17 cells.\nDocument 3 provides evidence that Jarid2 is required for the expression of Il22 in Th17 cells. The study found that deletion of Jarid2 in the miR-155-deficient CD4+ T cells results in partial rescue of Th17 cell-associated cytokine expression, including Il22. This suggests that Jarid2 is necessary for the proper differentiation of Th17 cells and the expression of their cytokines.\nDocument 4 shows that the function of Jarid2 in adult somatic cells such as lymphocytes is not known, but the study was able to identify direct targets of PRC2 in Th17 cells using ChIP analyses. This suggests that Jarid2 may play a role in regulating the expression of genes involved in Th17 cell differentiation and function.\nDocument 5 provides further evidence that Jarid2 is involved in the regulation of Th17 cell function. The study found that miR-155 activates cytokine gene expression in Th17 cells by regulating the DNA-binding protein Jarid2 to relieve polycomb-mediated repression. This suggests that Jarid2 is a key regulator of Th17 cell function and that miR-155 plays a role in modulating this function.\nFinally, Document 7 shows that miR-155-deficient cells, coinciding with failure to express Il22, Il10, Il9, and Atf3, could be partially suppressed by Jarid2 deletion. This suggests that",
    "llama-2-7b-chat-hf_fact_raw": "1. Jarid2 associates with the polycomb repressive complex 2 (PRC2) in various cell types, including ESCs and thymocytes.\n2. PRC2 binding to chromatin and H3K27 histone methylation is increased in miR-155-deficient cells.\n3. Deletion of Jarid2 in miR-155-deficient CD4+ T cells results in partial rescue of Th17 cell-associated cytokine expression, including Il22.\n4. Jarid2 is necessary for the proper differentiation of Th17 cells and the expression of their cytokines.\n5. miR-155 activates cytokine gene expression in Th17 cells by regulating the DNA-binding protein Jarid2.",
    "llama-2-7b-chat-hf_fact": [
      "Jarid2 associates with the polycomb repressive complex 2 (PRC2) in various cell types, including ESCs and thymocytes.",
      "PRC2 binding to chromatin and H3K27 histone methylation is increased in miR-155-deficient cells.",
      "Deletion of Jarid2 in miR-155-deficient CD4+ T cells results in partial rescue of Th17 cell-associated cytokine expression, including Il22.",
      "Jarid2 is necessary for the proper differentiation of Th17 cells and the expression of their cytokines.",
      "miR-155 activates cytokine gene expression in Th17 cells by regulating the DNA-binding protein Jarid2."
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the human HoxD cluster contains 9 genes: HOXD1, HOXD2, HOXD3, HOXD4, HOXD5, HOXD6, HOXD7, HOXD8, and HOXD9.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human HoxD cluster contains 9 genes.",
    "llama-2-7b-chat-hf_fact": [
      "The human HoxD cluster contains 9 genes."
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-2-7b-chat-hf_response": "Based on the provided documents, the consensus phosphorylation motifs for Casein Kinase 1 (CK1) are:\n1. D/E-X-X-S/T (where X is any amino acid)\n2. S/T-X-X-S/T\n3. pS/T-X-X-S/T\nThese consensus motifs are found in various documents, including Documents 1, 3, 5, and 7. These motifs are recognized by CK1 and are phosphorylated by the kinase. The specific amino acid residues underlined in the motifs are the phosphorylation sites.\nIt is important to note that these consensus motifs are not exclusive to CK1 and may be recognized by other kinases as well. Additionally, the specific context and substrate of the phosphorylation reaction can influence the actual phosphorylation sites and motifs recognized by CK1.",
    "llama-2-7b-chat-hf_fact_raw": "1. The consensus phosphorylation motif for Casein Kinase 1 (CK1) includes D/E-X-X-S/T, where X can be any amino acid.\n2. Another consensus motif for CK1 is S/T-X-X-S/T.\n3. CK1 also recognizes the motif pS/T-X-X-S/T for phosphorylation.\n4. The specific amino acid residues underlined in the motifs are the sites of phosphorylation by CK1.\n5. These consensus motifs are not exclusive to CK1 and may be recognized by other kinases.",
    "llama-2-7b-chat-hf_fact": [
      "The consensus phosphorylation motif for Casein Kinase 1 (CK1) includes D/E-X-X-S/T, where X can be any amino acid.",
      "Another consensus motif for CK1 is S/T-X-X-S/T.",
      "CK1 also recognizes the motif pS/T-X-X-S/T for phosphorylation.",
      "The specific amino acid residues underlined in the motifs are the sites of phosphorylation by CK1.",
      "These consensus motifs are not exclusive to CK1 and may be recognized by other kinases."
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, there are several different proteins/isoforms encoded by the ASPH gene in humans:\n1. Aspartyl/asparaginyl beta-hydroxylase (AspH): This is the longest isoform, which includes a C-terminal Aspartyl/Asparaginyl beta-hydroxylase domain that hydroxylates aspartic acid or asparagine residues in the epidermal growth factor (EGF)-like domains of some proteins.\n2. Aspartate beta-hydroxylase (ASPH): This gene is thought to play an important role in calcium homeostasis, and the encoded set of proteins share varying amounts of overlap near their N-termini but have substantial variations in their C-terminal domains resulting in distinct functional properties.\n3. Lavaissiere et al. (1996) reported cDNA cloning of the human gene encoding this antigen, aspartyl (asparaginyl)-beta-hydroxylase (symbolized HAAH by them), and demonstrated that in these tumor lines it is expressed in an enzymatically active form.\n4. AβH-J-J isoforms: Aspartyl beta-hydroxylase (AβH), junctin and junctate are three functionally distinct isoforms encoded from a single genomic locus, AβH-J-J, by alternative splicing.\n5. Humbug: It also has been shown to contribute to Ca2+ homeostasis by forming a multi-molecular Ca2+ entry channel.\nTherefore, the different proteins/isoforms encoded by the ASPH gene in humans are:\n* Aspartyl/asparaginyl beta-hydroxylase (AspH)\n* Aspartate beta-hydroxylase (ASPH)\n* Lavaissiere et al. (1996) reported cDNA cloning of the human gene encoding this antigen, aspartyl (asparaginyl)-beta-hydroxylase (symbolized HAAH by them)\n* AβH-J-J isoforms\n* Humbug\nIt is important to note that these isoforms may have different functions and",
    "llama-2-7b-chat-hf_fact_raw": "1. The ASPH gene encodes the protein isoform aspartyl/asparaginyl beta-hydroxylase (AspH), which hydroxylates aspartic acid or asparagine residues in EGF-like domains of some proteins.\n2. The ASPH gene plays a role in calcium homeostasis.\n3. Lavaissiere et al. (1996) cloned the cDNA of the human gene encoding aspartyl (asparaginyl)-beta-hydroxylase, which is expressed in an enzymatically active form in some tumor lines.\n4. The AβH-J-J isoforms, including aspartyl beta-hydroxylase (AβH), junctin, and junctate, are encoded from a single genomic locus by alternative splicing.\n5. The protein isoform Humbug contributes to calcium homeostasis by forming a multi-molecular calcium entry channel.",
    "llama-2-7b-chat-hf_fact": [
      "The ASPH gene encodes the protein isoform aspartyl/asparaginyl beta-hydroxylase (AspH), which hydroxylates aspartic acid or asparagine residues in EGF-like domains of some proteins.",
      "The ASPH gene plays a role in calcium homeostasis.",
      "Lavaissiere et al. (1996) cloned the cDNA of the human gene encoding aspartyl (asparaginyl)-beta-hydroxylase, which is expressed in an enzymatically active form in some tumor lines.",
      "The AβH-J-J isoforms, including aspartyl beta-hydroxylase (AβH), junctin, and junctate, are encoded from a single genomic locus by alternative splicing.",
      "The protein isoform Humbug contributes to calcium homeostasis by forming a multi-molecular calcium entry channel."
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, empagliflozin was FDA approved on August 1, 2014.",
    "llama-2-7b-chat-hf_fact_raw": "1. Empagliflozin was FDA approved on August 1, 2014.",
    "llama-2-7b-chat-hf_fact": [
      "Empagliflozin was FDA approved on August 1, 2014."
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-2-7b-chat-hf_response": "Based on the provided documents, the loss of the protein Lon1 in the plant Arabidopsis has several consequences. Here are some of the key findings:\n1. Changes in mitochondrial protein homeostasis: Loss of Lon1 leads to alterations in the mitochondrial proteome, including changes in the abundance of nuclear-encoded mitochondrial proteins and mitochondrial-encoded proteins.\n2. Growth retardation: Loss of Lon1 in Arabidopsis leads to stunted plant growth.\n3. Modified respiratory function: Lon1 is an ATP-dependent protease that plays a crucial role in mitochondrial protein homeostasis. The loss of Lon1 significantly modifies respiratory function and plant performance by subtly changing steady-state protein assembly, stability, and damage of a range of components that debilitate an anaplerotic role for mitochondria in cellular carbon metabolism.\n4. Increased accumulation of nuclear-encoded mitochondrial proteins: Loss of Lon1 leads to the accumulation of nuclear-encoded mitochondrial proteins, including Lon1 substrates.\n5. Developmental disorders and aging-related diseases: Loss of Lon1 has been linked to developmental disorders and aging-related diseases in humans.\n6. Impaired protein degradation: A recent study compared protein degradation rates in the wild type and mitochondrial LON1 loss-of-function mutants and found that 140 mitochondrial proteins exhibited higher degradation rates in the lon1-1 mutant, while another 65 proteins were less degraded in the lon1-1 mutant relative to the wild type.\n7. Novel protein interactions: A combination of BN-PAGE and size-exclusion chromatography has been used to capture both transient and stable protein interactions in the plant mitochondria. This study identified both known and novel interactions, including some that are conditional and can be analyzed further to understand their dynamics.\nIn summary, the loss of Lon1 in Arabidopsis has significant consequences for mitochondrial protein homeostasis, growth, and development, and may contribute to developmental disorders and aging-related",
    "llama-2-7b-chat-hf_fact_raw": "1. Loss of Lon1 in Arabidopsis leads to changes in mitochondrial protein homeostasis.\n2. Arabidopsis plants with loss of Lon1 exhibit stunted growth.\n3. The loss of Lon1 significantly modifies respiratory function in Arabidopsis.\n4. There is an increased accumulation of nuclear-encoded mitochondrial proteins due to the loss of Lon1 in Arabidopsis.\n5. Loss of Lon1 has been linked to developmental disorders and aging-related diseases in humans.",
    "llama-2-7b-chat-hf_fact": [
      "Loss of Lon1 in Arabidopsis leads to changes in mitochondrial protein homeostasis.",
      "Arabidopsis plants with loss of Lon1 exhibit stunted growth.",
      "The loss of Lon1 significantly modifies respiratory function in Arabidopsis.",
      "There is an increased accumulation of nuclear-encoded mitochondrial proteins due to the loss of Lon1 in Arabidopsis.",
      "Loss of Lon1 has been linked to developmental disorders and aging-related diseases in humans."
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it appears that there is no direct evidence or consensus on whether a linker histone exists in the yeast genome.\nDocument 0 suggests that Hmo1, but not Hho1, is involved in chromatin assembly in yeast nucleoplasmic extracts, but does not directly address the existence of a linker histone.\nDocument 1 mentions that Hho1p is a protein with sequence similarity to histone H1 in yeast, but does not provide any information on the existence of a linker histone.\nDocument 2 suggests that Hmo1 may function as a linker histone in yeast, but this is based on indirect observation and does not provide conclusive evidence.\nDocument 3 highlights the compact nature of chromatin in eukaryotic cells and mentions that histone transcription is tightly regulated during the S phase of the cell cycle, but does not specifically address the existence of a linker histone.\nDocument 4 provides evidence that the temporal transcription of histones, including linker histones, is cell-cycle-regulated in yeast.\nDocument 5 discusses the semi-interdependence of subnucleosomal histone marks/variants and the asymmetry of these marks in the direction of transcription, but does not directly address the existence of a linker histone.\nDocument 6 provides evidence that linker histone variant H1t is associated with repressed repeat-element chromatin domains in pachytene spermatocytes.\nDocument 7 highlights the importance of histone variants in eukaryotic chromatin biology and mentions that the incorporation of histone variants into nucleosomes has important functional consequences.\nDocument 8 discusses the mechanism of histone exchange in yeast, which involves the removal of parts of the nucleosome or the entire nucleosome, followed by replacement with either a new or existing nucleosome.\nDocument 9 provides a general overview of the role of histones in packaging DNA into chromatin.\nIn conclusion, while there is some evidence to suggest that a linker histone may exist in yeast, there is no direct consensus or conclusive evidence to support this idea. Further research is needed to fully understand the composition and structure of chromatin in yeast.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hmo1 is involved in chromatin assembly in yeast nucleoplasmic extracts.\n2. Hho1p is a protein with sequence similarity to histone H1 in yeast.\n3. Document 2 suggests that Hmo1 may function as a linker histone in yeast based on indirect observation.\n4. Document 4 indicates that the transcription of histones, including linker histones, is cell-cycle-regulated in yeast.\n5. Linker histone variant H1t is associated with repressed repeat-element chromatin domains in pachytene spermatocytes according to Document 6.",
    "llama-2-7b-chat-hf_fact": [
      "Hmo1 is involved in chromatin assembly in yeast nucleoplasmic extracts.",
      "Hho1p is a protein with sequence similarity to histone H1 in yeast.",
      "Document 2 suggests that Hmo1 may function as a linker histone in yeast based on indirect observation.",
      "Document 4 indicates that the transcription of histones, including linker histones, is cell-cycle-regulated in yeast.",
      "Linker histone variant H1t is associated with repressed repeat-element chromatin domains in pachytene spermatocytes according to Document 6."
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, there is evidence to suggest that tomato juice may lower cholesterol levels.\nDocument 0 suggests that a high dietary intake of tomato products, including tomato juice, can reduce LDL cholesterol levels and increase LDL resistance to oxidation in healthy individuals. The study found that serum lycopene, β-carotene, and γ-carotene levels were also significantly increased in the study participants.\nDocument 1 provides further evidence that tomato juice may have atheroprotective effects, including reducing inflammation and improving insulin resistance. The study found that tomato juice consumption was associated with a reduced risk of metabolic syndrome, a cluster of conditions that increase the risk of heart disease and diabetes.\nDocument 2 suggests that high dietary intakes of tomato products are often associated with a reduced risk of cardiovascular disease (CVD), but the atheroprotective mechanisms have not been established.\nDocument 3 provides additional evidence that tomato juice consumption may lower cholesterol levels. The study found that subjects who consumed 10 or more servings of tomato products per week had lower levels of LDL cholesterol compared to those who consumed less than 10 servings per week.\nDocument 4 suggests that there is no sufficient evidence to support the claim that vitamin C and vitamin E can help prevent cancer.\nDocument 5 provides evidence that cranberry juice cocktail may lower cholesterol levels, and that lycopene-rich tomato consumption can decrease cholesterol levels.\nDocument 6 provides evidence that tomato juice may improve the recovery of anaerobically trained athletes, as it led to a significant decrease in LDH and CPK levels compared to a carbohydrate supplementation beverage.\nDocument 7 suggests that using liquid vegetable oils such as canola, sunflower, safflower, and others in place of butter, lard, or shortening when cooking or at the table can lower LDL cholesterol levels.\nDocument 8 suggests that consuming tomato juice on an empty stomach may amplify its cholester",
    "llama-2-7b-chat-hf_fact_raw": "1. A study indicated that a high dietary intake of tomato products, including tomato juice, can reduce LDL cholesterol levels and increase LDL resistance to oxidation in healthy individuals.\n2. Tomato juice consumption was associated with a reduced risk of metabolic syndrome, according to a study.\n3. Subjects who consumed 10 or more servings of tomato products per week had lower levels of LDL cholesterol compared to those who consumed less than 10 servings per week, as found in a study.\n4. Cranberry juice cocktail may lower cholesterol levels, and lycopene-rich tomato consumption can decrease cholesterol levels, as evidenced by research.\n5. Tomato juice may improve the recovery of anaerobically trained athletes, leading to a significant decrease in LDH and CPK levels compared to a carbohydrate supplementation beverage.",
    "llama-2-7b-chat-hf_fact": [
      "A study indicated that a high dietary intake of tomato products, including tomato juice, can reduce LDL cholesterol levels and increase LDL resistance to oxidation in healthy individuals.",
      "Tomato juice consumption was associated with a reduced risk of metabolic syndrome, according to a study.",
      "Subjects who consumed 10 or more servings of tomato products per week had lower levels of LDL cholesterol compared to those who consumed less than 10 servings per week, as found in a study.",
      "Cranberry juice cocktail may lower cholesterol levels, and lycopene-rich tomato consumption can decrease cholesterol levels, as evidenced by research.",
      "Tomato juice may improve the recovery of anaerobically trained athletes, leading to a significant decrease in LDH and CPK levels compared to a carbohydrate supplementation beverage."
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it appears that Hsp70 and Hsp110 proteins play a role in regulating mRNA stability by binding to specific RNA motifs.\nDocument 0 shows that Hsp70 and Hsp110 proteins preferentially bind to AU-rich RNA in vitro, which suggests that they may play a role in regulating the stability of mRNAs that contain these sequences.\nDocument 1 provides additional information on the role of Hsp70 in mRNA stability. It suggests that Hsp70 can bind to U-rich RNA, including some AU-rich elements (AREs), and stabilize some ARE-containing transcripts.\nDocument 2 provides further insight into the mechanism by which Hsp70 proteins regulate mRNA stability. It shows that the C-terminal domain of Hsp70 can bind to RNA and that this binding can be modified by deletion or rearrangement of the C-terminal domain.\nDocument 4 provides a comprehensive overview of the mechanisms by which Hsp70 proteins affect mRNA metabolism. It suggests that Hsp70 proteins can regulate mRNA stability, folding, and degradation in an mRNA-specific manner.\nDocument 5 highlights the importance of understanding the mechanisms by which Hsp70 proteins regulate mRNA stability in order to understand the role of these proteins in disease. It suggests that abnormal environmental and physiological conditions can damage protein structures, leading to a toxic state in the cell.\nDocument 6 provides additional information on the homologues of Hsp70, including Hsp110 and other members of the Hsp70 family. It suggests that these proteins may play similar roles in regulating mRNA stability and folding.\nDocument 7 highlights the need for further research to fully understand the mechanisms by which Hsp70 proteins regulate mRNA stability. It suggests that the detailed characterization of the effect of post-translational modifications (PTMs) on the ATPase activity of Hsp70 and Hsp110, as well as the conformation of the three components of this system, is necessary to fully understand how these",
    "llama-2-7b-chat-hf_fact_raw": "1. Hsp70 and Hsp110 proteins bind to specific RNA motifs to regulate mRNA stability.\n2. Hsp70 and Hsp110 proteins preferentially bind to AU-rich RNA in vitro.\n3. Hsp70 can bind to U-rich RNA, including some AU-rich elements (AREs), and stabilize some ARE-containing transcripts.\n4. The C-terminal domain of Hsp70 is capable of binding to RNA, and this binding can be affected by modifications to the domain.\n5. Hsp70 proteins can regulate mRNA stability, folding, and degradation in an mRNA-specific manner.",
    "llama-2-7b-chat-hf_fact": [
      "Hsp70 and Hsp110 proteins bind to specific RNA motifs to regulate mRNA stability.",
      "Hsp70 and Hsp110 proteins preferentially bind to AU-rich RNA in vitro.",
      "Hsp70 can bind to U-rich RNA, including some AU-rich elements (AREs), and stabilize some ARE-containing transcripts.",
      "The C-terminal domain of Hsp70 is capable of binding to RNA, and this binding can be affected by modifications to the domain.",
      "Hsp70 proteins can regulate mRNA stability, folding, and degradation in an mRNA-specific manner."
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, there are two types of deiodinases present in skeletal muscle:\n1. Type 2 deiodinase (DIO2): Documents 1 and 6 mention that DIO2 is present in skeletal muscle and plays a role in the activation of T4 to T3.\n2. Type 3 deiodinase (DIO3): Documents 1 and 6 also mention that DIO3 is present in skeletal muscle and inactivates both T4 and T3 by removing an inner ring iodine.\nIt is worth noting that the expression of DIO2 is tightly regulated in skeletal muscle, and it is mainly present in satellite cells, which are the muscle stem cell equivalent (Document 2).\nIn summary, the two deiodinases present in skeletal muscle are DIO2 and DIO3, which play important roles in the regulation of thyroid hormone activity in the muscle.",
    "llama-2-7b-chat-hf_fact_raw": "1. Type 2 deiodinase (DIO2) is present in skeletal muscle and is involved in the activation of T4 to T3.\n2. Type 3 deiodinase (DIO3) is present in skeletal muscle and inactivates both T4 and T3 by removing an inner ring iodine.\n3. The expression of DIO2 in skeletal muscle is tightly regulated.\n4. DIO2 is mainly present in satellite cells within skeletal muscle.\n5. Both DIO2 and DIO3 play important roles in the regulation of thyroid hormone activity in skeletal muscle.",
    "llama-2-7b-chat-hf_fact": [
      "Type 2 deiodinase (DIO2) is present in skeletal muscle and is involved in the activation of T4 to T3.",
      "Type 3 deiodinase (DIO3) is present in skeletal muscle and inactivates both T4 and T3 by removing an inner ring iodine.",
      "The expression of DIO2 in skeletal muscle is tightly regulated.",
      "DIO2 is mainly present in satellite cells within skeletal muscle.",
      "Both DIO2 and DIO3 play important roles in the regulation of thyroid hormone activity in skeletal muscle."
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the following are the inflammatory caspase proteins:\n1. Caspase-1\n2. Caspase-4\n3. Caspase-5\n4. Caspase-11\nThese proteins are grouped together as inflammatory caspases and share a CARD-domain at the N-terminal end. They are encoded by three main genes in humans (caspase-1, caspase-4, and caspase-5) and three main genes in mice (caspase-1, caspase-11, and caspase-4). The apoptotic caspases can be further sub-categorized into initiator- and executioner caspases. Caspase-12 and Anti-Inflammation are also mentioned in Document 4, which suggests that caspase-12 may have an inhibitory effect on inflammatory responses.",
    "llama-2-7b-chat-hf_fact_raw": "1. Caspase-1 is an inflammatory caspase protein.\n2. Caspase-4 is an inflammatory caspase protein.\n3. Caspase-5 is an inflammatory caspase protein.\n4. Caspase-11 is an inflammatory caspase protein.\n5. Inflammatory caspases share a CARD-domain at the N-terminal end.",
    "llama-2-7b-chat-hf_fact": [
      "Caspase-1 is an inflammatory caspase protein.",
      "Caspase-4 is an inflammatory caspase protein.",
      "Caspase-5 is an inflammatory caspase protein.",
      "Caspase-11 is an inflammatory caspase protein.",
      "Inflammatory caspases share a CARD-domain at the N-terminal end."
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, there is a link between the Aurora B kinase and the polycomb protein Ring1B. The documents suggest that both proteins play essential roles in regulating transcriptionally active genes in quiescent lymphocytes. They also show that Aurora B and Ring1B bind to a wide range of active promoters in resting B and T cells. Additionally, the documents mention that Aurora B concentrates early during mitosis in the proximity of centromeres and kinetochores, and that it phosphorylates a variety of other cell division proteins, including the kinetochore scaffolding protein KNL1. These findings suggest that Aurora B and Ring1B may be involved in regulating the expression of genes involved in cell division and transcription, and that they may work together to achieve these functions.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is a link between the Aurora B kinase and the polycomb protein Ring1B.\n2. Both Aurora B kinase and Ring1B play roles in regulating transcriptionally active genes in quiescent lymphocytes.\n3. Aurora B and Ring1B bind to a range of active promoters in resting B and T cells.\n4. Aurora B kinase concentrates early during mitosis near centromeres and kinetochores.\n5. Aurora B kinase phosphorylates a variety of cell division proteins, including the kinetochore scaffolding protein KNL1.",
    "llama-2-7b-chat-hf_fact": [
      "There is a link between the Aurora B kinase and the polycomb protein Ring1B.",
      "Both Aurora B kinase and Ring1B play roles in regulating transcriptionally active genes in quiescent lymphocytes.",
      "Aurora B and Ring1B bind to a range of active promoters in resting B and T cells.",
      "Aurora B kinase concentrates early during mitosis near centromeres and kinetochores.",
      "Aurora B kinase phosphorylates a variety of cell division proteins, including the kinetochore scaffolding protein KNL1."
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-2-7b-chat-hf_response": "Based on the provided documents, the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates are:\nDonor splice sites:\n* GU/AG/UR/URA (G/A/U/UA) motifs are the most common non-canonical motifs at donor splice sites in vertebrates, as shown in Documents 1, 3, and 8.\n* GU/AG/UR/URA (G/A/U/UA) motifs are recognized by sequence-specific transcription factors (TFs) and are involved in the regulation of critical molecular processes such as gene expression, as mentioned in Documents 0 and 1.\n* The frequency of non-canonical motifs at donor splice sites varies among species, with some studies suggesting that they are more common in certain vertebrate groups, such as mammals, as shown in Document 5.\nAcceptor splice sites:\n* GU/AG/UR/URA (G/A/U/UA) motifs are also the most common non-canonical motifs at acceptor splice sites in vertebrates, as shown in Documents 1, 3, and 8.\n* The recognition of these motifs by TFs is important for the regulation of gene expression, as mentioned in Documents 0 and 1.\n* The frequency of non-canonical motifs at acceptor splice sites may also vary among species, with some studies suggesting that they are more common in certain vertebrate groups, such as mammals, as shown in Document 5.\nIt is important to note that the frequency and distribution of non-canonical motifs at donor and acceptor splice sites can vary depending on the species, and some studies have identified additional non-canonical motifs for specific TFs, as shown in Documents 1 and 3.",
    "llama-2-7b-chat-hf_fact_raw": "1. GU/AG/UR/URA (G/A/U/UA) motifs are the most common non-canonical motifs at donor splice sites in vertebrates.\n2. These GU/AG/UR/URA (G/A/U/UA) motifs are recognized by sequence-specific transcription factors and are involved in the regulation of gene expression.\n3. The frequency of non-canonical motifs at donor splice sites varies among species, with some studies suggesting they are more common in certain vertebrate groups, such as mammals.\n4. GU/AG/UR/URA (G/A/U/UA) motifs are also the most common non-canonical motifs at acceptor splice sites in vertebrates.\n5. The frequency and distribution of non-canonical motifs at donor and acceptor splice sites can vary depending on the species.",
    "llama-2-7b-chat-hf_fact": [
      "GU/AG/UR/URA (G/A/U/UA) motifs are the most common non-canonical motifs at donor splice sites in vertebrates.",
      "These GU/AG/UR/URA (G/A/U/UA) motifs are recognized by sequence-specific transcription factors and are involved in the regulation of gene expression.",
      "The frequency of non-canonical motifs at donor splice sites varies among species, with some studies suggesting they are more common in certain vertebrate groups, such as mammals.",
      "GU/AG/UR/URA (G/A/U/UA) motifs are also the most common non-canonical motifs at acceptor splice sites in vertebrates.",
      "The frequency and distribution of non-canonical motifs at donor and acceptor splice sites can vary depending on the species."
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the event that results in the acetylation of S6K1 is its phosphorylation by p300/PCAF.\nDocument 4 mentions that p300/PCAF can induce the acetylation of Raptor, which is a downstream target of S6K1. The document also states that leucine deprivation decreases Raptor acetylation, leading to mTORC1-dependent phosphorylation of S6K1 at the C-terminus. This suggests that p300/PCAF-mediated acetylation of S6K1 is a key event in the regulation of S6K1 activity.\nIn contrast, documents 1 and 7 suggest that the acetylation of S6K1 is also regulated by other mechanisms, such as the inhibition of the CTR of S6K1 by class III histone deacetylases (SIRT1 and SIRT2) and the inhibition of the phosphorylation of S6K1 by mTORC1. However, these mechanisms are not directly related to the acetylation of S6K1 by p300/PCAF.\nTherefore, based on the information provided, the event that results in the acetylation of S6K1 is its phosphorylation by p300/PCAF.",
    "llama-2-7b-chat-hf_fact_raw": "1. The acetylation of S6K1 is induced by its phosphorylation by p300/PCAF.\n2. p300/PCAF can also induce the acetylation of Raptor, which is a downstream target of S6K1.\n3. Leucine deprivation decreases Raptor acetylation, which leads to mTORC1-dependent phosphorylation of S6K1 at the C-terminus.\n4. The acetylation of S6K1 is regulated by mechanisms other than p300/PCAF, including inhibition by class III histone deacetylases (SIRT1 and SIRT2).\n5. The phosphorylation of S6K1 by mTORC1 is inhibited by mechanisms that are not directly related to the acetylation of S6K1 by p300/PCAF.",
    "llama-2-7b-chat-hf_fact": [
      "The acetylation of S6K1 is induced by its phosphorylation by p300/PCAF.",
      "p300/PCAF can also induce the acetylation of Raptor, which is a downstream target of S6K1.",
      "Leucine deprivation decreases Raptor acetylation, which leads to mTORC1-dependent phosphorylation of S6K1 at the C-terminus.",
      "The acetylation of S6K1 is regulated by mechanisms other than p300/PCAF, including inhibition by class III histone deacetylases (SIRT1 and SIRT2).",
      "The phosphorylation of S6K1 by mTORC1 is inhibited by mechanisms that are not directly related to the acetylation of S6K1 by p300/PCAF."
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the cause of episodic ataxia type 6 (EA6) is a mutation in the SLC1A3 gene, which encodes for the excitatory amino acid transporter 1 (EAAT1). This mutation is monoallelic and affects the function of the transporter in the cerebellum, diencephalon, and brainstem. The mutation can also be associated with seizures, migraine, and hemiplegia, similar to episodic ataxia type 2 (EA2).",
    "llama-2-7b-chat-hf_fact_raw": "1. Episodic ataxia type 6 (EA6) is caused by a mutation in the SLC1A3 gene.\n2. The SLC1A3 gene encodes for the excitatory amino acid transporter 1 (EAAT1).\n3. The mutation in the SLC1A3 gene that causes EA6 is monoallelic.\n4. This mutation affects the function of the EAAT1 transporter in the cerebellum, diencephalon, and brainstem.\n5. The mutation associated with EA6 can also be linked to seizures, migraine, and hemiplegia.",
    "llama-2-7b-chat-hf_fact": [
      "Episodic ataxia type 6 (EA6) is caused by a mutation in the SLC1A3 gene.",
      "The SLC1A3 gene encodes for the excitatory amino acid transporter 1 (EAAT1).",
      "The mutation in the SLC1A3 gene that causes EA6 is monoallelic.",
      "This mutation affects the function of the EAAT1 transporter in the cerebellum, diencephalon, and brainstem.",
      "The mutation associated with EA6 can also be linked to seizures, migraine, and hemiplegia."
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it is clear that chromomethylases are present in plant genomes, as Document 0 specifically states that CHROMOMETHYLASES (CMTs) are an important class of plant-specific DNA methylation enzymes. However, there is no direct information in the documents to suggest that chromomethylases are present in animal genomes.\nDocument 1 mentions that methylation in the bodies of active genes is common in animals and vascular plants, but it does not provide any information about the specific enzymes involved in this process. Document 2 mentions that 5-cytosine methylation (5mC) is the most prevalent modification in eukaryotic genomes, but it does not mention chromomethylases specifically.\nDocument 3 provides some information about the evolutionary history of DNA methylation in prokaryotes and eukaryotes, but it does not mention chromomethylases. Document 4 mentions that the genomes of non-bilaterian metazoans are key to understanding the molecular basis of early animal evolution, but it does not provide any information about the presence of chromomethylases in animal genomes.\nDocument 5 mentions that although DNA methyltransferase content is generally conserved across eukaryotes, there is extensive variation in how this modified base is used for a variety of cellular processes. However, it does not provide any information about the presence of chromomethylases in eukaryotic genomes.\nDocument 6 compares the DNA methylomes across more than 20 eukaryote genomes and finds that most of the genomes undergo DNA methylation, while only a few eukaryotes show zero or little evidence of DNA methylation. However, it does not mention chromomethylases specifically.\nDocument 7 provides more detailed information about the evolutionary history of chromomethylases in Viridiplantae, including the fact that duplication events gave rise to what are now referred to as CMT1, 2 and 3. However, it does not provide any information about the presence of chromomethylases in animal genomes.\nDocument 8 mentions that the targeting of chromomethylases involves",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromomethylases (CMTs) are an important class of plant-specific DNA methylation enzymes.\n2. Methylation in the bodies of active genes is common in animals and vascular plants.\n3. 5-cytosine methylation (5mC) is the most prevalent modification in eukaryotic genomes.\n4. DNA methyltransferase content is generally conserved across eukaryotes.\n5. Duplication events in Viridiplantae gave rise to what are now referred to as CMT1, 2, and 3.",
    "llama-2-7b-chat-hf_fact": [
      "Chromomethylases (CMTs) are an important class of plant-specific DNA methylation enzymes.",
      "Methylation in the bodies of active genes is common in animals and vascular plants.",
      "5-cytosine methylation (5mC) is the most prevalent modification in eukaryotic genomes.",
      "DNA methyltransferase content is generally conserved across eukaryotes.",
      "Duplication events in Viridiplantae gave rise to what are now referred to as CMT1, 2, and 3."
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-2-7b-chat-hf_response": "Based on the information provided, here are some packages available in R/Bioconductor for transcription factor binding site (TFBS) analysis:\n1. TFBSTools: This is a comprehensive package for the analysis and manipulation of TFBSs and their associated transcription factor profile matrices. It provides a toolkit for handling TFBS profile matrices, scanning sequences and alignments including whole genomes, and querying the JASPAR database.\n2. JASPAR: This is an open-access database of curated, non-redundant TF-binding profiles stored as position frequency matrices (PFMs) for TFs across multiple species in six taxonomic groups.\nOther packages that may be relevant for TFBS analysis include:\n1. ChIPseek: This package provides tools for the analysis of ChIP-Seq data, including the identification of TFBSs.\n2. HISAT2: This package provides tools for the alignment of RNA-seq and ChIP-seq data.\n3. STAR: This package provides tools for the alignment of RNA-seq data.\n4. Bedtools: This package provides tools for the manipulation and analysis of genomic data, including the identification of TFBSs.\n5. GTFutils: This package provides tools for the manipulation and analysis of genomic data, including the identification of TFBSs.\n6. GenomicAlignments: This package provides tools for the alignment of genomic data, including the identification of TFBSs.\n7. RNA-seq: This package provides tools for the analysis of RNA-seq data, including the identification of TFBSs.\n8. ChIP-Seq: This package provides tools for the analysis of ChIP-Seq data, including the identification of TFBSs.\nThese packages can be used for various tasks such as:\n1. Identifying TFBSs in a given genomic region.\n2. Analyzing the binding affinity of a transcription factor to its binding sites.\n3. Predicting the binding sites of a transcription factor in a given genomic region.\n4. Identifying the regulatory elements in a given genomic region.\n5. Analyzing the expression of a transcription factor and its binding sites across different samples.\n6. Ident",
    "llama-2-7b-chat-hf_fact_raw": "1. TFBSTools is a package in R/Bioconductor for transcription factor binding site analysis.\n2. JASPAR is an open-access database of curated, non-redundant transcription factor-binding profiles.\n3. ChIPseek is a package in R/Bioconductor that provides tools for the analysis of ChIP-Seq data.\n4. HISAT2 is a package in R/Bioconductor that provides tools for the alignment of RNA-seq and ChIP-seq data.\n5. Bedtools is a package in R/Bioconductor that provides tools for the manipulation and analysis of genomic data.",
    "llama-2-7b-chat-hf_fact": [
      "TFBSTools is a package in R/Bioconductor for transcription factor binding site analysis.",
      "JASPAR is an open-access database of curated, non-redundant transcription factor-binding profiles.",
      "ChIPseek is a package in R/Bioconductor that provides tools for the analysis of ChIP-Seq data.",
      "HISAT2 is a package in R/Bioconductor that provides tools for the alignment of RNA-seq and ChIP-seq data.",
      "Bedtools is a package in R/Bioconductor that provides tools for the manipulation and analysis of genomic data."
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, there are several clinical trials that have been conducted on the prevention of sarcopenia. Here are some of the trials mentioned in the documents:\n1. The Fit and Strong in Sarcopenia (FAST-Sarcopenia) trial, which evaluated the effectiveness of a 12-month exercise program in preventing sarcopenia in older adults.\n2. The Sarcopenia Prevention with Exercise (SPE) trial, which tested the effectiveness of a 12-month exercise program in preventing sarcopenia in older adults with mild cognitive impairment.\n3. The Nutrition and Exercise for Sarcopenia Prevention (NESP) trial, which evaluated the effectiveness of a combination of nutritional interventions and exercise in preventing sarcopenia in older adults.\n4. The Pharmaceutical Interventions for Sarcopenia Prevention (PISP) trial, which tested the effectiveness of a drug therapy in preventing sarcopenia in older adults.\nIt is important to note that these trials are ongoing and have not yet been completed, so the results are not yet available. However, these trials suggest that exercise and nutritional interventions may be effective in preventing sarcopenia, and that drug therapy may also be a viable option in the future.\nIn addition to these specific trials, there are also several ongoing and planned clinical trials that are focused on the prevention of sarcopenia, including the Sarcopenia Prevention and Exercise (SPEX) trial, the Nutrition and Exercise for Sarcopenia Prevention (NESP) trial, and the Pharmaceutical Interventions for Sarcopenia Prevention (PISP) trial.\nOverall, the evidence suggests that prevention of sarcopenia is a complex and multifaceted issue, and that a combination of exercise, nutrition, and drug therapy may be necessary to effectively prevent or treat sarcopenia.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Fit and Strong in Sarcopenia (FAST-Sarcopenia) trial evaluated the effectiveness of a 12-month exercise program in preventing sarcopenia in older adults.\n2. The Sarcopenia Prevention with Exercise (SPE) trial tested the effectiveness of a 12-month exercise program in preventing sarcopenia in older adults with mild cognitive impairment.\n3. The Nutrition and Exercise for Sarcopenia Prevention (NESP) trial evaluated the effectiveness of a combination of nutritional interventions and exercise in preventing sarcopenia in older adults.\n4. The Pharmaceutical Interventions for Sarcopenia Prevention (PISP) trial tested the effectiveness of drug therapy in preventing sarcopenia in older adults.\n5. The trials mentioned (FAST-Sarcopenia, SPE, NESP, PISP) are ongoing and have not yet been completed.",
    "llama-2-7b-chat-hf_fact": [
      "The Fit and Strong in Sarcopenia (FAST-Sarcopenia) trial evaluated the effectiveness of a 12-month exercise program in preventing sarcopenia in older adults.",
      "The Sarcopenia Prevention with Exercise (SPE) trial tested the effectiveness of a 12-month exercise program in preventing sarcopenia in older adults with mild cognitive impairment.",
      "The Nutrition and Exercise for Sarcopenia Prevention (NESP) trial evaluated the effectiveness of a combination of nutritional interventions and exercise in preventing sarcopenia in older adults.",
      "The Pharmaceutical Interventions for Sarcopenia Prevention (PISP) trial tested the effectiveness of drug therapy in preventing sarcopenia in older adults.",
      "The trials mentioned (FAST-Sarcopenia, SPE, NESP, PISP) are ongoing and have not yet been completed."
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the database of molecular recognition features in membrane proteins is mpMoRFsDB. This database was created by Foivos Gypas, Georgios N. Tsaousis, and Stavros J. Hamodrakas, and it provides valuable information related to disordered-based protein-protein interactions in membrane proteins. The database contains information on molecular recognition features (MoRFs) in membrane proteins, including their structure, function, and binding affinity data.\nAccording to Document 1, MoRFs are small, intrinsically disordered regions in proteins that undergo a disorder-to-order transition upon binding to their partners. These regions are involved in protein-protein interactions and may function as the initial step in molecular recognition.\nDocument 2 provides an overview of the database and its contents, including a Jmol applet for visualization of the structures. The database contains all membrane proteins that contain MoRFs, organized and stored in a publicly available MySQL database with a user-friendly web interface.\nDocument 3 provides a detailed analysis of MoRFs in membrane proteins, including their structure, function, and binding affinity data. The authors suggest that MoRFs play a crucial role in protein-protein interactions in membrane proteins.\nDocument 6 defines MoRFs as short, intrinsically disordered regions in proteins that undergo disorder-to-order transition upon binding to their partners. These regions are implicated in molecular recognition, which serves as the initial step for protein-protein interactions.\nDocument 7 is a database of binding affinity data for membrane protein-protein complexes, known as MPAD. The database contains over 5400 experimental binding affinity data from 950 proteins in 675 articles, along with details on protein sequence, structure, function, experimental conditions, thermodynamic data, and literature.\nIn summary, the database of molecular recognition features in membrane proteins is mpMoRFsDB, which provides valuable information related to disordered-based protein-protein interactions in membrane proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. The database of molecular recognition features in membrane proteins is called mpMoRFsDB.\n2. Foivos Gypas, Georgios N. Tsaousis, and Stavros J. Hamodrakas created the mpMoRFsDB.\n3. Molecular recognition features (MoRFs) are small, intrinsically disordered regions in proteins that undergo a disorder-to-order transition upon binding to their partners.\n4. The mpMoRFsDB contains all membrane proteins that have MoRFs and is stored in a publicly available MySQL database with a web interface.\n5. The MPAD database contains over 5400 experimental binding affinity data from 950 proteins in 675 articles.",
    "llama-2-7b-chat-hf_fact": [
      "The database of molecular recognition features in membrane proteins is called mpMoRFsDB.",
      "Foivos Gypas, Georgios N. Tsaousis, and Stavros J. Hamodrakas created the mpMoRFsDB.",
      "Molecular recognition features (MoRFs) are small, intrinsically disordered regions in proteins that undergo a disorder-to-order transition upon binding to their partners.",
      "The mpMoRFsDB contains all membrane proteins that have MoRFs and is stored in a publicly available MySQL database with a web interface.",
      "The MPAD database contains over 5400 experimental binding affinity data from 950 proteins in 675 articles."
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it can be concluded that rivaroxaban is metabolized in the kidneys to some extent. Document 2 states that rivaroxaban is metabolized and cleared via the kidney and liver, and Document 6 mentions that approximately two-thirds of the dose is metabolized. However, the exact extent of kidney involvement in rivaroxaban metabolism is not specified in the documents.\nIt is worth noting that rivaroxaban is also metabolized by the liver, as mentioned in Documents 2 and 6. The drug is metabolized by cytochrome P450 enzymes, including CYP3A4, CYP3A5, CYP2J2, and CYP-independent mechanisms (Document 6). Therefore, the metabolism of rivaroxaban is a complex process involving both the kidneys and liver.\nIn conclusion, while the documents do not provide specific information on the percentage of rivaroxaban metabolized in the kidneys, it is clear that the drug is metabolized in both the kidneys and liver. Patients with renal impairment may require reduced dosages of rivaroxaban due to impaired clearance (Document 2).",
    "llama-2-7b-chat-hf_fact_raw": "1. Rivaroxaban is metabolized in the kidneys to some extent.\n2. Rivaroxaban is also metabolized by the liver.\n3. The drug rivaroxaban is metabolized by cytochrome P450 enzymes, including CYP3A4, CYP3A5, CYP2J2.\n4. Rivaroxaban metabolism involves CYP-independent mechanisms.\n5. Patients with renal impairment may require reduced dosages of rivaroxaban due to impaired clearance.",
    "llama-2-7b-chat-hf_fact": [
      "Rivaroxaban is metabolized in the kidneys to some extent.",
      "Rivaroxaban is also metabolized by the liver.",
      "The drug rivaroxaban is metabolized by cytochrome P450 enzymes, including CYP3A4, CYP3A5, CYP2J2.",
      "Rivaroxaban metabolism involves CYP-independent mechanisms.",
      "Patients with renal impairment may require reduced dosages of rivaroxaban due to impaired clearance."
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the genes that are regulated by TRalpha2 in the heart are:\n1. THRA (encoding TRalpha1)\n2. THRB (encoding TRalpha2)\nThese genes are involved in the regulation of heart rate and the expression of other genes involved in cardiovascular physiology. The documents mention that TRalpha2 is the predominant isoform expressed in the heart, and that it plays a critical role in mediating the effects of T3 on the heart. Overexpression of TRalpha2 in the mouse hypothalamus abrogates T3-dependent repression of Trh and T3 activation of positively regulated promoters, suggesting that TRalpha2 plays a key role in regulating the expression of genes involved in cardiovascular physiology.\nIt is worth noting that the documents do not provide direct information on the specific genes regulated by TRalpha2 in the heart, but rather suggest that TRalpha2 is involved in the regulation of genes involved in heart rate and cardiovascular physiology. Further research would be needed to identify the specific genes regulated by TRalpha2 in the heart.",
    "llama-2-7b-chat-hf_fact_raw": "1. TRalpha2 is involved in the regulation of heart rate.\n2. TRalpha2 plays a role in the expression of genes involved in cardiovascular physiology.\n3. TRalpha2 is the predominant isoform expressed in the heart.\n4. TRalpha2 mediates the effects of T3 on the heart.\n5. Overexpression of TRalpha2 in the mouse hypothalamus affects T3-dependent repression of Trh and T3 activation of positively regulated promoters.",
    "llama-2-7b-chat-hf_fact": [
      "TRalpha2 is involved in the regulation of heart rate.",
      "TRalpha2 plays a role in the expression of genes involved in cardiovascular physiology.",
      "TRalpha2 is the predominant isoform expressed in the heart.",
      "TRalpha2 mediates the effects of T3 on the heart.",
      "Overexpression of TRalpha2 in the mouse hypothalamus affects T3-dependent repression of Trh and T3 activation of positively regulated promoters."
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-2-7b-chat-hf_response": "Based on the provided documents, here are some available biomedical question answering systems:\n1. BioASQ 3: A biomedical semantic indexing and question answering system that pushes research towards highly precise biomedical information access systems through a series of evaluation campaigns.\n2. SemBioNLQA: A fully automatic semantic biomedical question answering system that integrates NLP methods in question classification, document retrieval, passage retrieval, and answer extraction modules.\n3. BioBERT: A pre-trained language model that can improve the performance of biomedical question answering models by leveraging general domain question answering corpora such as SQuAD.\n4. Biomedical question answering (QA) systems: These systems aim to answer a question in the biomedical field based on one or more related passages and can provide people with accurate healthcare-related information.\n5. Traditional and end-to-end neural biomedical QA systems: These systems have been developed to extract and provide one direct and exact answer to a question in the biomedical field.\n6. MEDLINE abstracts: Many biomedical QA systems make use of MEDLINE abstracts as an information source.\n7. askHERMES and EAGLi: Two systems that use MEDLINE as a major source of answers and also leverage other sources such as eMedicine, clinical guidelines, PubMedCentral full text documents, and Wikipedia.\n8. Task 8b: A large-scale question answering challenge that provides participating teams with the opportunity to develop systems for all the stages of question answering in the biomedical domain, including question classification, document retrieval, passage retrieval, and answer extraction.\nThese are some of the available biomedical question answering systems and datasets mentioned in the provided documents.",
    "llama-2-7b-chat-hf_fact_raw": "1. BioASQ 3 is a biomedical semantic indexing and question answering system.\n2. SemBioNLQA is a fully automatic semantic biomedical question answering system.\n3. BioBERT is a pre-trained language model used to improve biomedical question answering models.\n4. MEDLINE abstracts are used as an information source by many biomedical QA systems.\n5. askHERMES and EAGLi are biomedical QA systems that use MEDLINE and other sources for answers.",
    "llama-2-7b-chat-hf_fact": [
      "BioASQ 3 is a biomedical semantic indexing and question answering system.",
      "SemBioNLQA is a fully automatic semantic biomedical question answering system.",
      "BioBERT is a pre-trained language model used to improve biomedical question answering models.",
      "MEDLINE abstracts are used as an information source by many biomedical QA systems.",
      "askHERMES and EAGLi are biomedical QA systems that use MEDLINE and other sources for answers."
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the trancription factor that activates the betalain pathway is MYB.\nDocument 1 mentions that MYB transcription factors play an important role in the transcriptional regulation of betalain biosynthesis. Document 7 also mentions that the anthocyanin biosynthetic pathway is regulated by a well-characterized MBW transcription factor complex consisting of MYB, bHLH, and WD-repeat proteins.\nDocument 8 discusses the optimization of the betalain pathway in a heterologous expression system, which may involve selecting the best-performing isozymes from betalain-producing species and the optimal combination of regulatory elements that drive their expression. This suggests that MYB transcription factors play a crucial role in regulating the expression of genes involved in the betalain pathway.\nDocument 9 provides an overview of current knowledge on the biosynthetic pathway of betalains, including the characteristic 4,5-DOPA-dioxygenase that forms the structural unit of the pigments. However, the document also mentions that enzyme-catalyzed reactions and chemical side reactions leave alternative ways open, which suggests that the regulation of the betalain pathway is complex and involves multiple transcription factors, including MYB.\nTherefore, based on the information provided in the documents, it can be concluded that MYB transcription factors activate the betalain pathway in plants.",
    "llama-2-7b-chat-hf_fact_raw": "1. MYB transcription factors play an important role in the transcriptional regulation of betalain biosynthesis.\n2. The anthocyanin biosynthetic pathway is regulated by an MBW transcription factor complex that includes MYB.\n3. MYB transcription factors are crucial in regulating the expression of genes involved in the betalain pathway.\n4. The biosynthetic pathway of betalains includes the enzyme 4,5-DOPA-dioxygenase.\n5. The regulation of the betalain pathway involves multiple transcription factors, including MYB.",
    "llama-2-7b-chat-hf_fact": [
      "MYB transcription factors play an important role in the transcriptional regulation of betalain biosynthesis.",
      "The anthocyanin biosynthetic pathway is regulated by an MBW transcription factor complex that includes MYB.",
      "MYB transcription factors are crucial in regulating the expression of genes involved in the betalain pathway.",
      "The biosynthetic pathway of betalains includes the enzyme 4,5-DOPA-dioxygenase.",
      "The regulation of the betalain pathway involves multiple transcription factors, including MYB."
    ]
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the preferred technologies for enrichment of phosphorylated peptides for global quantitative phosphoproteomic analyses are:\n1. 2D gel electrophoresis: This is a widely used technique for phosphoproteome analysis, which separates proteins based on their isoelectric point and molecular weight.\n2. Liquid chromatography-tandem mass spectrometry (LC-MS/MS): This is a powerful tool for identifying and quantifying phosphorylated peptides, as it allows for the separation and analysis of peptides based on their properties.\n3. Pre-fractionation methods: These methods involve the enrichment of phosphorylated peptides before analysis, such as using immobilized phospho-specific antibodies or ion exchange chromatography.\n4. Phospho-specific enrichment methods: These methods involve the use of phospho-specific probes or antibodies to enrich for phosphorylated peptides, such as using a phospho-specific affinity matrix or immunoprecipitation.\n5. Mass spectrometry-based methods: These methods involve the use of mass spectrometry to identify and quantify phosphorylated peptides, such as using matrix-assisted laser desorption/ionization (MALDI) or electrospray ionization (ESI).\nIt is important to note that the choice of technology will depend on the specific research question and experimental design. For example, 2D gel electrophoresis may be more suitable for large-scale analyses, while LC-MS/MS may be more suitable for smaller-scale analyses or for the analysis of specific phosphorylation sites.",
    "llama-2-7b-chat-hf_fact_raw": "1. 2D gel electrophoresis is used for phosphoproteome analysis and separates proteins based on isoelectric point and molecular weight.\n2. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is used for identifying and quantifying phosphorylated peptides.\n3. Pre-fractionation methods are used to enrich phosphorylated peptides before analysis.\n4. Phospho-specific enrichment methods use probes or antibodies to enrich for phosphorylated peptides.\n5. Mass spectrometry-based methods, such as MALDI or ESI, are used to identify and quantify phosphorylated peptides.",
    "llama-2-7b-chat-hf_fact": [
      "2D gel electrophoresis is used for phosphoproteome analysis and separates proteins based on isoelectric point and molecular weight.",
      "Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is used for identifying and quantifying phosphorylated peptides.",
      "Pre-fractionation methods are used to enrich phosphorylated peptides before analysis.",
      "Phospho-specific enrichment methods use probes or antibodies to enrich for phosphorylated peptides.",
      "Mass spectrometry-based methods, such as MALDI or ESI, are used to identify and quantify phosphorylated peptides."
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the disorder that is rated by Palmini classification is Focal Cortical Dysplasia (FCD). The Palmini classification divides FCD into four subtypes:\n1. Mild Malformation of Cortical Development (mild MCD) - with ectopically placed neurons in or adjacent to layer I.\n2. Type I FCD - with microscopic neuronal heterotopia outside layer I.\n3. Type II FCD - with microscopic neuronal heterotopia outside layer I and a more severe degree of cortical malformation.\n4. Focal Cortical Dysplasia with Hippocampal Sclerosis (FCDIII) - a combination of FCD and hippocampal sclerosis.\nThe Palmini classification is widely used to categorize FCD and has been shown to be useful in predicting the likelihood of seizure control with surgery.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Palmini classification is used to rate Focal Cortical Dysplasia (FCD).\n2. The Palmini classification divides FCD into four subtypes.\n3. Type I FCD is characterized by microscopic neuronal heterotopia outside layer I.\n4. Type II FCD includes microscopic neuronal heterotopia outside layer I and a more severe degree of cortical malformation.\n5. Focal Cortical Dysplasia with Hippocampal Sclerosis (FCDIII) is a combination of FCD and hippocampal sclerosis.",
    "llama-2-7b-chat-hf_fact": [
      "The Palmini classification is used to rate Focal Cortical Dysplasia (FCD).",
      "The Palmini classification divides FCD into four subtypes.",
      "Type I FCD is characterized by microscopic neuronal heterotopia outside layer I.",
      "Type II FCD includes microscopic neuronal heterotopia outside layer I and a more severe degree of cortical malformation.",
      "Focal Cortical Dysplasia with Hippocampal Sclerosis (FCDIII) is a combination of FCD and hippocampal sclerosis."
    ]
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it is likely that viruses are involved in the etiology of human subacute thyroiditis. The documents mention several viruses that have been linked to subacute thyroiditis, including mumps, measles, rubella, coxsackie, and adenovirus. Additionally, the documents suggest that SARS-CoV-2 infection/vaccination has been associated with subacute thyroiditis cases. The review article \"Viruses and thyroiditis: an update\" (Document 2) states that \"viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases.\"\nIt is important to note that subacute thyroiditis is a self-limiting inflammatory disorder of the thyroid gland, and the exact cause of the condition is not fully understood. However, the available evidence suggests that viral infections play a role in the etiology of subacute thyroiditis.\nIn conclusion, based on the information provided in the documents, it is likely that viruses are involved in the etiology of human subacute thyroiditis. Further research is needed to fully understand the relationship between viruses and subacute thyroiditis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viruses are likely involved in the etiology of human subacute thyroiditis.\n2. Mumps, measles, rubella, coxsackie, and adenovirus have been linked to subacute thyroiditis.\n3. SARS-CoV-2 infection/vaccination has been associated with cases of subacute thyroiditis.\n4. Subacute thyroiditis is a self-limiting inflammatory disorder of the thyroid gland.\n5. The exact cause of subacute thyroiditis is not fully understood.",
    "llama-2-7b-chat-hf_fact": [
      "Viruses are likely involved in the etiology of human subacute thyroiditis.",
      "Mumps, measles, rubella, coxsackie, and adenovirus have been linked to subacute thyroiditis.",
      "SARS-CoV-2 infection/vaccination has been associated with cases of subacute thyroiditis.",
      "Subacute thyroiditis is a self-limiting inflammatory disorder of the thyroid gland.",
      "The exact cause of subacute thyroiditis is not fully understood."
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it appears that STAT3 is involved in the suppression of autophagy through its interaction with EIF2AK2.\nDocument 1 suggests that STAT3 can inhibit autophagy by sequestering EIF2AK2 and interacting with other autophagy-related signaling molecules. Document 3 also supports this idea, as it shows that pharmacological or genetic inhibition of STAT3 stimulates EIF2AK2-dependent EIF2S1 phosphorylation and autophagy.\nDocument 4 provides further evidence of the interaction between STAT3 and EIF2AK2, as it shows that in control conditions, when autophagy is off, STAT3 and EIF2AK2 interact with each other in the cytoplasm. This interaction is specific, as EIF2AK2 failed to co-immunoprecipitate with STAT family members other than STAT3.\nDocument 7 suggests that the autophagy-inhibitory functions of STAT3 rely on the physical interaction between its SH2 domain and the EIF2AK3-related kinase EIF2AK2, also known as protein kinase, RNA-activated (PKR). This interaction resolves upon exposure to autophagy inducers, leading to the stimulation of autophagy.\nOverall, the information provided in the documents suggests that STAT3 plays a negative role in the regulation of autophagy by interacting with EIF2AK2 and inhibiting its enzymatic activity.",
    "llama-2-7b-chat-hf_fact_raw": "1. STAT3 can inhibit autophagy by sequestering EIF2AK2 and interacting with other autophagy-related signaling molecules.\n2. Inhibition of STAT3 stimulates EIF2AK2-dependent EIF2S1 phosphorylation and autophagy.\n3. STAT3 and EIF2AK2 interact with each other in the cytoplasm under control conditions when autophagy is not active.\n4. The interaction between STAT3 and EIF2AK2 is specific, as EIF2AK2 does not co-immunoprecipitate with other STAT family members besides STAT3.\n5. The autophagy-inhibitory functions of STAT3 involve the physical interaction between its SH2 domain and EIF2AK2.",
    "llama-2-7b-chat-hf_fact": [
      "STAT3 can inhibit autophagy by sequestering EIF2AK2 and interacting with other autophagy-related signaling molecules.",
      "Inhibition of STAT3 stimulates EIF2AK2-dependent EIF2S1 phosphorylation and autophagy.",
      "STAT3 and EIF2AK2 interact with each other in the cytoplasm under control conditions when autophagy is not active.",
      "The interaction between STAT3 and EIF2AK2 is specific, as EIF2AK2 does not co-immunoprecipitate with other STAT family members besides STAT3.",
      "The autophagy-inhibitory functions of STAT3 involve the physical interaction between its SH2 domain and EIF2AK2."
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that Theatre is a software tool used for genomic analysis, particularly in the context of comparative genomics and variant analysis. Here are some of the key ways in which Theatre can be used:\n1. Identification of coding regions, repetitive sequences, and transcription factor binding sites: Theatre can be used to determine or predict the positions of these features in DNA sequences from different organisms.\n2. Comparative analysis of genomic sequences: Theatre can be used to compare the genomic sequences of different organisms and identify differences, such as variations in the p53 promoter region between mammals.\n3. Identification of genomic variations: With the complete sequence of the human genome and advancements in sequencing technologies, Theatre can be used to identify all variants in human coding and non-coding sequences.\n4. Data format and software for whole-genome sequencing: Theatre can be used to develop data formats and software for manipulating and analyzing whole-genome sequencing data.\n5. Reassembly of read fragments: Theatre can be used to reassemble read fragments back into an entire genome sequence, allowing for the inference of genomic variations that make an individual genetically different from another.\n6. Integrative analysis of diverse data types: Theatre can be used to integrate data from multiple sources and software tools to perform genomic analysis.\n7. Visualization of genomic tracks: Theatre can be used to visualize genomic tracks in a web browser or with a stand-alone graphical user interface.\n8. Medical AI applications: Theatre can be used to develop medical AI applications, such as interpreting and prioritizing variant analysis in a diagnostic context.\nOverall, Theatre appears to be a versatile software tool for genomic analysis, with a wide range of applications in fields such as comparative genomics, variant analysis, and medical AI.",
    "llama-2-7b-chat-hf_fact_raw": "1. Theatre is a software tool used for genomic analysis.\n2. Theatre can be used to identify coding regions, repetitive sequences, and transcription factor binding sites in DNA sequences.\n3. Theatre allows for comparative analysis of genomic sequences between different organisms.\n4. Theatre can be utilized to identify all variants in human coding and non-coding sequences.\n5. Theatre can reassemble read fragments back into an entire genome sequence.",
    "llama-2-7b-chat-hf_fact": [
      "Theatre is a software tool used for genomic analysis.",
      "Theatre can be used to identify coding regions, repetitive sequences, and transcription factor binding sites in DNA sequences.",
      "Theatre allows for comparative analysis of genomic sequences between different organisms.",
      "Theatre can be utilized to identify all variants in human coding and non-coding sequences.",
      "Theatre can reassemble read fragments back into an entire genome sequence."
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences is O(m \\* n), where m and n are the lengths of the sequences.\nThis is mentioned in Document 5, which states that the algorithm takes (mn) time to align two sequences, where m and n are the lengths of the sequences. This is a linear time complexity, as the time required to align two sequences grows linearly with the length of the sequences.\nAdditionally, Document 7 mentions that the Smith-Waterman algorithm based on dynamic programming is a well-known classical method for high precision sequence matching and has become the gold standard to evaluate sequence alignment software. This further supports the fact that the algorithm has a linear time complexity.\nIt's worth noting that the time complexity of the Smith-Waterman algorithm can be improved through the use of heuristic algorithms such as X-drop [94] and BLAST [85], as mentioned in Document 5. These algorithms can reduce the time required for alignment, but they may also sacrifice some of the accuracy of the alignment.",
    "llama-2-7b-chat-hf_fact_raw": "1. The execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences is O(m * n).\n2. The variables m and n represent the lengths of the two sequences being aligned.\n3. The Smith-Waterman algorithm is based on dynamic programming.\n4. The Smith-Waterman algorithm is considered a gold standard for evaluating sequence alignment software.\n5. Heuristic algorithms such as X-drop and BLAST can improve the time complexity of the Smith-Waterman algorithm.",
    "llama-2-7b-chat-hf_fact": [
      "The execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences is O(m * n).",
      "The variables m and n represent the lengths of the two sequences being aligned.",
      "The Smith-Waterman algorithm is based on dynamic programming.",
      "The Smith-Waterman algorithm is considered a gold standard for evaluating sequence alignment software.",
      "Heuristic algorithms such as X-drop and BLAST can improve the time complexity of the Smith-Waterman algorithm."
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 1-9, FLVCR1 is a member of the SLC49 family of transporter proteins. Specifically, it is a member of the SLC49A1 subfamily, which includes three other paralogous genes in the human genome (SLC49A2, SLC49A3, and SLC49A4). The SLC49 family contains seven members in total, with the largest, SLC25, containing 53 members. One member of this family, SLC5A4, has been found to act as a glucose sensor in the plasma membrane rather than a transporter.\nFLVCR1 is a cell surface heme exporter that is essential for erythropoiesis and systemic iron homeostasis. It is highly expressed in tissues that either transport heme (intestinal or hepatic cells) or synthesize high levels of heme (erythroid cells). FLVCR1 exports cytoplasmic heme from these cells, protecting them from heme toxicity.\nIn summary, FLVCR1 is a member of the SLC49 family of transporter proteins, specifically the SLC49A1 subfamily, and is involved in the export of cytoplasmic heme from cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. FLVCR1 is a member of the SLC49 family of transporter proteins.\n2. FLVCR1 belongs to the SLC49A1 subfamily, which includes a total of four paralogous genes in the human genome.\n3. The SLC49 family has seven members in total.\n4. FLVCR1 is a cell surface heme exporter that is essential for erythropoiesis and systemic iron homeostasis.\n5. FLVCR1 is highly expressed in tissues that transport or synthesize high levels of heme, such as intestinal, hepatic, and erythroid cells.",
    "llama-2-7b-chat-hf_fact": [
      "FLVCR1 is a member of the SLC49 family of transporter proteins.",
      "FLVCR1 belongs to the SLC49A1 subfamily, which includes a total of four paralogous genes in the human genome.",
      "The SLC49 family has seven members in total.",
      "FLVCR1 is a cell surface heme exporter that is essential for erythropoiesis and systemic iron homeostasis.",
      "FLVCR1 is highly expressed in tissues that transport or synthesize high levels of heme, such as intestinal, hepatic, and erythroid cells."
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the following are some of the interacting partners of GATA-1 that have been identified through the biotinylation tagging approach:\n1. HES6: Document 1 and Document 2 mention HES6 as an abundant cofactor expressed at the gene level during normal erythropoiesis. GATA-1 interacts with HES6, which is an essential transcriptional cofactor for human erythropoiesis.\n2. Brd3: Document 5 identifies Brd3 as an acetylated GATA-1 interacting partner. Brd3 belongs to the BET protein family and is characterized by tandem bromodomains and an extraterminal domain.\n3. PU.1: Document 6 mentions that PU.1 interacts with GATA-1 on DNA and recruits pRB and Suv39h, creating a repressed chromatin structure that is further occupied by H3K9Me3-binding protein HP1α.\n4. Chromatin remodeling proteins: Document 9 mentions that GATA-1 associates with chromatin remodeling proteins, including the CBP/p300 histone acetyltransferase and the SWI/SNF chromatin remodeling complex.\nThese interacting partners play important roles in regulating gene expression patterns during normal erythropoiesis and are essential for the functionality of GATA-1. Disruption of these interactions has been implicated in hematopoietic disorders, such as thrombocytopenia and anemia.",
    "llama-2-7b-chat-hf_fact_raw": "1. HES6 is identified as an interacting partner of GATA-1 and is expressed at the gene level during normal erythropoiesis.\n2. Brd3, which belongs to the BET protein family, is an acetylated GATA-1 interacting partner.\n3. PU.1 interacts with GATA-1 on DNA and is involved in recruiting pRB and Suv39h to create a repressed chromatin structure.\n4. GATA-1 associates with chromatin remodeling proteins, including the CBP/p300 histone acetyltransferase.\n5. The SWI/SNF chromatin remodeling complex is an interacting partner of GATA-1.",
    "llama-2-7b-chat-hf_fact": [
      "HES6 is identified as an interacting partner of GATA-1 and is expressed at the gene level during normal erythropoiesis.",
      "Brd3, which belongs to the BET protein family, is an acetylated GATA-1 interacting partner.",
      "PU.1 interacts with GATA-1 on DNA and is involved in recruiting pRB and Suv39h to create a repressed chromatin structure.",
      "GATA-1 associates with chromatin remodeling proteins, including the CBP/p300 histone acetyltransferase.",
      "The SWI/SNF chromatin remodeling complex is an interacting partner of GATA-1."
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it can be concluded that TAF10 interacts directly with the GATA1 transcription factor and plays a crucial role in controlling mouse erythropoiesis. TAF10 is a subunit of both the TFIID and the SAGA co-activator HAT complexes, and its role is indispensable for early embryonic transcription and mouse development. The interaction between TAF10 and GATA1 is observed in both human and mouse cells, and it is maintained during erythroid cell differentiation and development. The enrichment of TAF10 on the GATA1 locus in human fetal erythroid cells suggests a cross talk between canonical TFIID and SAGA complexes and cell-specific transcription activators during development and differentiation.\nIn addition, the documents mention that TAF10 interacts with other transcription factors, including GATA1, and that these transcription factors are categorized as a family due to their ability to bind to the DNA consensus sequence (A/T)GATA (A/G) by two characteristic C 4 (Cys-X 2 -Cys-X 17 -Cys-X 2 -Cys) zinc-finger motifs specific to the GATA family.\nOverall, the information provided in the documents suggests that TAF10 plays a critical role in regulating erythropoiesis by interacting with the GATA1 transcription factor and other transcription factors in a cell-specific manner.",
    "llama-2-7b-chat-hf_fact_raw": "1. TAF10 interacts directly with the GATA1 transcription factor.\n2. TAF10 plays a crucial role in controlling mouse erythropoiesis.\n3. TAF10 is a subunit of both the TFIID and the SAGA co-activator HAT complexes.\n4. The interaction between TAF10 and GATA1 is observed in both human and mouse cells.\n5. TAF10's role is indispensable for early embryonic transcription and mouse development.",
    "llama-2-7b-chat-hf_fact": [
      "TAF10 interacts directly with the GATA1 transcription factor.",
      "TAF10 plays a crucial role in controlling mouse erythropoiesis.",
      "TAF10 is a subunit of both the TFIID and the SAGA co-activator HAT complexes.",
      "The interaction between TAF10 and GATA1 is observed in both human and mouse cells.",
      "TAF10's role is indispensable for early embryonic transcription and mouse development."
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are several decision support systems for chronic pain management that have been developed and studied. Here are some of the key findings:\n1. Clinical decision support systems (CDSSs) have been shown to be effective in improving the accuracy of pain assessment and offering better support for clinical decision-making (Document 3).\n2. CDSSs integrated into electronic medical records may be useful for encouraging practice change compliant with clinical practice guidelines (Document 2).\n3. Computerized decision-support systems (CDSSs) have great potential for improving chronic pain management, particularly in the primary care setting, where physicians often lack sufficient pain-specific clinical expertise and communication skills (Document 1).\n4. There is a need for more research on the effectiveness and harms of CDSSs for referral within chronic pain practice (Document 6).\n5. A decision support system for pain management based on data imputation and statistical models has been developed and evaluated (Document 7).\n6. CDSSs aid clinicians in decision-making during diagnosis, when referring to another healthcare professional, or to commence a treatment (Document 8).\n7. There is a need for more research on the extent and range of the current evidence on CDSSs for opioid prescribing for chronic noncancer pain in primary care (Document 9).\nBased on these findings, it appears that CDSSs have the potential to improve chronic pain management by providing clinicians with evidence-based recommendations and alerts, and by improving communication and coordination of care. However, more research is needed to fully understand the effectiveness and safety of CDSSs for chronic pain management, and to identify the best approaches for implementing and evaluating these systems.",
    "llama-2-7b-chat-hf_fact_raw": "1. Clinical decision support systems (CDSSs) have been shown to be effective in improving the accuracy of pain assessment and offering better support for clinical decision-making.\n2. CDSSs integrated into electronic medical records may be useful for encouraging practice change compliant with clinical practice guidelines.\n3. Computerized decision-support systems (CDSSs) have potential for improving chronic pain management in the primary care setting.\n4. A decision support system for pain management based on data imputation and statistical models has been developed and evaluated.\n5. CDSSs aid clinicians in decision-making during diagnosis, when referring to another healthcare professional, or to commence a treatment.",
    "llama-2-7b-chat-hf_fact": [
      "Clinical decision support systems (CDSSs) have been shown to be effective in improving the accuracy of pain assessment and offering better support for clinical decision-making.",
      "CDSSs integrated into electronic medical records may be useful for encouraging practice change compliant with clinical practice guidelines.",
      "Computerized decision-support systems (CDSSs) have potential for improving chronic pain management in the primary care setting.",
      "A decision support system for pain management based on data imputation and statistical models has been developed and evaluated.",
      "CDSSs aid clinicians in decision-making during diagnosis, when referring to another healthcare professional, or to commence a treatment."
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, angiogenin is localized to the nucleus.\nDocument 2 mentions that the fused protein angiogenin-EGF was expressed in HUVECs and its subcellular localization was determined through confocal microscopy and TEM assay. The results showed that angiogenin accumulates in the pars granulosa of the nucleus, where it forms ribonucleoprotein particles.\nDocument 6 also mentions that angiogenin is localized to the pars granulosa of the nucleus, where it is concentrated in ribonucleoprotein particles.\nTherefore, based on the information provided in the documents, angiogenin is localized to the nucleus.",
    "llama-2-7b-chat-hf_fact_raw": "1. Angiogenin is localized to the nucleus.\n2. The fused protein angiogenin-EGF was expressed in HUVECs.\n3. The subcellular localization of angiogenin was determined through confocal microscopy and TEM assay.\n4. Angiogenin accumulates in the pars granulosa of the nucleus.\n5. Angiogenin is concentrated in ribonucleoprotein particles within the nucleus.",
    "llama-2-7b-chat-hf_fact": [
      "Angiogenin is localized to the nucleus.",
      "The fused protein angiogenin-EGF was expressed in HUVECs.",
      "The subcellular localization of angiogenin was determined through confocal microscopy and TEM assay.",
      "Angiogenin accumulates in the pars granulosa of the nucleus.",
      "Angiogenin is concentrated in ribonucleoprotein particles within the nucleus."
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, ranolazine appears to affect kinase signaling activation in the heart by modulating intracellular calcium levels and inflammatory signaling pathways.\nDocument 0 suggests that ranolazine inhibits the late phase of the inward sodium current in ventricular myocardial cells, which reduces intracellular calcium overload and associated diastolic contractile dysfunction. This suggests that ranolazine may have a direct effect on the regulation of calcium signaling pathways in the heart.\nDocument 1 provides an overview of the pathophysiology of heart failure, including the role of inflammation and oxidative stress in the development and progression of the disease. The document mentions that ranolazine has been shown to reduce inflammation and oxidative stress in the heart, which may contribute to its therapeutic effects in heart failure.\nDocument 2 discusses the use of ranolazine in atrial fibrillation, including its ability to improve coronary blood flow and reduce the severity of the arrhythmia. The document does not provide information on the effect of ranolazine on kinase signaling activation, but it suggests that the drug may have a direct effect on the electrical activity of the heart.\nDocument 3 provides information on the pharmacology of ranolazine, including its mechanism of action and the results of animal studies. The document suggests that ranolazine acts on the cardiac ion channels and reduces the late phase of the inward sodium current, which leads to a decrease in intracellular calcium levels and a reduction in the contractile force of the heart.\nDocument 4 presents the results of a clinical study on the use of ranolazine in heart failure patients. The study found that ranolazine improved cardiac function and reduced the risk of hospitalization for heart failure in these patients.\nDocument 5 discusses the role of calcium signaling in the regulation of cardiac contractility and the development of heart failure. The document suggests that dysregulation of calcium signaling pathways is central to the pathophysiology of heart failure and that drugs that target these pathways may have therapeutic effects in the disease.\nDocument 6 provides information on the role of the NF",
    "llama-2-7b-chat-hf_fact_raw": "1. Ranolazine inhibits the late phase of the inward sodium current in ventricular myocardial cells.\n2. Inhibition of the late phase of the inward sodium current by ranolazine reduces intracellular calcium overload and associated diastolic contractile dysfunction.\n3. Ranolazine has been shown to reduce inflammation and oxidative stress in the heart.\n4. Ranolazine can improve coronary blood flow and reduce the severity of atrial fibrillation.\n5. Ranolazine improved cardiac function and reduced the risk of hospitalization for heart failure in patients, according to a clinical study.",
    "llama-2-7b-chat-hf_fact": [
      "Ranolazine inhibits the late phase of the inward sodium current in ventricular myocardial cells.",
      "Inhibition of the late phase of the inward sodium current by ranolazine reduces intracellular calcium overload and associated diastolic contractile dysfunction.",
      "Ranolazine has been shown to reduce inflammation and oxidative stress in the heart.",
      "Ranolazine can improve coronary blood flow and reduce the severity of atrial fibrillation.",
      "Ranolazine improved cardiac function and reduced the risk of hospitalization for heart failure in patients, according to a clinical study."
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it appears that the regulation of Vsr endonuclease is growth phase dependent in Escherichia coli.\nDocument 1 and Document 2 suggest that Vsr endonucase levels are decreased during the log phase of growth, which may contribute to the mutability of 5-methylcytosine. Document 3 provides evidence that the key enzyme in the VSP system, Vsr endonuclease, can cleave mismatched DNA independently of accessory proteins.\nDocument 5 shows that the cellular levels of Dcm, another cytosine methylase, are independent of growth phase, suggesting that the regulation of Vsr endonucase may be specific to this enzyme.\nDocument 6 describes the growth phase-dependent production of Vsr, which is independent of the dcm promoter and operon structure. Document 7 demonstrates cooperation between MMR and VSP repair, which involves the stimulation of Vsr endonuclease in a MutS- and MutL-dependent manner.\nDocument 8 explains that cleavage by Vsr endonuclease is a major component of the VSR pathway, which repairs damaged methylated cytosines. Document 9 provides further evidence of the role of Vsr endonuclease in repairing mismatched TG base pairs.\nBased on these findings, it appears that the regulation of Vsr endonuclease is growth phase dependent in Escherichia coli, and that this enzyme plays a critical role in the repair of methylated cytosines and other DNA mismatches.",
    "llama-2-7b-chat-hf_fact_raw": "1. The regulation of Vsr endonuclease in Escherichia coli is growth phase dependent.\n2. Vsr endonucase levels decrease during the log phase of growth in Escherichia coli.\n3. Vsr endonuclease can cleave mismatched DNA independently of accessory proteins.\n4. The cellular levels of Dcm, a cytosine methylase, are independent of the growth phase in Escherichia coli.\n5. Vsr endonuclease plays a critical role in the repair of methylated cytosines and other DNA mismatches in Escherichia coli.",
    "llama-2-7b-chat-hf_fact": [
      "The regulation of Vsr endonuclease in Escherichia coli is growth phase dependent.",
      "Vsr endonucase levels decrease during the log phase of growth in Escherichia coli.",
      "Vsr endonuclease can cleave mismatched DNA independently of accessory proteins.",
      "The cellular levels of Dcm, a cytosine methylase, are independent of the growth phase in Escherichia coli.",
      "Vsr endonuclease plays a critical role in the repair of methylated cytosines and other DNA mismatches in Escherichia coli."
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are several computational tools available for predicting the structure and topology of beta-barrel transmembrane proteins. Here are some of the tools mentioned in the documents:\n1. TMBHMM: This is a hidden Markov model-based method for predicting the structure and topology of beta-barrel transmembrane proteins. It can also predict the exposure status of residues predicted to be in the membrane. TMBHMM has been implemented as a web server and has been compared with other methods in the literature.\n2. BetAware-Deep: This is a deep learning-based method for predicting the topology of beta-barrel transmembrane proteins. It outperforms other state-of-the-art methods in predicting the correct topologies of proteins.\n3. DeepTMHMM: This is a deep learning encoder-decoder sequence-to-sequence model that takes a protein sequence as input and outputs the corresponding per-residue transmembrane topology.\n4. Transmembrane β-barrel proteins occur only in the outer membranes of bacteria, mitochondria, and chloroplasts. They assume astonishingly regular conformations giving rise to numerous rules for their construction.\n5. Arne Elofsson's group has developed a method for predicting the topology of transmembrane proteins using a combination of sequence analysis and structural information.\n6. The rapid development of deep learning-based methods has considerably advanced the field of protein structure prediction.\n7. Cyc2 is a protein that contains transmembrane beta barrel (TMBB) domains that act as pores to control intercellular transport.\nThese tools and methods can be used to predict the structure and topology of beta-barrel transmembrane proteins, including their transmembrane segments, exposure status, and overall structure. They can also be used to identify the presence of TMBB domains in proteins and predict their function.",
    "llama-2-7b-chat-hf_fact_raw": "1. TMBHMM is a computational tool that uses a hidden Markov model to predict the structure and topology of beta-barrel transmembrane proteins.\n2. BetAware-Deep is a deep learning-based method for predicting the topology of beta-barrel transmembrane proteins.\n3. DeepTMHMM is a deep learning encoder-decoder sequence-to-sequence model designed for per-residue transmembrane topology prediction.\n4. Transmembrane β-barrel proteins are found in the outer membranes of bacteria, mitochondria, and chloroplasts.\n5. Arne Elofsson's group has developed a method for predicting the topology of transmembrane proteins that combines sequence analysis with structural information.",
    "llama-2-7b-chat-hf_fact": [
      "TMBHMM is a computational tool that uses a hidden Markov model to predict the structure and topology of beta-barrel transmembrane proteins.",
      "BetAware-Deep is a deep learning-based method for predicting the topology of beta-barrel transmembrane proteins.",
      "DeepTMHMM is a deep learning encoder-decoder sequence-to-sequence model designed for per-residue transmembrane topology prediction.",
      "Transmembrane β-barrel proteins are found in the outer membranes of bacteria, mitochondria, and chloroplasts.",
      "Arne Elofsson's group has developed a method for predicting the topology of transmembrane proteins that combines sequence analysis with structural information."
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the Galassi classification is used to classify arachnoid cysts in the middle cranial fossa. The Galassi classification system was developed by Galassi et al. in 1982 and is still the most widely used system for classifying these types of cysts.\nAccording to the information provided, there are four types of arachnoid cysts in the middle cranial fossa based on the Galassi classification:\n1. Type I cysts are typically small and asymptomatic, located in the anterior middle cranial fossa.\n2. Type II cysts are larger and may cause symptoms such as headache, nausea, and vomiting.\n3. Type III cysts are the largest and most symptomatic, causing compression of surrounding structures such as the brain, nerves, and blood vessels.\n4. Type IV cysts are rare and located in the posterior middle cranial fossa.\nIt is important to note that the Galassi classification is not used to classify arachnoid cysts in other locations in the brain, such as the spinal cord.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Galassi classification is used to classify arachnoid cysts in the middle cranial fossa.\n2. The Galassi classification system was developed by Galassi et al. in 1982.\n3. Type I arachnoid cysts are typically small and asymptomatic, located in the anterior middle cranial fossa.\n4. Type II arachnoid cysts are larger and may cause symptoms such as headache, nausea, and vomiting.\n5. Type III arachnoid cysts are the largest and most symptomatic, causing compression of surrounding structures such as the brain, nerves, and blood vessels.",
    "llama-2-7b-chat-hf_fact": [
      "The Galassi classification is used to classify arachnoid cysts in the middle cranial fossa.",
      "The Galassi classification system was developed by Galassi et al. in 1982.",
      "Type I arachnoid cysts are typically small and asymptomatic, located in the anterior middle cranial fossa.",
      "Type II arachnoid cysts are larger and may cause symptoms such as headache, nausea, and vomiting.",
      "Type III arachnoid cysts are the largest and most symptomatic, causing compression of surrounding structures such as the brain, nerves, and blood vessels."
    ]
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the common features of Shapiro syndrome are:\n1. Spontaneous periodic hypothermia: This is the most common feature of Shapiro syndrome, and it is characterized by recurrent episodes of hypothermia that occur without any obvious trigger.\n2. Hyperhidrosis: Patients with Shapiro syndrome experience excessive sweating, which can occur at any time and is not limited to the hypothermic episodes.\n3. Corpus callosum agenesis: This is a hallmark feature of Shapiro syndrome, and it refers to the absence of the corpus callosum, a bundle of nerve fibers that connects the two hemispheres of the brain.\n4. Recurrent episodes of hypothermia: These episodes can occur at any time and are not limited to any specific age or sex.\n5. Lethargy and confusion: Some patients with Shapiro syndrome may experience lethargy and confusion during the hypothermic episodes.\n6. Weight loss: Some patients may experience weight loss due to the frequent episodes of hypothermia.\n7. Dysregulation of the hypothalamic-pituitary-adrenal axis: This can lead to changes in the body's temperature regulation and sweat production.\n8. Rarely, other symptoms such as seizures, developmental delays, and intellectual disability may also occur.\nIt is important to note that the symptoms of Shapiro syndrome can vary in severity and frequency, and some patients may have a more mild or severe form of the condition. The exact cause of Shapiro syndrome is still unknown, but it is believed to be related to genetic mutations or other factors that affect the development of the brain and the regulation of body temperature.",
    "llama-2-7b-chat-hf_fact_raw": "1. Shapiro syndrome is characterized by spontaneous periodic hypothermia without any obvious trigger.\n2. Patients with Shapiro syndrome experience excessive sweating, known as hyperhidrosis.\n3. A hallmark feature of Shapiro syndrome is the absence of the corpus callosum, known as corpus callosum agenesis.\n4. Recurrent episodes of hypothermia in Shapiro syndrome can occur at any time and are not limited to any specific age or sex.\n5. Some patients with Shapiro syndrome may experience lethargy and confusion during hypothermic episodes.",
    "llama-2-7b-chat-hf_fact": [
      "Shapiro syndrome is characterized by spontaneous periodic hypothermia without any obvious trigger.",
      "Patients with Shapiro syndrome experience excessive sweating, known as hyperhidrosis.",
      "A hallmark feature of Shapiro syndrome is the absence of the corpus callosum, known as corpus callosum agenesis.",
      "Recurrent episodes of hypothermia in Shapiro syndrome can occur at any time and are not limited to any specific age or sex.",
      "Some patients with Shapiro syndrome may experience lethargy and confusion during hypothermic episodes."
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the disease that is linked to mutations within BRAG1 is X-linked intellectual disability (XLID). This is because mutations in the BRAG1 gene have been identified in families with XLID, and these mutations have been found to map to either the catalytic domain or an IQ-like motif. The pathophysiological basis of these mutations remains unknown, but they are believed to play a role in the development of XLID.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations within BRAG1 are linked to X-linked intellectual disability (XLID).\n2. Mutations in the BRAG1 gene have been identified in families with XLID.\n3. These mutations in BRAG1 map to either the catalytic domain or an IQ-like motif.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations within BRAG1 are linked to X-linked intellectual disability (XLID).",
      "Mutations in the BRAG1 gene have been identified in families with XLID.",
      "These mutations in BRAG1 map to either the catalytic domain or an IQ-like motif."
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the main inhibitor of protein phosphatase 1 (PP1) is Inhibitor-2 (I-2). Document 4 mentions that I-2 is a prototypic inhibitor of PP1, and Document 6 specifically highlights I-2 as a key inhibitor of PP1. Additionally, Document 7 mentions that NIPP1 (nuclear inhibitor of protein Ser/Thr phosphatase-1) is also an interactor of PP1, but it does not appear to be a main inhibitor of the enzyme.\nIt is worth noting that there are other inhibitors of PP1 mentioned in the documents, such as Inhibitor-1 (I-1) and DARPP-32 (dopamine- and cAMP-regulated phosphoprotein; molecular weight 32 kDa), but their roles and functions in regulating PP1 are not as clearly defined as those of I-2.",
    "llama-2-7b-chat-hf_fact_raw": "1. Inhibitor-2 (I-2) is the main inhibitor of protein phosphatase 1 (PP1).\n2. Document 4 describes I-2 as a prototypic inhibitor of PP1.\n3. Document 6 highlights I-2 as a key inhibitor of PP1.\n4. NIPP1 (nuclear inhibitor of protein Ser/Thr phosphatase-1) is an interactor of PP1 but not the main inhibitor.\n5. Inhibitor-1 (I-1) and DARPP-32 are other inhibitors of PP1, but their roles are not as clearly defined as I-2's.",
    "llama-2-7b-chat-hf_fact": [
      "Inhibitor-2 (I-2) is the main inhibitor of protein phosphatase 1 (PP1).",
      "Document 4 describes I-2 as a prototypic inhibitor of PP1.",
      "Document 6 highlights I-2 as a key inhibitor of PP1.",
      "NIPP1 (nuclear inhibitor of protein Ser/Thr phosphatase-1) is an interactor of PP1 but not the main inhibitor.",
      "Inhibitor-1 (I-1) and DARPP-32 are other inhibitors of PP1, but their roles are not as clearly defined as I-2's."
    ]
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-2-7b-chat-hf_response": "Based on the provided documents, the mechanisms that underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis are:\n1. Non-lethal selective pressure: The documents suggest that stationary-phase mutations may arise in response to non-lethal selective pressure, such as nutrient-limited environments (Documents 1 and 6).\n2. Mismatch DNA repair (MMR) system: The documents suggest that the MMR system may play a role in regulating the rate of mutations under stressful conditions (Document 9).\n3. Multiple mechanisms: The documents suggest that multiple mechanisms are involved in generating mutations in stationary-phase bacteria (Documents 2, 4, and 7).\n4. Adaptive mutagenic process: The documents suggest that an adaptive mutagenic process occurs in nongrowing Bacillus subtilis cells under stress, and that this process is likely regulated by multiple mechanisms (Documents 2, 4, and 7).\nOverall, the mechanisms underlying adaptive mutagenesis in Bacillus subtilis involve a complex interplay of genetic and environmental factors, including non-lethal selective pressure, the MMR system, and multiple mutational mechanisms.",
    "llama-2-7b-chat-hf_fact_raw": "1. Stationary-phase mutations in Bacillus subtilis may arise in response to non-lethal selective pressure such as nutrient-limited environments.\n2. The mismatch DNA repair (MMR) system may regulate the rate of mutations in Bacillus subtilis under stressful conditions.\n3. Multiple mechanisms are involved in generating mutations in stationary-phase Bacillus subtilis.\n4. An adaptive mutagenic process occurs in nongrowing Bacillus subtilis cells under stress.\n5. The adaptive mutagenic process in Bacillus subtilis is likely regulated by multiple mechanisms.",
    "llama-2-7b-chat-hf_fact": [
      "Stationary-phase mutations in Bacillus subtilis may arise in response to non-lethal selective pressure such as nutrient-limited environments.",
      "The mismatch DNA repair (MMR) system may regulate the rate of mutations in Bacillus subtilis under stressful conditions.",
      "Multiple mechanisms are involved in generating mutations in stationary-phase Bacillus subtilis.",
      "An adaptive mutagenic process occurs in nongrowing Bacillus subtilis cells under stress.",
      "The adaptive mutagenic process in Bacillus subtilis is likely regulated by multiple mechanisms."
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, erucism is caused by the toxins released by caterpillar bristles when they enter the skin. The toxins contain thermolabile proteins, proteolytic enzymes, and histamine, which can cause inflammation, pain, heat, redness, and itching. The bristles are hollow and when they enter the skin, they release these toxins, leading to the symptoms of erucism. The documents mention several species of caterpillars that are known to cause erucism, including the puss caterpillar (Megalopyge opercularis) and the white flannel moth caterpillar (Norape ovina). The documents also mention that some species of ants and aquatic insects of the Belostomatidae family can cause painful bites and stings.",
    "llama-2-7b-chat-hf_fact_raw": "1. Erucism is caused by toxins released by caterpillar bristles when they enter the skin.\n2. The toxins that cause erucism include thermolabile proteins, proteolytic enzymes, and histamine.\n3. Symptoms of erucism include inflammation, pain, heat, redness, and itching.\n4. The puss caterpillar (Megalopyge opercularis) is known to cause erucism.\n5. The white flannel moth caterpillar (Norape ovina) is also known to cause erucism.",
    "llama-2-7b-chat-hf_fact": [
      "Erucism is caused by toxins released by caterpillar bristles when they enter the skin.",
      "The toxins that cause erucism include thermolabile proteins, proteolytic enzymes, and histamine.",
      "Symptoms of erucism include inflammation, pain, heat, redness, and itching.",
      "The puss caterpillar (Megalopyge opercularis) is known to cause erucism.",
      "The white flannel moth caterpillar (Norape ovina) is also known to cause erucism."
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the indications for hydrochlorothiazide are:\n1. Treatment of high blood pressure (hypertension)\n2. Treatment of fluid retention (edema) in people with congestive heart failure, cirrhosis of the liver, or kidney disorders, or edema caused by taking steroids or estrogen.\nHydrochlorothiazide is contraindicated in individuals who are unable to urinate. It is important to note that hydrochlorothiazide is a diuretic, which means it increases urine production and can cause dehydration if not properly monitored.\nThe drug interactions associated with hydrochlorothiazide include:\n1. Aminolevulinic acid oral\n2. Aminolevulinic acid topical\n3. Estrogen\n4. Corticosteroids\nThe absorption of hydrochlorothiazide is affected by food intake, with a lower bioavailability when taken with a meal. The volume of distribution of hydrochlorothiazide varies widely between studies, with values ranging from 0.83-4 L/kg.\nThe adverse reactions and side effects of hydrochlorothiazide include:\n1. Dizziness\n2. Lightheadedness\n3. Fatigue\n4. Headache\n5. Nausea\n6. Vomiting\n7. Diarrhea\n8. Constipation\n9. Muscle weakness\n10. Rash\nOverdosage of hydrochlorothiazide can lead to excessive diuresis, dehydration, and electrolyte imbalances. The dosage and administration of hydrochlorothiazide should be carefully monitored to avoid these complications.\nIn summary, hydrochlorothiazide is a diuretic medication used to treat high blood pressure and fluid retention in various medical conditions. It is important to be aware of the drug interactions, adverse reactions, and proper dosing and administration of hydrochlorothiazide to ensure safe and effective treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hydrochlorothiazide is used for the treatment of high blood pressure (hypertension).\n2. Hydrochlorothiazide is used to treat fluid retention (edema) in people with congestive heart failure, cirrhosis of the liver, or kidney disorders.\n3. Hydrochlorothiazide is contraindicated in individuals who are unable to urinate.\n4. Hydrochlorothiazide is a diuretic that increases urine production.\n5. Overdosage of hydrochlorothiazide can lead to excessive diuresis, dehydration, and electrolyte imbalances.",
    "llama-2-7b-chat-hf_fact": [
      "Hydrochlorothiazide is used for the treatment of high blood pressure (hypertension).",
      "Hydrochlorothiazide is used to treat fluid retention (edema) in people with congestive heart failure, cirrhosis of the liver, or kidney disorders.",
      "Hydrochlorothiazide is contraindicated in individuals who are unable to urinate.",
      "Hydrochlorothiazide is a diuretic that increases urine production.",
      "Overdosage of hydrochlorothiazide can lead to excessive diuresis, dehydration, and electrolyte imbalances."
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, silicon has not been directly mentioned as a treatment for urinary incontinence. However, there are some mentions of materials used in pessaries, which are vaginal support devices that can be used to treat symptoms of urinary incontinence. These materials include silicone or plastic.\nIt is worth noting that while silicon is not specifically mentioned as a treatment for urinary incontinence, there are some studies and articles that discuss the use of silicone-based materials in the treatment of urinary incontinence. For example, one study published in the Journal of Urology found that the use of a silicone-coated pessary was effective in improving symptoms of urinary incontinence in women (1).\nIn summary, while silicon is not a commonly discussed treatment for urinary incontinence, there is some evidence to suggest that silicone-based materials can be effective in the treatment of this condition. However, it is important to consult with a healthcare professional for proper diagnosis and treatment.\nReferences:\n1. Rahn DD, et al. Pelvic floor symptoms improve similarly after pessary and behavioral treatment for stress incontinence. Female Pelvic Med Reconstr Surg. 2017;23(3):157-163. doi:10.1097/SPV.0000000000000370",
    "llama-2-7b-chat-hf_fact_raw": "1. Pessaries, which are vaginal support devices, can be used to treat symptoms of urinary incontinence.\n2. Materials used in pessaries include silicone or plastic.\n3. A study published in the Journal of Urology reported that a silicone-coated pessary was effective in improving symptoms of urinary incontinence in women.\n4. The study mentioned is referenced as: Rahn DD, et al. Pelvic floor symptoms improve similarly after pessary and behavioral treatment for stress incontinence. Female Pelvic Med Reconstr Surg. 2017;23(3):157-163. doi:10.1097/SPV.0000000000000370.",
    "llama-2-7b-chat-hf_fact": [
      "Pessaries, which are vaginal support devices, can be used to treat symptoms of urinary incontinence.",
      "Materials used in pessaries include silicone or plastic.",
      "A study published in the Journal of Urology reported that a silicone-coated pessary was effective in improving symptoms of urinary incontinence in women.",
      "The study mentioned is referenced as: Rahn DD, et al. Pelvic floor symptoms improve similarly after pessary and behavioral treatment for stress incontinence. Female Pelvic Med Reconstr Surg. 2017;23(3):157-163. doi:10.1097/SPV.0000000000000370."
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, there is no clear association between the moon cycle and the risk of intracranial aneurysm rupture. While some studies have investigated the potential relationship between lunar illumination and aneurysm rupture, the results have been inconsistent and inconclusive.\nOne study found that there was no significant association between the lunar phase and the incidence of intracranial aneurysm rupture (1). Another study suggested that there may be a myth surrounding the association between lunar phase and aneurysm rupture, and that further research is needed to clarify the relationship (2).\nA more recent study examined the relationship between wall shear stress (WSS) and rupture risk in intracranial aneurysms, and found that WSS was significantly associated with higher risk of rupture (3). The study also identified other factors that may contribute to aneurysm rupture, such as aneurysm dome size, COX-2 expression, and wall motion patterns.\nOverall, while the moon cycle may have some cultural or symbolic significance, there is no scientific evidence to support a direct association between the moon cycle and the risk of intracranial aneurysm rupture. The risk of aneurysm rupture is determined by a complex interplay of genetic, environmental, and hemodynamic factors, and further research is needed to fully understand these factors and to develop effective strategies for preventing and treating aneurysm rupture.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no clear association between the moon cycle and the risk of intracranial aneurysm rupture based on the information provided.\n2. Some studies have investigated the potential relationship between lunar illumination and aneurysm rupture, but the results are inconsistent and inconclusive.\n3. One study found no significant association between the lunar phase and the incidence of intracranial aneurysm rupture.\n4. A more recent study found that wall shear stress (WSS) was significantly associated with a higher risk of intracranial aneurysm rupture.\n5. Factors such as aneurysm dome size, COX-2 expression, and wall motion patterns may contribute to aneurysm rupture.",
    "llama-2-7b-chat-hf_fact": [
      "There is no clear association between the moon cycle and the risk of intracranial aneurysm rupture based on the information provided.",
      "Some studies have investigated the potential relationship between lunar illumination and aneurysm rupture, but the results are inconsistent and inconclusive.",
      "One study found no significant association between the lunar phase and the incidence of intracranial aneurysm rupture.",
      "A more recent study found that wall shear stress (WSS) was significantly associated with a higher risk of intracranial aneurysm rupture.",
      "Factors such as aneurysm dome size, COX-2 expression, and wall motion patterns may contribute to aneurysm rupture."
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it is clear that HuR protein does regulate the splicing process.\nDocument 1 shows that HuR regulates the splicing and abundance of mRNAs required for entry into and transition through the S phase of the cell cycle, and modulates a gene signature associated with cell cycle progression. This suggests that HuR plays a role in regulating the splicing of mRNAs involved in cell cycle progression.\nDocument 2 shows that Hu proteins, including HuR, regulate splicing through binding to AU-rich elements on pre-mRNA. This suggests that HuR binds to specific sequences on pre-mRNAs to regulate their splicing.\nDocument 3 shows that HuR promotes Fas exon 6 skipping by binding to an exonic splicing silencer. This suggests that HuR can regulate the splicing of specific pre-mRNAs by binding to specific sequences and modulating their splicing.\nDocument 4 highlights the importance of RNA metabolism, including splicing, in eukaryotic gene expression and cellular function. This suggests that HuR is one of the many RNA-binding proteins that play a critical role in regulating gene expression through splicing.\nDocument 7 shows that RNA-binding proteins bound to nascent RNA can alter chromatin composition in ways that impact elongation and splicing. This suggests that HuR may also regulate splicing by altering chromatin structure.\nFinally, Document 9 highlights the importance of alternative splicing in immune cell development and regulation of immune activity. This suggests that HuR may play a role in regulating the splicing of genes involved in immune cell development and function.\nIn conclusion, based on the information provided in the documents, it is clear that HuR protein regulates the splicing process by binding to specific sequences on pre-mRNAs and modulating their splicing. HuR plays a critical role in regulating gene expression through splicing, and its dysregulation can lead to a variety of diseases, including cancer and immune disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. HuR protein regulates the splicing and abundance of mRNAs required for entry into and transition through the S phase of the cell cycle.\n2. HuR protein modulates a gene signature associated with cell cycle progression.\n3. Hu proteins, including HuR, regulate splicing by binding to AU-rich elements on pre-mRNA.\n4. HuR promotes Fas exon 6 skipping by binding to an exonic splicing silencer.\n5. HuR may play a role in regulating the splicing of genes involved in immune cell development and function.",
    "llama-2-7b-chat-hf_fact": [
      "HuR protein regulates the splicing and abundance of mRNAs required for entry into and transition through the S phase of the cell cycle.",
      "HuR protein modulates a gene signature associated with cell cycle progression.",
      "Hu proteins, including HuR, regulate splicing by binding to AU-rich elements on pre-mRNA.",
      "HuR promotes Fas exon 6 skipping by binding to an exonic splicing silencer.",
      "HuR may play a role in regulating the splicing of genes involved in immune cell development and function."
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-2-7b-chat-hf_response": "Based on the provided documents, the known functions of the prothymosin alpha c-terminal peptide are:\n1. Immunomodulation: ProTα and its C-terminal decapeptide (ProTα(100–109)) have been shown to act as immunomodulators in vitro, promoting T helper type 1 (Th1) responses.\n2. Regulation of cell death: ProTα has been implicated in regulated cell death (RCD), specifically immunogenic cell death (ICD), which is a type of RCD that occurs in response to infection or injury.\n3. Thymus-related functions: ProTα is produced in the thymus and plays a role in the generation and maintenance of T cells.\n4. Pleiotropy and redundancy: ProTα is a biologic response modifier (BRM) that regulates, among others, the type, duration, and intensity of immune responses, and is characterized by pleiotropy and redundancy.\n5. Cellular localization: The function of ProTα seems to be determined by its cellular localization, with different functions in different cell types.\n6. Proteolytic modifications: ProTα undergoes two types of protease proteolytic modifications, which can provide insight into its interactions with other molecules and its roles.\n7. Danger-associated molecular patterns (DAMPs): ProTα and its C-terminal peptide have been shown to act as immunomodulators in response to DAMPs.\n8. Thymic peptides: ProTα is a member of the α-thymosin family of peptides, which have been studied for their immunostimulating properties.\nOverall, the prothymosin alpha c-terminal peptide appears to play a complex and multifaceted role in the immune system, with functions that include immunomodulation, regulation of cell death, and thymus-related activities.",
    "llama-2-7b-chat-hf_fact_raw": "1. Prothymosin alpha c-terminal peptide (ProTα(100–109)) acts as an immunomodulator promoting T helper type 1 (Th1) responses in vitro.\n2. Prothymosin alpha is implicated in regulated cell death, specifically immunogenic cell death, which occurs in response to infection or injury.\n3. Prothymosin alpha is produced in the thymus and is involved in the generation and maintenance of T cells.\n4. Prothymosin alpha functions as a biologic response modifier that regulates the type, duration, and intensity of immune responses.\n5. Prothymosin alpha's function is influenced by its cellular localization, with different functions in different cell types.",
    "llama-2-7b-chat-hf_fact": [
      "Prothymosin alpha c-terminal peptide (ProTα(100–109)) acts as an immunomodulator promoting T helper type 1 (Th1) responses in vitro.",
      "Prothymosin alpha is implicated in regulated cell death, specifically immunogenic cell death, which occurs in response to infection or injury.",
      "Prothymosin alpha is produced in the thymus and is involved in the generation and maintenance of T cells.",
      "Prothymosin alpha functions as a biologic response modifier that regulates the type, duration, and intensity of immune responses.",
      "Prothymosin alpha's function is influenced by its cellular localization, with different functions in different cell types."
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the peptide that plays a pivotal role in human cystatin C fibrillization is LQVVR. This peptide was identified in Document 3, which states that the (47)LQVVR(51) peptide seems to have an important role in HCC fibrillization. Additionally, Document 9 mentions that the LQVVR peptide forms amyloid fibrils in vitro, further supporting its role in HCC fibrillization.",
    "llama-2-7b-chat-hf_fact_raw": "1. The peptide LQVVR plays a pivotal role in human cystatin C fibrillization.\n2. The peptide sequence (47)LQVVR(51) is specifically identified as important in HCC fibrillization.\n3. The LQVVR peptide can form amyloid fibrils in vitro.",
    "llama-2-7b-chat-hf_fact": [
      "The peptide LQVVR plays a pivotal role in human cystatin C fibrillization.",
      "The peptide sequence (47)LQVVR(51) is specifically identified as important in HCC fibrillization.",
      "The LQVVR peptide can form amyloid fibrils in vitro."
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, there is evidence to suggest that the concentration of protein HIF-1α may increase after the administration of the cytoprotective prodrug \"amifostine\" (ethyol).\nDocument 1 mentions that recent advances in cancer biology have highlighted the HIF-1α pathway as a crucial survival pathway, and that novel strategies of cancer therapy could be developed targeting this pathway. This suggests that HIF-1α is involved in cellular responses to hypoxia and may play a role in cancer survival.\nDocument 2 mentions that toxic metal exposure may modulate HIF-1α signal transduction pathway, although the existing data are scarce. This suggests that HIF-1α may be involved in cellular responses to toxic metals, and that its activity may be modulated by exposure to these metals.\nDocument 3 provides a comprehensive overview of the mechanisms of hypoxia signaling activation, the control of HIF signaling, and the function of HIF signaling in human health and diseases. This document does not specifically mention the effect of amifostine on HIF-1α concentration, but it does provide a framework for understanding the regulation of HIF-1α activity under different conditions.\nDocument 4 reports on the replacement of HIF-1α by HIF-2α in human umbilical vein endothelial cells (HUVECs) exposed to hypoxia. This suggests that HIF-1α may be involved in cellular responses to hypoxia, and that its activity may be modulated by exposure to hypoxia.\nDocument 5 mentions that during stroke, hypoxia-inducible factor-1 (HIF-1) is involved in the pathological process by regulating multiple pathways, such as glucose metabolism, angiogenesis, erythropoiesis, and cell survival. This suggests that HIF-1α may play a role in the response to hypoxia in the context of stroke.\nDocument 6 provides an overview of the role of HIF-1 in response to hypoxia, including its involvement in glucose metabolism, angiogenesis,",
    "llama-2-7b-chat-hf_fact_raw": "1. The concentration of protein HIF-1α may increase after the administration of the cytoprotective prodrug \"amifostine\" (ethyol).\n2. HIF-1α is involved in cellular responses to hypoxia and may play a role in cancer survival.\n3. HIF-1α may be involved in cellular responses to toxic metals, and its activity may be modulated by exposure to these metals.\n4. HIF-1α may be replaced by HIF-2α in human umbilical vein endothelial cells (HUVECs) exposed to hypoxia.\n5. HIF-1α is involved in the pathological process of stroke by regulating multiple pathways, such as glucose metabolism, angiogenesis, erythropoiesis, and cell survival.",
    "llama-2-7b-chat-hf_fact": [
      "The concentration of protein HIF-1α may increase after the administration of the cytoprotective prodrug \"amifostine\" (ethyol).",
      "HIF-1α is involved in cellular responses to hypoxia and may play a role in cancer survival.",
      "HIF-1α may be involved in cellular responses to toxic metals, and its activity may be modulated by exposure to these metals.",
      "HIF-1α may be replaced by HIF-2α in human umbilical vein endothelial cells (HUVECs) exposed to hypoxia.",
      "HIF-1α is involved in the pathological process of stroke by regulating multiple pathways, such as glucose metabolism, angiogenesis, erythropoiesis, and cell survival."
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, Set7 deposits the histone mark H4K20me1.",
    "llama-2-7b-chat-hf_fact_raw": "1. Set7 deposits the histone mark H4K20me1.",
    "llama-2-7b-chat-hf_fact": [
      "Set7 deposits the histone mark H4K20me1."
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the protein hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact": [
      "The protein hepcidin has 4 disulfide bridges."
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the localization of the protein encoded by the gene DNAJC11 is likely to be cytoplasmic.\nDocument 1 mentions that NLS-dependent protein trafficking from the cytoplasm into the nucleus is a facilitated process mediated by members of the importin (also referred to as karyopherin) family. This suggests that proteins can be imported into the nucleus through a process that involves the Ran GTPase. However, there is no information in the documents to suggest that DNAJC11 is specifically localized to the nucleus.\nDocument 2 mentions that mRNA transcripts that encode non-membrane proteins are not evenly distributed across the cytoplasm, but instead are enriched in functional groups in non-membranous compartments. This suggests that the localization of proteins encoded by DNAJC11 may also be influenced by the localization of its mRNA transcripts.\nDocument 4 mentions that the functions of proteins are mainly determined by their subcellular localizations in cells. However, there is no information in the documents to suggest that DNAJC11 has a specific subcellular localization.\nDocument 6 mentions that the dystrophin complex is localized to the sarcolemma, but there is no information in the documents to suggest that DNAJC11 is a component of the dystrophin complex.\nDocument 7 mentions that approximately 99% of mitochondrial proteins are encoded by nuclear genes and depend on specific targeting signals to direct them from the cytosol to mitochondria. However, there is no information in the documents to suggest that DNAJC11 is a mitochondrial protein.\nIn summary, based on the information provided in the documents, there is no clear evidence to suggest that the protein encoded by DNAJC11 is localized to any specific subcellular compartment, including the nucleus.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein encoded by the gene DNAJC11 is likely to be cytoplasmic.\n2. NLS-dependent protein trafficking from the cytoplasm into the nucleus is mediated by members of the importin family.\n3. mRNA transcripts that encode non-membrane proteins are enriched in functional groups in non-membranous compartments.\n4. The functions of proteins are mainly determined by their subcellular localizations in cells.\n5. Approximately 99% of mitochondrial proteins are encoded by nuclear genes and require specific targeting signals for mitochondrial localization.",
    "llama-2-7b-chat-hf_fact": [
      "The protein encoded by the gene DNAJC11 is likely to be cytoplasmic.",
      "NLS-dependent protein trafficking from the cytoplasm into the nucleus is mediated by members of the importin family.",
      "mRNA transcripts that encode non-membrane proteins are enriched in functional groups in non-membranous compartments.",
      "The functions of proteins are mainly determined by their subcellular localizations in cells.",
      "Approximately 99% of mitochondrial proteins are encoded by nuclear genes and require specific targeting signals for mitochondrial localization."
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-2-7b-chat-hf_response": "Based on the provided documents, it is clear that ultraconserved elements (UCEs) are depleted among copy number variants (CNVs) in the human genome. Documents 0, 1, 3, 5, and 7 all suggest that UCEs are significantly underrepresented in CNVs, indicating that these regions are preferentially lost or deleted during the process of CNV formation.\nFor example, Document 0 states that \"Mammalian ultraconserved elements are strongly depleted among segmental duplications and copy number variants.\" Similarly, Document 1 states that \"Mammalian ultraconserved elements are strongly depleted among segmental duplications and copy number variants Adnan Derti1–4, Frederick P Roth1,5, George M Church2,3 & C-ting Wu6.\" These findings are consistent across multiple species, as Document 3 notes that \"Across the human genome, there are nearly 500 ‘ultraconserved’ elements: regions of at least 200 contiguous nucleotides that are perfectly conserved in both the mouse and rat.\"\nThe depletion of UCEs among CNVs is thought to be due to the preferential loss or deletion of these regions during the process of CNV formation. Document 5 suggests that \"Ultraconserved elements (UCEs) are strongly depleted from segmental duplications and copy number variations (CNVs) in the human genome, suggesting that deletion or duplication of a UCE can be deleterious to the mammalian cell.\" Similarly, Document 7 states that \"Mammalian ultraconserved elements are strongly depleted among segmental duplications and copy number variants Nat. Genet. , 38 ( 2006 ) , pp. 1216 - 1220 CrossRef View in Scopus Google Scholar.\"\nIn summary, the evidence from these documents suggests that UCEs are depleted among CNVs in the human genome, and that this depletion is likely due to the preferential loss or deletion of these regions during the process of CNV formation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ultraconserved elements (UCEs) are depleted among copy number variants (CNVs) in the human genome.\n2. Documents 0, 1, 3, 5, and 7 suggest that UCEs are significantly underrepresented in CNVs.\n3. Ultraconserved elements are regions of at least 200 contiguous nucleotides that are perfectly conserved in both the mouse and rat genomes.\n4. The depletion of UCEs among CNVs is thought to be due to the preferential loss or deletion of these regions during CNV formation.\n5. Deletion or duplication of a UCE can be deleterious to the mammalian cell.",
    "llama-2-7b-chat-hf_fact": [
      "Ultraconserved elements (UCEs) are depleted among copy number variants (CNVs) in the human genome.",
      "Documents 0, 1, 3, 5, and 7 suggest that UCEs are significantly underrepresented in CNVs.",
      "Ultraconserved elements are regions of at least 200 contiguous nucleotides that are perfectly conserved in both the mouse and rat genomes.",
      "The depletion of UCEs among CNVs is thought to be due to the preferential loss or deletion of these regions during CNV formation.",
      "Deletion or duplication of a UCE can be deleterious to the mammalian cell."
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the substrate of the Haspin kinase during mitosis is histone H3 at threonine 3 (H3T3).",
    "llama-2-7b-chat-hf_fact_raw": "1. The substrate of the Haspin kinase during mitosis is histone H3.\n2. Histone H3 is phosphorylated at threonine 3 (H3T3) by Haspin kinase during mitosis.",
    "llama-2-7b-chat-hf_fact": [
      "The substrate of the Haspin kinase during mitosis is histone H3.",
      "Histone H3 is phosphorylated at threonine 3 (H3T3) by Haspin kinase during mitosis."
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the mechanism of viroid replication appears to involve an RNA-based rolling-circle mechanism with three steps. These steps are:\n1. Synthesis of longer-than-unit strands: Viroids use the host's RNA polymerase II or a nuclear-encoded chloroplastic RNA polymerase to synthesize longer-than-unit strands of RNA.\n2. Cleavage: The synthesized RNA is then cleaved into smaller fragments, which are then ligated back together to form a circular RNA molecule.\n3. Ligation: The circular RNA molecule is then ligated back together to form a complete circle.\nThis mechanism is thought to occur in both polarity strands, meaning that the replication process is the same in both the sense and antisense strands of the RNA molecule.\nIt is worth noting that viroids are single-stranded circular noncoding RNAs that infect plants, and they must rely on their hosts for replication. Therefore, the replication mechanism of viroids is an RNA-based rolling-circle mechanism that involves the host's RNA machinery.\nIn summary, the mechanism of viroid replication involves an RNA-based rolling-circle mechanism with three steps, which are synthesis of longer-than-unit strands, cleavage, and ligation. This mechanism is thought to occur in both polarity strands and relies on the host's RNA machinery for replication.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viroid replication involves an RNA-based rolling-circle mechanism.\n2. The replication process includes the synthesis of longer-than-unit strands of RNA using the host's RNA polymerase II or a nuclear-encoded chloroplastic RNA polymerase.\n3. The synthesized RNA is cleaved into smaller fragments during replication.\n4. The smaller RNA fragments are ligated back together to form a circular RNA molecule.\n5. Viroid replication occurs in both the sense and antisense strands of the RNA molecule.",
    "llama-2-7b-chat-hf_fact": [
      "Viroid replication involves an RNA-based rolling-circle mechanism.",
      "The replication process includes the synthesis of longer-than-unit strands of RNA using the host's RNA polymerase II or a nuclear-encoded chloroplastic RNA polymerase.",
      "The synthesized RNA is cleaved into smaller fragments during replication.",
      "The smaller RNA fragments are ligated back together to form a circular RNA molecule.",
      "Viroid replication occurs in both the sense and antisense strands of the RNA molecule."
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, fibronectin does constitute a serum biomarker for Duchenne muscular dystrophy (DMD). Documents 0, 1, and 2 suggest that fibronectin levels may differ between DMD patients and controls, and that it may be a promising biomarker for monitoring disease progression. Document 3 also confirms that fibronectin is a serum biomarker for DMD. Additionally, Documents 4, 5, and 6 highlight the potential of biomarkers, including fibronectin, to improve the development and approval of therapies, clinical management of DMD, and patients' quality of life. Finally, Document 7 provides an overview of the key studies investigating various types of biomarkers in DMD, including fibronectin.\nTherefore, based on the information provided, fibronectin can be considered a serum biomarker for DMD, which may be useful for monitoring disease progression and identifying potential therapeutic targets.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fibronectin is considered a serum biomarker for Duchenne muscular dystrophy (DMD).\n2. Fibronectin levels may differ between DMD patients and controls.\n3. Fibronectin may be a promising biomarker for monitoring disease progression in DMD.\n4. Biomarkers, including fibronectin, have the potential to improve the development and approval of therapies for DMD.\n5. Biomarkers, such as fibronectin, can aid in the clinical management of DMD and improve patients' quality of life.",
    "llama-2-7b-chat-hf_fact": [
      "Fibronectin is considered a serum biomarker for Duchenne muscular dystrophy (DMD).",
      "Fibronectin levels may differ between DMD patients and controls.",
      "Fibronectin may be a promising biomarker for monitoring disease progression in DMD.",
      "Biomarkers, including fibronectin, have the potential to improve the development and approval of therapies for DMD.",
      "Biomarkers, such as fibronectin, can aid in the clinical management of DMD and improve patients' quality of life."
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the following epigenome projects are contained in the DeepBlue epigenomic data server:\n1. ENCODE (ENCyclopedia Of DNA Elements)\n2. ROADMAP (Roadmap Epigenomics Consortium)\n3. BLUEPRINT (Blueprint Epigenomics Project)\n4. DEEP (Deep Epigenomics Project)\nThe documents mention that DeepBlue comes with a user manual, examples, and a well-documented application programming interface (API) that allows access to the data via the XML-RPC protocol supported by many programming languages. Additionally, the documents mention that the server provides programmatic data retrieval and analysis of epigenome region sets, and that it is designed to streamline epigenomic data analysis as well as software development.",
    "llama-2-7b-chat-hf_fact_raw": "1. The DeepBlue epigenomic data server contains data from the ENCODE project.\n2. The DeepBlue epigenomic data server contains data from the ROADMAP Epigenomics Consortium.\n3. The DeepBlue epigenomic data server contains data from the BLUEPRINT Epigenomics Project.\n4. The DeepBlue epigenomic data server contains data from the DEEP Epigenomics Project.\n5. The DeepBlue server allows access to the data via the XML-RPC protocol.",
    "llama-2-7b-chat-hf_fact": [
      "The DeepBlue epigenomic data server contains data from the ENCODE project.",
      "The DeepBlue epigenomic data server contains data from the ROADMAP Epigenomics Consortium.",
      "The DeepBlue epigenomic data server contains data from the BLUEPRINT Epigenomics Project.",
      "The DeepBlue epigenomic data server contains data from the DEEP Epigenomics Project.",
      "The DeepBlue server allows access to the data via the XML-RPC protocol."
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the tool that employs self-organizing maps for analyzing synonymous codon usage is Document 4: A Tool for Analyzing and Annotating Genomic Sequences. The tool uses self-organizing maps to perform codon usage analysis and clustering.",
    "llama-2-7b-chat-hf_fact_raw": "1. Document 4: A Tool for Analyzing and Annotating Genomic Sequences employs self-organizing maps for analyzing synonymous codon usage.\n2. The tool uses self-organizing maps to perform codon usage analysis and clustering.",
    "llama-2-7b-chat-hf_fact": [
      "Document 4: A Tool for Analyzing and Annotating Genomic Sequences employs self-organizing maps for analyzing synonymous codon usage.",
      "The tool uses self-organizing maps to perform codon usage analysis and clustering."
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, \"MINDY-1\" appears to be a term related to deubiquitinating enzymes, which are enzymes that remove a small protein called ubiquitin from other proteins. Document 1 mentions that MINDY-1 is a member of a new family of deubiquitinating enzymes that is evolutionarily conserved and structurally distinct. Document 2 provides more information on the topic, stating that MINDY-1 is a deubiquitinating enzyme that is involved in various cellular processes, including protein degradation and cell signaling.\nAs for the user's question, \"What is MINDY-1?\", the answer is that MINDY-1 is a deubiquitinating enzyme that is a member of a new family of enzymes that is evolutionarily conserved and structurally distinct. It is involved in various cellular processes and is a topic of research in the field of molecular cell biology.",
    "llama-2-7b-chat-hf_fact_raw": "1. MINDY-1 is a deubiquitinating enzyme.\n2. MINDY-1 removes ubiquitin from other proteins.\n3. MINDY-1 is a member of a new family of deubiquitinating enzymes.\n4. MINDY-1 is evolutionarily conserved and structurally distinct.\n5. MINDY-1 is involved in various cellular processes, including protein degradation and cell signaling.",
    "llama-2-7b-chat-hf_fact": [
      "MINDY-1 is a deubiquitinating enzyme.",
      "MINDY-1 removes ubiquitin from other proteins.",
      "MINDY-1 is a member of a new family of deubiquitinating enzymes.",
      "MINDY-1 is evolutionarily conserved and structurally distinct.",
      "MINDY-1 is involved in various cellular processes, including protein degradation and cell signaling."
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the software package available for the analysis of conserved genomic loci is PHYLUCE. This is mentioned in Documents 0, 1, and 3 of the provided information. In particular, Document 1 states that \"PHYLUCE is a software package for the analysis of conserved genomic loci.\"",
    "llama-2-7b-chat-hf_fact_raw": "1. PHYLUCE is a software package used for the analysis of conserved genomic loci.\n2. PHYLUCE is mentioned in Documents 0, 1, and 3 of the provided information as being relevant for such analysis.",
    "llama-2-7b-chat-hf_fact": [
      "PHYLUCE is a software package used for the analysis of conserved genomic loci.",
      "PHYLUCE is mentioned in Documents 0, 1, and 3 of the provided information as being relevant for such analysis."
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the following are 3 diseases associated with the PIEZO2 gene:\n1. Distal arthrogryposis with impaired proprioception and touch (DAIPT): This is a recessive disease caused by mutations in the PIEZO2 gene. It is characterized by hypotonia, perinatal respiratory distress, significantly delayed motor milestones, and progressive symptoms of distal arthrogryposis and scoliosis.\n2. Marden-Walker syndrome (MWS): This is a rare genetic disorder caused by mutations in the PIEZO2 gene. It is characterized by intellectual disability, delayed speech and language development, distinctive facial features, and congenital anomalies such as scoliosis, hip dysplasia, and clubfoot.\n3. Gordon syndrome (GS): This is a rare genetic disorder caused by mutations in the PIEZO2 gene. It is characterized by intellectual disability, delayed speech and language development, distinctive facial features, and congenital anomalies such as scoliosis, hip dysplasia, and clubfoot.\nIt is important to note that these are just three of the diseases associated with the PIEZO2 gene, and there may be other diseases as well.",
    "llama-2-7b-chat-hf_fact_raw": "1. Distal arthrogryposis with impaired proprioception and touch (DAIPT) is a recessive disease caused by mutations in the PIEZO2 gene.\n2. Marden-Walker syndrome (MWS) is a rare genetic disorder caused by mutations in the PIEZO2 gene.\n3. Gordon syndrome (GS) is a rare genetic disorder caused by mutations in the PIEZO2 gene.",
    "llama-2-7b-chat-hf_fact": [
      "Distal arthrogryposis with impaired proprioception and touch (DAIPT) is a recessive disease caused by mutations in the PIEZO2 gene.",
      "Marden-Walker syndrome (MWS) is a rare genetic disorder caused by mutations in the PIEZO2 gene.",
      "Gordon syndrome (GS) is a rare genetic disorder caused by mutations in the PIEZO2 gene."
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, ERAP1-ERAP2 dimerization appears to play a role in the processing and presentation of antigens to the immune system. The documents suggest that ERAP1 and ERAP2 are two homologous enzymes that work together to generate optimal length peptides for MHC class I binding in the endoplasmic reticulum (ER). The dimerization of these enzymes allows for increased affinity for peptides with hydrophilic and hydrophobic N and C termini.\nThe documents also suggest that the expression of ERAP1/2 is altered in different cancers compared to normal cells, and that this affects anti-cancer immune responses and cancer growth. The authors of Document 4 propose that the altered expression of ERAP1/2 may be a mechanism by which cancers evade the immune system.\nAdditionally, the documents mention that ERAP1/2 are involved in the immune-mediated diseases, such as hypertension, pre-eclampsia, and viral infections like COVID-19.\nIn summary, ERAP1-ERAP2 dimerization appears to play a crucial role in the processing and presentation of antigens to the immune system, and its altered expression in cancers may be a mechanism by which cancers evade the immune system.",
    "llama-2-7b-chat-hf_fact_raw": "1. ERAP1-ERAP2 dimerization is involved in the processing and presentation of antigens to the immune system.\n2. ERAP1 and ERAP2 generate optimal length peptides for MHC class I binding in the endoplasmic reticulum.\n3. The dimerization of ERAP1 and ERAP2 increases affinity for peptides with hydrophilic and hydrophobic N and C termini.\n4. The expression of ERAP1/2 is altered in different cancers compared to normal cells.\n5. ERAP1/2 are involved in immune-mediated diseases, such as hypertension, pre-eclampsia, and viral infections like COVID-19.",
    "llama-2-7b-chat-hf_fact": [
      "ERAP1-ERAP2 dimerization is involved in the processing and presentation of antigens to the immune system.",
      "ERAP1 and ERAP2 generate optimal length peptides for MHC class I binding in the endoplasmic reticulum.",
      "The dimerization of ERAP1 and ERAP2 increases affinity for peptides with hydrophilic and hydrophobic N and C termini.",
      "The expression of ERAP1/2 is altered in different cancers compared to normal cells.",
      "ERAP1/2 are involved in immune-mediated diseases, such as hypertension, pre-eclampsia, and viral infections like COVID-19."
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, R-spondin 1 and noggin appear to play a role in the growth and differentiation of gallbladder-derived organoids. Document 0 suggests that these two factors stimulate the growth of gallbladder-derived organoids, while Document 7 suggests that they act by neutralizing transmembrane E3 ligases that remove Wnt receptors from the stem cell surface. This suggests that R-spondin 1 and noggin may be involved in regulating the Wnt signaling pathway in gallbladder-derived stem cells.\nAdditionally, Document 3 suggests that R-spondin 1 and noggin facilitate the expansion of resident stem cells from non-damaged gallbladders, and Document 8 suggests that these cells can be expanded for more than one year as organoids in vitro in the presence of R-spondin 1 and noggin. This suggests that R-spondin 1 and noggin may be involved in maintaining the stem cell population in the gallbladder and promoting its expansion in vitro.\nFinally, Document 5 suggests that R-spondins are widely expressed in Xenopus and during mouse embryogenesis, and Document 6 suggests that R-spondins are expressed in several embryonic tissues and in the adult, with adequate expression levels being essential for organism development and homeostasis maintenance. This suggests that R-spondins may play a more general role in regulating cell proliferation, differentiation, and death in various tissues, including the gallbladder.\nIn summary, based on the information provided, R-spondin 1 and noggin appear to play a role in regulating the Wnt signaling pathway in gallbladder-derived stem cells, and may be involved in maintaining the stem cell population in the gallbladder and promoting its expansion in vitro.",
    "llama-2-7b-chat-hf_fact_raw": "1. R-spondin 1 and noggin stimulate the growth of gallbladder-derived organoids.\n2. R-spondin 1 and noggin act by neutralizing transmembrane E3 ligases that remove Wnt receptors from the stem cell surface.\n3. R-spondin 1 and noggin facilitate the expansion of resident stem cells from non-damaged gallbladders.\n4. Gallbladder-derived stem cells can be expanded for more than one year as organoids in vitro in the presence of R-spondin 1 and noggin.\n5. R-spondins are expressed in several embryonic tissues and in the adult, with adequate expression levels being essential for organism development and homeostasis maintenance.",
    "llama-2-7b-chat-hf_fact": [
      "R-spondin 1 and noggin stimulate the growth of gallbladder-derived organoids.",
      "R-spondin 1 and noggin act by neutralizing transmembrane E3 ligases that remove Wnt receptors from the stem cell surface.",
      "R-spondin 1 and noggin facilitate the expansion of resident stem cells from non-damaged gallbladders.",
      "Gallbladder-derived stem cells can be expanded for more than one year as organoids in vitro in the presence of R-spondin 1 and noggin.",
      "R-spondins are expressed in several embryonic tissues and in the adult, with adequate expression levels being essential for organism development and homeostasis maintenance."
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it is clear that NADPH oxidase 5 (NOX5) is a unique member of the NADPH oxidase family, as it does not require any subunits for its function. Document 5 states that NOX5 is the only Nox isoform that has been crystalized and that it generates ROS from a single gene product without requiring classical NADPH oxidase subunits (p22phox, p47phox, and p67phox) for its activation.\nTherefore, the answer to the user's question is that NOX5 does not require any subunits for its function.",
    "llama-2-7b-chat-hf_fact_raw": "1. NADPH oxidase 5 (NOX5) does not require any subunits for its function.\n2. NOX5 is a unique member of the NADPH oxidase family.\n3. NOX5 generates reactive oxygen species (ROS) from a single gene product.\n4. Classical NADPH oxidase subunits such as p22phox, p47phox, and p67phox are not required for NOX5 activation.\n5. NOX5 is the only Nox isoform that has been crystalized.",
    "llama-2-7b-chat-hf_fact": [
      "NADPH oxidase 5 (NOX5) does not require any subunits for its function.",
      "NOX5 is a unique member of the NADPH oxidase family.",
      "NOX5 generates reactive oxygen species (ROS) from a single gene product.",
      "Classical NADPH oxidase subunits such as p22phox, p47phox, and p67phox are not required for NOX5 activation.",
      "NOX5 is the only Nox isoform that has been crystalized."
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there appears to be a connection between furin and hepcidin in the regulation of iron metabolism.\nFurin is a post-translational regulator of hepcidin, meaning that it plays a role in the maturation and activation of hepcidin. Hepcidin is a peptide hormone that regulates iron metabolism by binding to the iron-exporting protein ferroportin and inducing its internalization and degradation, thereby limiting the amount of iron released into the blood.\nDocument 1 suggests that hepcidin is thought to be the key regulator of iron metabolism in humans through its inhibition of ferroportin. Document 2 provides additional information on the structure and synthesis of hepcidin, noting that it is synthesized in hepatocytes as a larger, inactive pre-prohepcidin that is then cleaved by the prohormone convertase furin to generate mature hepcidin.\nDocument 3 highlights the importance of understanding the relationship between systemic and local hepcidin in the heart, as this can help explain how the fine balance between the actions of two hepcidins affects heart function.\nDocument 4 notes that increased hepcidin correlates with the pathophysiology of anemia of chronic disease, while a deficiency in hepcidin production can result in iron overload, as seen in hereditary hemochromatosis. This suggests that hepcidin plays a critical role in regulating iron metabolism and that dysregulation of hepcidin can lead to iron-related disorders.\nDocument 5 mentions an evolutionary connection between the viral spike protein and hepcidin, but does not provide further information on this topic.\nDocument 6 highlights the up-regulation of furin and down-regulation of hepcidin in response to hypoxia, suggesting that furin may play a role in regulating hepcidin expression in response to changes in oxygen availability.\nDocument 7 investigates the changes in furin and related factors in parenteral iron-overloaded mice, including those with β-thalassemia. The study finds that furin is up-reg",
    "llama-2-7b-chat-hf_fact_raw": "1. Furin is a post-translational regulator of hepcidin, involved in its maturation and activation.\n2. Hepcidin is a peptide hormone that regulates iron metabolism by binding to ferroportin and inducing its internalization and degradation.\n3. Hepcidin is synthesized in hepatocytes as pre-prohepcidin and is cleaved by furin to generate mature hepcidin.\n4. Increased hepcidin levels are associated with the pathophysiology of anemia of chronic disease, while a deficiency in hepcidin production can lead to iron overload conditions like hereditary hemochromatosis.\n5. Furin expression is up-regulated and hepcidin expression is down-regulated in response to hypoxia.",
    "llama-2-7b-chat-hf_fact": [
      "Furin is a post-translational regulator of hepcidin, involved in its maturation and activation.",
      "Hepcidin is a peptide hormone that regulates iron metabolism by binding to ferroportin and inducing its internalization and degradation.",
      "Hepcidin is synthesized in hepatocytes as pre-prohepcidin and is cleaved by furin to generate mature hepcidin.",
      "Increased hepcidin levels are associated with the pathophysiology of anemia of chronic disease, while a deficiency in hepcidin production can lead to iron overload conditions like hereditary hemochromatosis.",
      "Furin expression is up-regulated and hepcidin expression is down-regulated in response to hypoxia."
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the largest metabolic gene cluster in yeast is the DAL cluster. This cluster consists of six adjacent genes encoding proteins that enable Saccharomyces cerevisiae to use allantoin as a nitrogen source. The documents mention that this cluster is the largest metabolic gene cluster in yeast and that it is formed by epistatic selection, which means that the genes in the cluster are coadapted and have evolved together to perform their metabolic function. The documents also mention that the DAL cluster is not exceeding ten genes or few kilobases in size, which is smaller than the clusters of multicellular eukaryotes consisting of 20-30 genes. Therefore, based on the information provided in the documents, the answer to the user's question is that the DAL cluster is the largest metabolic gene cluster in yeast.",
    "llama-2-7b-chat-hf_fact_raw": "1. The largest metabolic gene cluster in yeast is the DAL cluster.\n2. The DAL cluster consists of six adjacent genes.\n3. These genes enable Saccharomyces cerevisiae to use allantoin as a nitrogen source.\n4. The genes in the DAL cluster are coadapted and have evolved together due to epistatic selection.\n5. The DAL cluster is smaller than the gene clusters of multicellular eukaryotes, which consist of 20-30 genes.",
    "llama-2-7b-chat-hf_fact": [
      "The largest metabolic gene cluster in yeast is the DAL cluster.",
      "The DAL cluster consists of six adjacent genes.",
      "These genes enable Saccharomyces cerevisiae to use allantoin as a nitrogen source.",
      "The genes in the DAL cluster are coadapted and have evolved together due to epistatic selection.",
      "The DAL cluster is smaller than the gene clusters of multicellular eukaryotes, which consist of 20-30 genes."
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-2-7b-chat-hf_response": "Based on the provided documents, it appears that LIMT (LncRNA Inhibiting Metastasis) is a long non-coding RNA that plays a critical role in inhibiting metastasis in various types of cancer, including breast, ovarian, and hepatocellular carcinoma.\nDocument 2 suggests that knockdown of LIMT in MDA-MB-231 cells leads to a large, opposite effect on migration, indicating that LIMT may be a tumor suppressor factor. Document 4 provides evidence that long non-coding RNAs (lncRNAs) are widely expressed and have key roles in gene regulation, and Document 7 suggests that an EGF-downregulated lncRNA, LIMT, is a critical regulator of mammary cell migration and invasion.\nDocument 1 defines lncRNAs as transcripts >200 nucleotides in length that lack protein-coding potential, and Document 3 mentions that the long non-coding RNA LIMT acts as a tumor suppressor factor in some cancers. Document 6 suggests that the biological role of LIMT in hepatocellular carcinoma (HCC) has not been explored, and Document 8 mentions that miRNAs, a class of small non-coding RNAs, play a crucial role in modulating various cellular and biological processes, including cell cycle regulation.\nBased on these documents, it can be inferred that LIMT is a critical regulator of metastasis in various types of cancer, and its expression is likely to be an important factor in tumor progression and metastasis. Further research is needed to fully understand the role of LIMT in different types of cancer and to explore its potential as a therapeutic target for cancer treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. LIMT (LncRNA Inhibiting Metastasis) is a long non-coding RNA that inhibits metastasis in various types of cancer.\n2. Knockdown of LIMT in MDA-MB-231 cells affects cell migration, suggesting that LIMT may function as a tumor suppressor.\n3. Long non-coding RNAs (lncRNAs) are defined as transcripts longer than 200 nucleotides that do not have protein-coding potential.\n4. An EGF-downregulated lncRNA, LIMT, is a critical regulator of mammary cell migration and invasion.\n5. The biological role of LIMT in hepatocellular carcinoma (HCC) has not been fully explored.",
    "llama-2-7b-chat-hf_fact": [
      "LIMT (LncRNA Inhibiting Metastasis) is a long non-coding RNA that inhibits metastasis in various types of cancer.",
      "Knockdown of LIMT in MDA-MB-231 cells affects cell migration, suggesting that LIMT may function as a tumor suppressor.",
      "Long non-coding RNAs (lncRNAs) are defined as transcripts longer than 200 nucleotides that do not have protein-coding potential.",
      "An EGF-downregulated lncRNA, LIMT, is a critical regulator of mammary cell migration and invasion.",
      "The biological role of LIMT in hepatocellular carcinoma (HCC) has not been fully explored."
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the R/Bioconductor package that is used for performing SNP enrichment analysis is traseR. Documents 6 and 8 mention traseR as an easy-to-use package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with flexible options, including testing method, type of background, and inclusion of SNPs in LD. Availability and implementation information is also provided for traseR in Documents 6 and 8.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R/Bioconductor package used for performing SNP enrichment analysis is called traseR.\n2. Documents 6 and 8 describe traseR as an easy-to-use package.\n3. traseR can perform enrichment analyses of trait-associated SNPs in arbitrary genomic intervals.\n4. traseR offers flexible options such as testing method, type of background, and inclusion of SNPs in LD.\n5. Availability and implementation information for traseR is provided in Documents 6 and 8.",
    "llama-2-7b-chat-hf_fact": [
      "The R/Bioconductor package used for performing SNP enrichment analysis is called traseR.",
      "Documents 6 and 8 describe traseR as an easy-to-use package.",
      "traseR can perform enrichment analyses of trait-associated SNPs in arbitrary genomic intervals.",
      "traseR offers flexible options such as testing method, type of background, and inclusion of SNPs in LD.",
      "Availability and implementation information for traseR is provided in Documents 6 and 8."
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it appears that Mcidas and GemC1/Lynkeas are key players in radial glial specification to ependymal cells. Documents 0, 1, and 4 highlight the role of these proteins in promoting ependymal cell differentiation, while Document 7 shows that they give rise to mature ependymal cells through an ordered process. Documents 2 and 6 also mention the importance of radial glial cells in guiding the migration of newborn neurons.\nFurthermore, Documents 3 and 8 suggest that Foxj1 and c-Myb regulate the differentiation of RGCs towards the ependymal cell lineage, while Document 5 highlights the intimate link between structure and function in neural stem cells, including radial glia.\nFinally, Document 9 mentions the heterogeneity of radial glia cells and their fate specification for glial lineages as early as E9.5, which may be relevant to the role of Mcidas and GemC1/Lynkeas in ependymal cell differentiation.\nIn summary, the key players in radial glial specification to ependymal cells are Mcidas and GemC1/Lynkeas, which promote ependymal cell differentiation through an ordered process, and Foxj1 and c-Myb, which regulate the differentiation of RGCs towards the ependymal cell lineage.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mcidas and GemC1/Lynkeas are key players in radial glial specification to ependymal cells.\n2. Mcidas and GemC1/Lynkeas promote ependymal cell differentiation through an ordered process.\n3. Foxj1 and c-Myb regulate the differentiation of radial glial cells (RGCs) towards the ependymal cell lineage.\n4. Radial glial cells are important in guiding the migration of newborn neurons.\n5. Radial glia cells have fate specification for glial lineages as early as embryonic day 9.5 (E9.5).",
    "llama-2-7b-chat-hf_fact": [
      "Mcidas and GemC1/Lynkeas are key players in radial glial specification to ependymal cells.",
      "Mcidas and GemC1/Lynkeas promote ependymal cell differentiation through an ordered process.",
      "Foxj1 and c-Myb regulate the differentiation of radial glial cells (RGCs) towards the ependymal cell lineage.",
      "Radial glial cells are important in guiding the migration of newborn neurons.",
      "Radial glia cells have fate specification for glial lineages as early as embryonic day 9.5 (E9.5)."
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-2-7b-chat-hf_response": "Based on the provided documents, triple negative gliomas are characterized as gliomas that lack the three major alterations typically found in glioblastomas, which are:\n1. IDH mutations\n2. P53 mutations\n3. Chromosome 1p/19q codeletion\nTriple negative gliomas are enigmatic tumors with highly heterogeneous backgrounds, and they may harbor some of the molecular alterations typical of primary glioblastomas, such as EGFR amplification, chromosome 7 gain, and chromosome 10 loss. The prognosis for these tumors is worse than that of IDH-mutant glioblastomas but better than that of TERT-mutant glioblastomas.\nIt is important to note that the term \"triple negative\" refers to the absence of these three major alterations, and it does not necessarily imply that the tumor is negative for all potential drivers of gliomagenesis. Further molecular analysis may identify additional driver mutations in these tumors.",
    "llama-2-7b-chat-hf_fact_raw": "1. Triple negative gliomas lack IDH mutations.\n2. Triple negative gliomas lack P53 mutations.\n3. Triple negative gliomas lack chromosome 1p/19q codeletion.\n4. The prognosis for triple negative gliomas is worse than that of IDH-mutant glioblastomas.\n5. The prognosis for triple negative gliomas is better than that of TERT-mutant glioblastomas.",
    "llama-2-7b-chat-hf_fact": [
      "Triple negative gliomas lack IDH mutations.",
      "Triple negative gliomas lack P53 mutations.",
      "Triple negative gliomas lack chromosome 1p/19q codeletion.",
      "The prognosis for triple negative gliomas is worse than that of IDH-mutant glioblastomas.",
      "The prognosis for triple negative gliomas is better than that of TERT-mutant glioblastomas."
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, TOPAZ1 appears to be a clinical trial investigating the use of immunotherapy in combination with chemotherapy for the treatment of advanced biliary tract cancer. The trial is global, open-label, and phase 3, and it has been published in several medical journals and presented at conferences.\nAccording to Document 2, TOPAZ-1 represents the first phase 3 trial to demonstrate positive results with the addition of an immune checkpoint inhibitor to standard first-line chemotherapy in biliary tract cancer. The trial showed that the combination of durvalumab and gemcitabine and cisplatin improved overall survival in patients with advanced biliary cancer.\nDocument 3 states that TOPAZ-1 is the first large clinical trial to show that initial treatment that includes immunotherapy can improve survival in patients with advanced biliary cancer. The trial demonstrated that the addition of durvalumab to gemcitabine and cisplatin improved overall survival in this patient population.\nDocument 4 highlights the significance of TOPAZ-1 in demonstrating the benefit of immunotherapy for improved overall survival in combination with chemotherapy, creating a new standard of care for the treatment of advanced biliary cancer.\nDocument 5 emphasizes that TOPAZ-1 is the first phase 3 trial to show that adding an immunotherapy to standard chemotherapy delivers a meaningful overall survival benefit for patients in this setting. The results of the trial provide new hope for patients with advanced biliary cancer.\nFinally, Document 6 explains that TOPAZ1 is a gene that is highly conserved in vertebrates and is involved in the regulation of germ cell development.\nIn summary, TOPAZ1 appears to be a clinical trial investigating the use of immunotherapy in combination with chemotherapy for the treatment of advanced biliary tract cancer, and the results of the trial have shown improved overall survival in this patient population.",
    "llama-2-7b-chat-hf_fact_raw": "1. TOPAZ1 is a clinical trial investigating the use of immunotherapy in combination with chemotherapy for the treatment of advanced biliary tract cancer.\n2. The TOPAZ1 trial is a global, open-label, phase 3 trial.\n3. The trial demonstrated that the combination of durvalumab with gemcitabine and cisplatin improved overall survival in patients with advanced biliary cancer.\n4. TOPAZ1 is the first phase 3 trial to show a positive result with the addition of an immune checkpoint inhibitor to standard first-line chemotherapy in biliary tract cancer.\n5. TOPAZ1 is also the name of a gene that is involved in the regulation of germ cell development and is highly conserved in vertebrates.",
    "llama-2-7b-chat-hf_fact": [
      "TOPAZ1 is a clinical trial investigating the use of immunotherapy in combination with chemotherapy for the treatment of advanced biliary tract cancer.",
      "The TOPAZ1 trial is a global, open-label, phase 3 trial.",
      "The trial demonstrated that the combination of durvalumab with gemcitabine and cisplatin improved overall survival in patients with advanced biliary cancer.",
      "TOPAZ1 is the first phase 3 trial to show a positive result with the addition of an immune checkpoint inhibitor to standard first-line chemotherapy in biliary tract cancer.",
      "TOPAZ1 is also the name of a gene that is involved in the regulation of germ cell development and is highly conserved in vertebrates."
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the gene that controls the expression of GATA-1 isoforms is GATA-1 itself. The documents suggest that GATA-1 is alternatively spliced to produce two isoforms, GATA-1FL and GATA-1S, and that the balance between these isoforms plays a crucial role in regulating hematopoiesis.\nDocument 1 mentions that K562 cells expressing GATA1s or GATA1FL transgenes were used to model the effects of the two isoforms on in vitro haematopoietic differentiation. This suggests that both isoforms have distinct effects on hematopoiesis and that the balance between them is important.\nDocument 2 states that GATA-1 is a key transcriptional factor controlling hematopoiesis-related gene expression, and that two GATA-1 isoforms, GATA-1FL and GATA-1S, are described. This confirms that GATA-1 is alternatively spliced to produce two isoforms.\nDocument 3 identifies novel combinatorial protein-protein interactions for GATA-1, PU.1, and C/EBPε isoforms in eosinophil gene transcription, including GATA-1/PU.1 synergy and repressor activity for C/EBPε. This suggests that the balance between GATA-1 isoforms and other transcription factors is important for regulating hematopoiesis.\nDocument 4 suggests that over-expression of GATA-1S, the short isoform of the hematopoietic transcription factor GATA-1, inhibits ferroptosis in K562 myeloid leukemia cells by preventing lipid peroxidation. This suggests that GATA-1S has a distinct function compared to GATA-1FL.\nDocument 5 shows that Gata1 (low) mice are a bona fide model of myelofibrosis (MF), which recapitulates the hyperactivation of the TPO/MPL/JAK2 axis observed in megakaryocytes from myelofibrotic patients. The Gata-1 gene was a T3-directly regulated gene, and TRa1",
    "llama-2-7b-chat-hf_fact_raw": "1. The gene that controls the expression of GATA-1 isoforms is GATA-1 itself.\n2. GATA-1 is alternatively spliced to produce two isoforms, GATA-1FL and GATA-1S.\n3. The balance between GATA-1 isoforms plays a crucial role in regulating hematopoiesis.\n4. Over-expression of GATA-1S inhibits ferroptosis in K562 myeloid leukemia cells by preventing lipid peroxidation.\n5. Gata1 (low) mice are a model of myelofibrosis, which recapitulates the hyperactivation of the TPO/MPL/JAK2 axis observed in megakaryocytes from myelofibrotic patients.",
    "llama-2-7b-chat-hf_fact": [
      "The gene that controls the expression of GATA-1 isoforms is GATA-1 itself.",
      "GATA-1 is alternatively spliced to produce two isoforms, GATA-1FL and GATA-1S.",
      "The balance between GATA-1 isoforms plays a crucial role in regulating hematopoiesis.",
      "Over-expression of GATA-1S inhibits ferroptosis in K562 myeloid leukemia cells by preventing lipid peroxidation.",
      "Gata1 (low) mice are a model of myelofibrosis, which recapitulates the hyperactivation of the TPO/MPL/JAK2 axis observed in megakaryocytes from myelofibrotic patients."
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, MIRA-seq is a method for genome-scale DNA methylation analysis that uses the high affinity of a methylated-CpG-binding protein complex (MBD2B and MBD3L1) to enrich regions with methylated CpG dinucleotides. The method can be applied to both array-based DNA analysis and next-generation sequencing (NGS) and is not limited by primer or probe design. MIRA-seq is a reliable and cost-effective platform for scoring DNA methylation differences at CpG-rich genomic regions.\nThe documents also mention that MIRA-seq is compatible with high-throughput microarray or NGS platforms, such as the Illumina Genome Analyzer, and that the method can be used to identify miRNA precursors in plants.\nIn addition, the documents provide information on the advantages of MIRA-seq over other methods, such as MeDIP-seq, including the fact that MIRA-seq does not require denaturing the DNA into single strand fragments, which provides a more stable product after the pull-down enrichment of the MBD-methylated DNA complex. MIRA-seq also requires less input DNA than MeDIP-seq, making it more practical for use with limited sample amounts.\nOverall, the information provided in the documents suggests that MIRA-seq is a powerful tool for genome-scale DNA methylation analysis that offers several advantages over other methods in the field.",
    "llama-2-7b-chat-hf_fact_raw": "1. MIRA-seq is a method for genome-scale DNA methylation analysis.\n2. MIRA-seq uses a methylated-CpG-binding protein complex (MBD2B and MBD3L1) to enrich regions with methylated CpG dinucleotides.\n3. MIRA-seq can be applied to both array-based DNA analysis and next-generation sequencing (NGS).\n4. MIRA-seq is compatible with high-throughput microarray or NGS platforms, such as the Illumina Genome Analyzer.\n5. MIRA-seq does not require denaturing the DNA into single strand fragments for the analysis.",
    "llama-2-7b-chat-hf_fact": [
      "MIRA-seq is a method for genome-scale DNA methylation analysis.",
      "MIRA-seq uses a methylated-CpG-binding protein complex (MBD2B and MBD3L1) to enrich regions with methylated CpG dinucleotides.",
      "MIRA-seq can be applied to both array-based DNA analysis and next-generation sequencing (NGS).",
      "MIRA-seq is compatible with high-throughput microarray or NGS platforms, such as the Illumina Genome Analyzer.",
      "MIRA-seq does not require denaturing the DNA into single strand fragments for the analysis."
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the indication of ARCALYST is:\n* Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS).\n* Treatment of recurrent pericarditis and reduction in risk of recurrence in adults and pediatric patients 12 years and older.\nARCALYST is an interleukin-1 blocker that is used to treat some of the symptoms of rare genetic conditions, such as FCAS and MWS, and to treat recurrent pericarditis and reduce the risk of recurrence in adults and children 12 years and older. It is important to note that ARCALYST may cause serious side effects, including hives, difficulty breathing, and an increased risk of infection. Therefore, it is important to use ARCALYST only as directed by a healthcare professional and to report any side effects immediately.",
    "llama-2-7b-chat-hf_fact_raw": "1. ARCALYST is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS).\n2. ARCALYST is also indicated for the treatment of recurrent pericarditis and reduction in the risk of recurrence in adults and pediatric patients 12 years and older.\n3. ARCALYST is an interleukin-1 blocker.\n4. ARCALYST is used to treat symptoms of rare genetic conditions such as FCAS and MWS.\n5. ARCALYST may cause serious side effects, including hives, difficulty breathing, and an increased risk of infection.",
    "llama-2-7b-chat-hf_fact": [
      "ARCALYST is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS).",
      "ARCALYST is also indicated for the treatment of recurrent pericarditis and reduction in the risk of recurrence in adults and pediatric patients 12 years and older.",
      "ARCALYST is an interleukin-1 blocker.",
      "ARCALYST is used to treat symptoms of rare genetic conditions such as FCAS and MWS.",
      "ARCALYST may cause serious side effects, including hives, difficulty breathing, and an increased risk of infection."
    ]
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the human acrocentric chromosomes involved in Robertsonian translocations are:\n1. Chromosome 13\n2. Chromosome 14\n3. Chromosome 15\n4. Chromosome 21\n5. Chromosome 22\nAll of these chromosomes are acrocentric, meaning they have a small short arm and a large long arm. The short arms of these chromosomes contain numerous copies of the genes coding for ribosomal RNA. Robertsonian translocations involve the fusion of two acrocentric chromosomes, resulting in a single chromosome with a rearranged genetic material. The distribution of different types of Robertsonian translocations in the general population is nonrandom, with certain types, such as der(13q14q) and der(14q21q), constituting the majority of all ROBs.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromosome 13 is an acrocentric chromosome involved in Robertsonian translocations.\n2. Chromosome 14 is an acrocentric chromosome involved in Robertsonian translocations.\n3. Chromosome 15 is an acrocentric chromosome involved in Robertsonian translocations.\n4. Chromosome 21 is an acrocentric chromosome involved in Robertsonian translocations.\n5. Chromosome 22 is an acrocentric chromosome involved in Robertsonian translocations.",
    "llama-2-7b-chat-hf_fact": [
      "Chromosome 13 is an acrocentric chromosome involved in Robertsonian translocations.",
      "Chromosome 14 is an acrocentric chromosome involved in Robertsonian translocations.",
      "Chromosome 15 is an acrocentric chromosome involved in Robertsonian translocations.",
      "Chromosome 21 is an acrocentric chromosome involved in Robertsonian translocations.",
      "Chromosome 22 is an acrocentric chromosome involved in Robertsonian translocations."
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the R package that could be used for the identification of pediatric brain tumors is \"MethPed\". This package is a DNA methylation classifier tool that can efficiently classify pediatric brain tumors using the developed MethPed classifier. The package is available via Bioconductor and can classify the following tumor diagnoses/subgroups: Diffuse Intrinsic Pontine Glioma (DIPG), Ependymoma, Embryonal tumors with Methylation (ETM), and Medulloblastoma, among others.\nThe package documentation provides detailed information on how to use the package, including the required R version, dependencies, and import statements. It also includes examples of how to use the package to classify tumor samples.\nIn summary, based on the information provided, \"MethPed\" is the R package that could be used for the identification of pediatric brain tumors.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R package \"MethPed\" can be used for the identification of pediatric brain tumors.\n2. \"MethPed\" is a DNA methylation classifier tool.\n3. The MethPed package can classify various tumor diagnoses/subgroups including Diffuse Intrinsic Pontine Glioma (DIPG), Ependymoma, Embryonal tumors with Methylation (ETM), and Medulloblastoma.\n4. The MethPed package is available via Bioconductor.\n5. The package documentation for MethPed includes information on the required R version, dependencies, import statements, and examples of usage.",
    "llama-2-7b-chat-hf_fact": [
      "The R package \"MethPed\" can be used for the identification of pediatric brain tumors.",
      "\"MethPed\" is a DNA methylation classifier tool.",
      "The MethPed package can classify various tumor diagnoses/subgroups including Diffuse Intrinsic Pontine Glioma (DIPG), Ependymoma, Embryonal tumors with Methylation (ETM), and Medulloblastoma.",
      "The MethPed package is available via Bioconductor.",
      "The package documentation for MethPed includes information on the required R version, dependencies, import statements, and examples of usage."
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0-9, it is clear that NEMO is indeed a zinc finger protein. The zinc finger domain of NEMO is a specific binding site for ubiquitin, which is involved in the regulation of the canonical NF-κB signaling pathway. This domain is essential for the function of NEMO as a regulator of NF-κB activity, and is involved in various cellular processes such as immune responses, cell proliferation, and antiapoptosis.\nTherefore, the answer to the user's question is: Yes, NEMO is a zinc finger protein.",
    "llama-2-7b-chat-hf_fact_raw": "1. NEMO is a zinc finger protein.\n2. The zinc finger domain of NEMO is a binding site for ubiquitin.\n3. NEMO is involved in the regulation of the canonical NF-κB signaling pathway.\n4. The zinc finger domain is essential for NEMO's function as a regulator of NF-κB activity.\n5. NEMO is involved in cellular processes such as immune responses, cell proliferation, and antiapoptosis.",
    "llama-2-7b-chat-hf_fact": [
      "NEMO is a zinc finger protein.",
      "The zinc finger domain of NEMO is a binding site for ubiquitin.",
      "NEMO is involved in the regulation of the canonical NF-κB signaling pathway.",
      "The zinc finger domain is essential for NEMO's function as a regulator of NF-κB activity.",
      "NEMO is involved in cellular processes such as immune responses, cell proliferation, and antiapoptosis."
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it appears that TFIIS does affect nucleosome positioning.\nDocument 0 states that lack of TFIIS influences nucleosome occupancy across the genome, particularly in genes that contain a canonical TATA box. This suggests that TFIIS plays a role in regulating nucleosome positioning in these genes.\nDocuments 1 and 2 also suggest that TFIIS contributes to nucleosome positioning in both gene promoters and bodies. These documents provide additional evidence that TFIIS is involved in nucleosome positioning.\nDocument 3 provides cryo-EM data that show H2A–H2B dimer loss and RNA polymerase II backtracking during nucleosomal traversal, and demonstrates how TFIIS stimulates the cleavage of the backtracked RNA to facilitate nucleosome passage. This further supports the idea that TFIIS affects nucleosome positioning.\nDocument 5 suggests that resolution of Pol II blocking can be facilitated by TFIIS-dependent RNA cleavage, which further suggests that TFIIS plays a role in regulating nucleosome positioning.\nDocument 6 states that TFIIS knockdown did not change the position of the major barrier location at the +1 nucleosome, which suggests that TFIIS does not directly affect nucleosome positioning. However, this does not necessarily mean that TFIIS does not play a role in nucleosome positioning, as it may act indirectly through other mechanisms.\nFinally, Document 7 provides additional evidence that TFIIS contributes to nucleosome positioning in both gene promoters and bodies.\nIn conclusion, based on the information provided in the documents, it appears that TFIIS does affect nucleosome positioning in eukaryotic cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. Lack of TFIIS influences nucleosome occupancy across the genome, particularly in genes that contain a canonical TATA box.\n2. TFIIS contributes to nucleosome positioning in both gene promoters and bodies, as suggested by Documents 1 and 2.\n3. Cryo-EM data show H2A–H2B dimer loss and RNA polymerase II backtracking during nucleosomal traversal, and TFIIS stimulates the cleavage of backtracked RNA to facilitate nucleosome passage, according to Document 3.\n4. TFIIS-dependent RNA cleavage can facilitate the resolution of Pol II blocking, which is related to nucleosome positioning, as suggested by Document 5.\n5. TFIIS knockdown did not change the position of the major barrier location at the +1 nucleosome, as stated in Document 6.",
    "llama-2-7b-chat-hf_fact": [
      "Lack of TFIIS influences nucleosome occupancy across the genome, particularly in genes that contain a canonical TATA box.",
      "TFIIS contributes to nucleosome positioning in both gene promoters and bodies, as suggested by Documents 1 and 2.",
      "Cryo-EM data show H2A–H2B dimer loss and RNA polymerase II backtracking during nucleosomal traversal, and TFIIS stimulates the cleavage of backtracked RNA to facilitate nucleosome passage, according to Document 3.",
      "TFIIS-dependent RNA cleavage can facilitate the resolution of Pol II blocking, which is related to nucleosome positioning, as suggested by Document 5.",
      "TFIIS knockdown did not change the position of the major barrier location at the +1 nucleosome, as stated in Document 6."
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it is difficult to make a definitive statement about whether origins of replication close to yeast centromeres fire early or late. However, there are some observations and findings that can be gleaned from the documents:\n1. Early replication of baker's yeast centromeres is one frequently cited example of temporal regulation, but the biological significance of early centromere replication remains speculative (Document 1).\n2. Early replication of histone genes may enhance the production of histones prior to duplication of the remaining genome (Mei et al. 2017) (Document 2).\n3. Chromatin determinants also regulate the dynamics of origin specification by licensing, and influence the activation timing (Document 3).\n4. Using a strain in which late origins can be induced to fire early, it was shown that replication termination is a largely passive phenomenon that does not rely on cis-acting sequences or replication fork pausing (Document 4).\n5. In yeast, origins of replication in the transcriptionally silent subtelomeric regions fire either late or not at all (Document 5).\n6. The centromeric regions of all Saccharomyces cerevisiae chromosomes are found in early replicating domains, a property conserved among centromeres in fungi and some higher eukaryotes (Document 7).\n7. While certain origins tend to fire early and others late, the timing of firing of each origin is not fully determined, giving rise to a semi-random timing pattern of initiation (Document 8).\nBased on these observations, it is possible that origins of replication close to yeast centromeres may fire at different times, with some firing early and others firing late. However, more research is needed to determine the specific firing times of these origins and to understand the underlying mechanisms that regulate them.",
    "llama-2-7b-chat-hf_fact_raw": "1. Early replication of baker's yeast centromeres is a frequently cited example of temporal regulation.\n2. Early replication of histone genes may enhance the production of histones prior to duplication of the remaining genome, according to Mei et al. 2017.\n3. Chromatin determinants regulate the dynamics of origin specification by licensing and influence the activation timing.\n4. In yeast, origins of replication in the transcriptionally silent subtelomeric regions fire either late or not at all.\n5. The centromeric regions of all Saccharomyces cerevisiae chromosomes are found in early replicating domains, a property conserved among centromeres in fungi and some higher eukaryotes.",
    "llama-2-7b-chat-hf_fact": [
      "Early replication of baker's yeast centromeres is a frequently cited example of temporal regulation.",
      "Early replication of histone genes may enhance the production of histones prior to duplication of the remaining genome, according to Mei et al. 2017.",
      "Chromatin determinants regulate the dynamics of origin specification by licensing and influence the activation timing.",
      "In yeast, origins of replication in the transcriptionally silent subtelomeric regions fire either late or not at all.",
      "The centromeric regions of all Saccharomyces cerevisiae chromosomes are found in early replicating domains, a property conserved among centromeres in fungi and some higher eukaryotes."
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the properties of mammalian GA-sequences can be summarized as follows:\n1. Frequency of incidence: The frequency of GA-sequences in mammalian genomes should be 10^-16 or smaller, but the chromosomes of human, chimpanzee, dog, cat, rat, and mouse contain many tens of thousands of them ubiquitously located along the chromosomes with a species-dependent distribution.\n2. Length: GA-sequences are longer than 50 bases in length, but consist exclusively of G's and A's.\n3. Distribution: GA-sequences are found in all mammalian genomes studied, including human, chimpanzee, dog, cat, rat, and mouse.\n4. Functions: The functions of pure GA-sequences are not known, but the article speculates that they may serve as genomic sign posts that help guide polymerases and transcription factors to their proper targets, and/or as spatial linkers that help generate the 3-dimensional organization of the genome.\n5. Sequence diversity: The sequence diversity of GA-sequences is greatest among the a subunits of G proteins, with at least 15 distinct Ga subunit genes identified in various organisms.\n6. Presence in G proteins: GA-sequences are present in G proteins, with subunits of G proteins found in several organisms.\n7. Distribution in organisms: GA-sequences are found in all organisms studied, including bacteria, archaea, and eukaryotes.\n8. Role in transcriptional regulation: The article suggests that GA-sequences may play a role in transcriptional regulation, possibly by serving as genomic sign posts or spatial linkers that help guide polymerases and transcription factors to their proper targets.\n9. Role in 3D genome organization: The article also suggests that GA-sequences may play a role in the 3-dimensional organization of the genome, possibly by serving as spatial linkers that help generate the 3-dimensional organization of the genome.\nIn summary, the properties of mammalian GA-sequences",
    "llama-2-7b-chat-hf_fact_raw": "1. Mammalian GA-sequences have a frequency of incidence that is ubiquitously located along the chromosomes with a species-dependent distribution.\n2. GA-sequences are longer than 50 bases in length and consist exclusively of G's and A's.\n3. GA-sequences are found in all mammalian genomes studied, including human, chimpanzee, dog, cat, rat, and mouse.\n4. The functions of pure GA-sequences are not known, but they may serve as genomic signposts or spatial linkers in the genome.\n5. The sequence diversity of GA-sequences is greatest among the α subunits of G proteins, with at least 15 distinct Gα subunit genes identified in various organisms.",
    "llama-2-7b-chat-hf_fact": [
      "Mammalian GA-sequences have a frequency of incidence that is ubiquitously located along the chromosomes with a species-dependent distribution.",
      "GA-sequences are longer than 50 bases in length and consist exclusively of G's and A's.",
      "GA-sequences are found in all mammalian genomes studied, including human, chimpanzee, dog, cat, rat, and mouse.",
      "The functions of pure GA-sequences are not known, but they may serve as genomic signposts or spatial linkers in the genome.",
      "The sequence diversity of GA-sequences is greatest among the α subunits of G proteins, with at least 15 distinct Gα subunit genes identified in various organisms."
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, there are 7 Groucho-related genes (GRGs) contained in the mouse genome:\n1. Grg1\n2. Grg2\n3. Grg3\n4. Grg4\n5. Grg5\n6. Grg6\n7. Grg7\nThese genes are also referred to as TLE genes in some documents, particularly Document 7. The Grg family is subdivided into two protein groups in mammals, the long GRGs (GRG 1-4) and the truncated family members (GRG5...).\nIt is worth noting that the nomenclature for these genes can be confusing, with different names being used in different documents and even within the same document. However, based on the information provided, there are 7 GRGs contained in the mouse genome.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are 7 Groucho-related genes (GRGs) in the mouse genome.\n2. The Groucho-related genes in the mouse genome are named Grg1, Grg2, Grg3, Grg4, Grg5, Grg6, and Grg7.\n3. Groucho-related genes are also referred to as TLE genes.\n4. The Grg family in mammals is subdivided into two protein groups: the long GRGs (GRG 1-4) and the truncated family members (GRG5 and beyond).",
    "llama-2-7b-chat-hf_fact": [
      "There are 7 Groucho-related genes (GRGs) in the mouse genome.",
      "The Groucho-related genes in the mouse genome are named Grg1, Grg2, Grg3, Grg4, Grg5, Grg6, and Grg7.",
      "Groucho-related genes are also referred to as TLE genes.",
      "The Grg family in mammals is subdivided into two protein groups: the long GRGs (GRG 1-4) and the truncated family members (GRG5 and beyond)."
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the RNA polymerase II subunit that carries RNA cleavage activity is Rpb9. Document 7 mentions that Rpb9-deficient Pol II is less able to respond to stimulation of transcript cleavage by TFIIS in vitro and generates different cleavage products than wild-type Pol II. The document also states that the Rpb9 subunit is highly conserved among eukaryotes and can correct the growth defect of cells lacking TFIIS. Therefore, it can be concluded that Rpb9 is the subunit responsible for carrying RNA cleavage activity in RNA polymerase II.",
    "llama-2-7b-chat-hf_fact_raw": "1. The RNA polymerase II subunit that carries RNA cleavage activity is Rpb9.\n2. Rpb9-deficient Pol II is less able to respond to stimulation of transcript cleavage by TFIIS in vitro.\n3. Rpb9-deficient Pol II generates different cleavage products than wild-type Pol II.\n4. The Rpb9 subunit is highly conserved among eukaryotes.\n5. The Rpb9 subunit can correct the growth defect of cells lacking TFIIS.",
    "llama-2-7b-chat-hf_fact": [
      "The RNA polymerase II subunit that carries RNA cleavage activity is Rpb9.",
      "Rpb9-deficient Pol II is less able to respond to stimulation of transcript cleavage by TFIIS in vitro.",
      "Rpb9-deficient Pol II generates different cleavage products than wild-type Pol II.",
      "The Rpb9 subunit is highly conserved among eukaryotes.",
      "The Rpb9 subunit can correct the growth defect of cells lacking TFIIS."
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the genetic basis of Ohdo syndrome is a mutation in the KAT6B gene. This gene provides instructions for making a type of enzyme called a histone acetyltransferase, which is involved in regulating gene expression. The SBBYS variant of Ohdo syndrome is caused by mutations in the KAT6B gene, which leads to intellectual disability, distinctive facial features, and abnormalities affecting other parts of the body. The Maat-Kievit-Brunner type of Ohdo syndrome is also caused by a mutation in the KAT6B gene, but it has only been reported in males. The diagnosis of Ohdo syndrome is typically made through a combination of clinical evaluation and genetic testing, and it is estimated to occur in fewer than 1 per million people.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ohdo syndrome is caused by a mutation in the KAT6B gene.\n2. The KAT6B gene is responsible for making an enzyme called a histone acetyltransferase.\n3. The SBBYS variant of Ohdo syndrome leads to intellectual disability, distinctive facial features, and abnormalities affecting other parts of the body.\n4. The Maat-Kievit-Brunner type of Ohdo syndrome has been reported only in males.\n5. Ohdo syndrome is diagnosed through clinical evaluation and genetic testing and occurs in fewer than 1 per million people.",
    "llama-2-7b-chat-hf_fact": [
      "Ohdo syndrome is caused by a mutation in the KAT6B gene.",
      "The KAT6B gene is responsible for making an enzyme called a histone acetyltransferase.",
      "The SBBYS variant of Ohdo syndrome leads to intellectual disability, distinctive facial features, and abnormalities affecting other parts of the body.",
      "The Maat-Kievit-Brunner type of Ohdo syndrome has been reported only in males.",
      "Ohdo syndrome is diagnosed through clinical evaluation and genetic testing and occurs in fewer than 1 per million people."
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the R/Bioconductor package that has been developed for the analysis of psychiatric disease genes is Psygenet2r. According to Document 0, Psygenet2r is especially suited for network medicine analysis of psychiatric disorders, and it is implemented in R and available under MIT license from Bioconductor.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R/Bioconductor package developed for the analysis of psychiatric disease genes is called Psygenet2r.\n2. Psygenet2r is particularly designed for network medicine analysis of psychiatric disorders.\n3. Psygenet2r is implemented in the R programming language.\n4. Psygenet2r is available under the MIT license.\n5. Psygenet2r can be obtained from Bioconductor.",
    "llama-2-7b-chat-hf_fact": [
      "The R/Bioconductor package developed for the analysis of psychiatric disease genes is called Psygenet2r.",
      "Psygenet2r is particularly designed for network medicine analysis of psychiatric disorders.",
      "Psygenet2r is implemented in the R programming language.",
      "Psygenet2r is available under the MIT license.",
      "Psygenet2r can be obtained from Bioconductor."
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_response": "Based on the provided documents, the swirl sign in intracerebral hemorrhage (ICH) refers to the non-contrast CT appearance of acute extravasation of blood into a hematoma. It represents unclotted fresh blood that is of lower attenuation than the clotted blood surrounding it. The swirl sign is seen in areas of low attenuation, radiolucency, or irregular density on CT imaging.\nThe documents suggest that the swirl sign is a useful diagnostic marker for ICH, as it can help identify patients with this condition. The prevalence of the swirl sign in ICH is not well established, but it is reported to be present in a significant proportion of cases. The reliability of subjective evaluation of the swirl sign on CT imaging has also been studied, and it is found to be moderate to good.\nThe swirl sign has been found to be associated with poorer prognostic factors, such as initial hematoma volume, age, low Glasgow Coma Scale score, and shorter duration of follow-up. However, the utility of the swirl sign in predicting hematoma expansion has not been thoroughly investigated.\nIn summary, the swirl sign in ICH is a non-contrast CT appearance of acute extravasation of blood into a hematoma, and it is a useful diagnostic marker for this condition. Further studies are needed to fully understand the prognostic value of the swirl sign in ICH.",
    "llama-2-7b-chat-hf_fact_raw": "1. The swirl sign in intracerebral hemorrhage refers to the non-contrast CT appearance of acute extravasation of blood into a hematoma.\n2. The swirl sign represents unclotted fresh blood that is of lower attenuation than the clotted blood surrounding it.\n3. The swirl sign is seen in areas of low attenuation, radiolucency, or irregular density on CT imaging.\n4. The swirl sign is a useful diagnostic marker for identifying patients with intracerebral hemorrhage.\n5. The swirl sign has been associated with poorer prognostic factors such as initial hematoma volume, age, low Glasgow Coma Scale score, and shorter duration of follow-up.",
    "llama-2-7b-chat-hf_fact": [
      "The swirl sign in intracerebral hemorrhage refers to the non-contrast CT appearance of acute extravasation of blood into a hematoma.",
      "The swirl sign represents unclotted fresh blood that is of lower attenuation than the clotted blood surrounding it.",
      "The swirl sign is seen in areas of low attenuation, radiolucency, or irregular density on CT imaging.",
      "The swirl sign is a useful diagnostic marker for identifying patients with intracerebral hemorrhage.",
      "The swirl sign has been associated with poorer prognostic factors such as initial hematoma volume, age, low Glasgow Coma Scale score, and shorter duration of follow-up."
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it can be concluded that Arabidopsis ROF1 expression is induced by heat stress and developmentally regulated. ROF1 binds heat shock proteins HSP90.1 via its tetratricopeptide repeat domain and localizes in the cytoplasm under normal conditions. The expression of ROF1 is differentially regulated in response to heat stress, with ROF2 being the only bona fide heat-stress protein among the two genes. The accumulation of ROF1/ROF2 proteins is sustained for at least 4 hours after recovery from heat stress, suggesting a role for ROF1 in prolonging thermotolerance by maintaining the levels of small heat shock proteins that are essential for survival at high temperatures.\nAdditionally, the documents suggest that ROF1 interacts with HSP90.1 and affects the accumulation of HsfA2-regulated small heat shock proteins, which are essential for survival at high temperatures. The interaction between ROF1 and HSP90.1 is mediated by the tetratricopeptide repeat domain of ROF1, and the calmodulin binding domain of ROF1 may also play a role in this process.\nOverall, the information provided in the documents suggests that ROF1 plays a critical role in regulating thermotolerance in Arabidopsis by interacting with heat shock proteins and modulating the accumulation of small heat shock proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. Arabidopsis ROF1 expression is induced by heat stress.\n2. ROF1 binds heat shock proteins HSP90.1 via its tetratricopeptide repeat domain.\n3. ROF1 localizes in the cytoplasm under normal conditions.\n4. The accumulation of ROF1/ROF2 proteins is sustained for at least 4 hours after recovery from heat stress.\n5. ROF1 interacts with HSP90.1 and affects the accumulation of HsfA2-regulated small heat shock proteins.",
    "llama-2-7b-chat-hf_fact": [
      "Arabidopsis ROF1 expression is induced by heat stress.",
      "ROF1 binds heat shock proteins HSP90.1 via its tetratricopeptide repeat domain.",
      "ROF1 localizes in the cytoplasm under normal conditions.",
      "The accumulation of ROF1/ROF2 proteins is sustained for at least 4 hours after recovery from heat stress.",
      "ROF1 interacts with HSP90.1 and affects the accumulation of HsfA2-regulated small heat shock proteins."
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 1-9, the most common protein associated with hereditary renal amyloidosis is Leukocyte cell-derived chemotaxin 2 (LECT2). This protein is a recently discovered form of amyloidosis that most often affects the kidneys and liver, and is inherited in an autosomal dominant manner. Therefore, if a user's parent has hereditary amyloidosis, they have a 50% chance of inheriting the gene mutation and developing the disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. Leukocyte cell-derived chemotaxin 2 (LECT2) is the most common protein associated with hereditary renal amyloidosis.\n2. LECT2 amyloidosis often affects the kidneys and liver.\n3. Hereditary amyloidosis associated with LECT2 is inherited in an autosomal dominant manner.\n4. A person with a parent who has hereditary amyloidosis has a 50% chance of inheriting the gene mutation.",
    "llama-2-7b-chat-hf_fact": [
      "Leukocyte cell-derived chemotaxin 2 (LECT2) is the most common protein associated with hereditary renal amyloidosis.",
      "LECT2 amyloidosis often affects the kidneys and liver.",
      "Hereditary amyloidosis associated with LECT2 is inherited in an autosomal dominant manner.",
      "A person with a parent who has hereditary amyloidosis has a 50% chance of inheriting the gene mutation."
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-2-7b-chat-hf_response": "Yes, the proteome of the mouse hippocampus has been analyzed in several studies. The studies you provided in Documents 0-9 investigate the proteome of the mouse hippocampus at different ages, under different conditions, and using different techniques. Here is a summary of the key findings:\nDocument 0: The study analyzed the hippocampal proteome at two ages (5 and 10 months) to reveal the relationship between proteomic changes and the progression of amyloid plaque deposition in the hippocampus. The study identified 9,313 total proteins and 1411 differentially expressed proteins (DEPs) in 5- and 10-month-old wild-type and 5XFAD mice.\nDocument 1: The study investigated the acute stress (AS) response in the mouse HC using a multiomic approach. The study identified a pronounced molecular response to AS, which starts with an immediate and sustained increase in protein abundance.\nDocument 2: The study characterized age-related proteomic changes in the brain using quantitative proteomics. The study examined brain tissues, cortex, and hippocampus of mice at three age points (3, 15, and 24 months) and identified 10,573 total proteins and 1,331 differentially expressed proteins (DEPs).\nDocument 3: The study analyzed the hippocampal proteome at two ages (5 and 10 months) to reveal the relationship between proteomic changes and the progression of amyloid plaque deposition in the hippocampus. The study identified 9,313 total proteins and 1411 differentially expressed proteins (DEPs) in 5- and 10-month-old wild-type and 5XFAD mice.\nDocument 4: The study investigated proteomic changes in the brain of young (4-month) and aged (16-month) B6129SF2/J male mice using nano liquid chromatography tandem mass spectrometry (NanoLC-ESI-MS/MS) combined with tandem mass tag (",
    "llama-2-7b-chat-hf_fact_raw": "1. The proteome of the mouse hippocampus has been analyzed in several studies.\n2. One study identified 9,313 total proteins and 1,411 differentially expressed proteins in the hippocampus of 5- and 10-month-old wild-type and 5XFAD mice.\n3. Another study investigated the acute stress response in the mouse hippocampus and found an immediate and sustained increase in protein abundance.\n4. A different study characterized age-related proteomic changes in the mouse brain and identified 10,573 total proteins and 1,331 differentially expressed proteins across three age points (3, 15, and 24 months).\n5. Proteomic changes in the brain of young (4-month) and aged (16-month) B6129SF2/J male mice were investigated using nano liquid chromatography tandem mass spectrometry (NanoLC-ESI-MS/MS) combined with tandem mass tag.",
    "llama-2-7b-chat-hf_fact": [
      "The proteome of the mouse hippocampus has been analyzed in several studies.",
      "One study identified 9,313 total proteins and 1,411 differentially expressed proteins in the hippocampus of 5- and 10-month-old wild-type and 5XFAD mice.",
      "Another study investigated the acute stress response in the mouse hippocampus and found an immediate and sustained increase in protein abundance.",
      "A different study characterized age-related proteomic changes in the mouse brain and identified 10,573 total proteins and 1,331 differentially expressed proteins across three age points (3, 15, and 24 months).",
      "Proteomic changes in the brain of young (4-month) and aged (16-month) B6129SF2/J male mice were investigated using nano liquid chromatography tandem mass spectrometry (NanoLC-ESI-MS/MS) combined with tandem mass tag."
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it can be concluded that mouse chromosomes are acrocentric. This is supported by multiple documents, including Document 0, which states that all mouse chromosomes are acrocentric, and Document 7, which mentions that telomeres are essential functional elements of eukaryotic chromosomes that are required for their accurate segregation. Additionally, Document 4 mentions that mouse chromosomes are telocentric, with centromeric satellite arrays located at or near one end of the chromosome, which is consistent with the acrocentric chromosome structure.\nIt is worth noting that some mammalian species, such as humans, have a combination of acrocentric, submetacentric, and metacentric chromosomes, as mentioned in Document 5. However, the documents provided do not provide information on the chromosome structure of other mammalian species, so it cannot be concluded whether all mammalian species have acrocentric chromosomes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mouse chromosomes are acrocentric.\n2. Document 0 states that all mouse chromosomes are acrocentric.\n3. Document 7 mentions that telomeres are essential functional elements of eukaryotic chromosomes required for their accurate segregation.\n4. Document 4 describes mouse chromosomes as telocentric, with centromeric satellite arrays located at or near one end of the chromosome.\n5. Humans have a combination of acrocentric, submetacentric, and metacentric chromosomes, as mentioned in Document 5.",
    "llama-2-7b-chat-hf_fact": [
      "Mouse chromosomes are acrocentric.",
      "Document 0 states that all mouse chromosomes are acrocentric.",
      "Document 7 mentions that telomeres are essential functional elements of eukaryotic chromosomes required for their accurate segregation.",
      "Document 4 describes mouse chromosomes as telocentric, with centromeric satellite arrays located at or near one end of the chromosome.",
      "Humans have a combination of acrocentric, submetacentric, and metacentric chromosomes, as mentioned in Document 5."
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the siRNA-based drug that is in clinical trials for the treatment of pancreatic cancer is Adagrasib.\nDocument 2 mentions that a multinational randomized phase 2b clinical trial is ongoing for the evaluation of efficacy of siRNA-based drug in combination with chemotherapy, and that both Adagrasib and Sotorasib showed promising results in pretreated Kras G12C pancreatic cancer patients with an acceptable safety profile.\nTherefore, it can be concluded that Adagrasib is the siRNA-based drug that is currently in clinical trials for the treatment of pancreatic cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. Adagrasib is an siRNA-based drug in clinical trials for the treatment of pancreatic cancer.\n2. There is a multinational randomized phase 2b clinical trial evaluating the efficacy of an siRNA-based drug in combination with chemotherapy for pancreatic cancer.\n3. Adagrasib and Sotorasib have shown promising results in pretreated Kras G12C pancreatic cancer patients.\n4. Adagrasib has an acceptable safety profile in clinical trials for pancreatic cancer treatment.",
    "llama-2-7b-chat-hf_fact": [
      "Adagrasib is an siRNA-based drug in clinical trials for the treatment of pancreatic cancer.",
      "There is a multinational randomized phase 2b clinical trial evaluating the efficacy of an siRNA-based drug in combination with chemotherapy for pancreatic cancer.",
      "Adagrasib and Sotorasib have shown promising results in pretreated Kras G12C pancreatic cancer patients.",
      "Adagrasib has an acceptable safety profile in clinical trials for pancreatic cancer treatment."
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the HPG Pore appears to be a toolkit for exploring and analyzing nanopore sequencing data. It can run on both individual computers and in the Hadoop distributed computing framework, which allows for easy scale-up to manage large amounts of data. The toolkit has several features in common with other programs such as poRe and Poretools, but also implements unique features related to quality control and other parameters of the sequence obtained. HPG Pore is efficient and scalable, allowing for virtually unlimited sequencing data scalability, and can run on both individual computers and in the Hadoop distributed computing framework.\nIn summary, the HPG Pore is a toolkit for analyzing nanopore sequencing data, it can run on both individual computers and in the Hadoop distributed computing framework, it has several features in common with other programs but also implements unique features, and it is efficient and scalable.",
    "llama-2-7b-chat-hf_fact_raw": "1. The HPG Pore is a toolkit for exploring and analyzing nanopore sequencing data.\n2. The HPG Pore can run on both individual computers and in the Hadoop distributed computing framework.\n3. The toolkit is designed to scale up to manage large amounts of data.\n4. The HPG Pore has features in common with other programs such as poRe and Poretools.\n5. The HPG Pore includes unique features related to quality control and other parameters of the sequence obtained.",
    "llama-2-7b-chat-hf_fact": [
      "The HPG Pore is a toolkit for exploring and analyzing nanopore sequencing data.",
      "The HPG Pore can run on both individual computers and in the Hadoop distributed computing framework.",
      "The toolkit is designed to scale up to manage large amounts of data.",
      "The HPG Pore has features in common with other programs such as poRe and Poretools.",
      "The HPG Pore includes unique features related to quality control and other parameters of the sequence obtained."
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the 959 Nematode Genomes initiative is a community-curated semantic wiki that aims to coordinate the sequencing efforts of individual labs to collectively sequence 959 genomes spanning the phylum Nematoda. The initiative was launched to inspire, promote, and coordinate genomic sequencing across the diversity of the phylum, with the ultimate goal of understanding the origins of parasitism, the dynamics of genomic change, and the adaptations that have made Nematoda one of the most successful animal phyla.\nThe initiative is built on the success of the sequencing of the complete genome of the nematode Caenorhabditis elegans, which was a landmark achievement that ushered in a new era of whole-organism, systems analyses of the biology of this powerful model organism. The 959 Nematode Genomes initiative is intended to build upon this success by collectively sequencing the genomes of 959 species across the phylum Nematoda, which is estimated to include around 25,000 nematode parasites of vertebrates, most of which remain undescribed.\nThe initiative is a community-curated wiki, which means that it is maintained and updated by a community of scientists and researchers who are interested in the study of nematodes. The wiki provides a platform for researchers to share information, resources, and data related to the sequencing of nematode genomes, and to track the progress of sequencing projects.\nOverall, the 959 Nematode Genomes initiative is an ambitious effort to explore the diversity of nematode genomes and to gain a better understanding of the biology of these fascinating organisms. By coordinating the sequencing efforts of individual labs and sharing data and resources, the initiative aims to make significant advances in the field of nematode genomics and to uncover new insights into the evolution, development, and behavior of these important organisms.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 959 Nematode Genomes initiative aims to coordinate the sequencing of 959 genomes spanning the phylum Nematoda.\n2. The initiative was launched to understand the origins of parasitism, the dynamics of genomic change, and adaptations in Nematoda.\n3. The complete genome of the nematode Caenorhabditis elegans has been sequenced prior to the launch of the initiative.\n4. The phylum Nematoda is estimated to include around 25,000 nematode parasites of vertebrates.\n5. The 959 Nematode Genomes initiative is a community-curated semantic wiki maintained by scientists and researchers.",
    "llama-2-7b-chat-hf_fact": [
      "The 959 Nematode Genomes initiative aims to coordinate the sequencing of 959 genomes spanning the phylum Nematoda.",
      "The initiative was launched to understand the origins of parasitism, the dynamics of genomic change, and adaptations in Nematoda.",
      "The complete genome of the nematode Caenorhabditis elegans has been sequenced prior to the launch of the initiative.",
      "The phylum Nematoda is estimated to include around 25,000 nematode parasites of vertebrates.",
      "The 959 Nematode Genomes initiative is a community-curated semantic wiki maintained by scientists and researchers."
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the R package that has been developed for analyzing Non-invasive prenatal testing (NIPT) data is NIPTeR. Document 2 and Document 9 specifically mention NIPTeR as an open-source R Package that enables fast NIPT analysis and simple but flexible workflow creation, including variation reduction, trisomy prediction algorithms, and quality control. Additionally, Document 9 mentions that recent studies have been focused on developing NIPD methods, including the use of fetal nucleated red blood cells (fNRBCs) or circulating trophoblasts (cTBs), which can be analyzed using NIPTeR. Therefore, it can be concluded that NIPTeR is the R package that has been developed for analyzing NIPT data.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R package developed for analyzing Non-invasive prenatal testing (NIPT) data is called NIPTeR.\n2. NIPTeR is mentioned as an open-source R Package in Document 2 and Document 9.\n3. NIPTeR enables fast NIPT analysis and the creation of a simple but flexible workflow.\n4. NIPTeR includes features for variation reduction, trisomy prediction algorithms, and quality control.\n5. Recent studies on developing NIPD methods, such as using fetal nucleated red blood cells (fNRBCs) or circulating trophoblasts (cTBs), can be analyzed using NIPTeR.",
    "llama-2-7b-chat-hf_fact": [
      "The R package developed for analyzing Non-invasive prenatal testing (NIPT) data is called NIPTeR.",
      "NIPTeR is mentioned as an open-source R Package in Document 2 and Document 9.",
      "NIPTeR enables fast NIPT analysis and the creation of a simple but flexible workflow.",
      "NIPTeR includes features for variation reduction, trisomy prediction algorithms, and quality control.",
      "Recent studies on developing NIPD methods, such as using fetal nucleated red blood cells (fNRBCs) or circulating trophoblasts (cTBs), can be analyzed using NIPTeR."
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbach’s syndrome.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, Achenbach's syndrome is a rare condition characterized by recurrent episodes of sudden pain, bruising, and swelling of one or more fingers. It is more common in middle-aged females, with a median age of onset of 48-50 years. The syndrome was first described by Walter Achenbach in 1958, and it is also known as paroxysmal finger hematoma or blue finger syndrome. The symptoms of Achenbach's syndrome include sudden pain onset in the fingers or hands, followed by blue discoloration. The condition is self-limiting and the diagnosis is based on history and clinical examination. It is important to recognize this rare syndrome in order to address patient concerns and provide appropriate treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Achenbach's syndrome is characterized by recurrent episodes of sudden pain, bruising, and swelling of one or more fingers.\n2. Achenbach's syndrome is more common in middle-aged females.\n3. The median age of onset for Achenbach's syndrome is between 48-50 years.\n4. Walter Achenbach first described Achenbach's syndrome in 1958.\n5. Achenbach's syndrome is also known as paroxysmal finger hematoma or blue finger syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Achenbach's syndrome is characterized by recurrent episodes of sudden pain, bruising, and swelling of one or more fingers.",
      "Achenbach's syndrome is more common in middle-aged females.",
      "The median age of onset for Achenbach's syndrome is between 48-50 years.",
      "Walter Achenbach first described Achenbach's syndrome in 1958.",
      "Achenbach's syndrome is also known as paroxysmal finger hematoma or blue finger syndrome."
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the algorithm used for detection of long repeat expansions is likely to be ExpansionHunter.\nDocument 2 mentions that ExpansionHunter was used to analyze WGS data from 3001 ALS patients and correctly classified all expanded samples as either expansions or potential expansions. This suggests that ExpansionHunter is effective in detecting long repeat expansions in WGS data.\nDocument 3 mentions that many algorithms use depth of coverage to detect long repeat expansions, but does not specifically mention ExpansionHunter. However, the document does provide a reference to a paper by Bekritsky et al. (2017) that describes a method for detecting long repeat expansions from PCR-free whole-genome sequence data, which is consistent with the approach used by ExpansionHunter.\nDocument 4 mentions that repeat-primed PCR (RP-PCR) is a widely used method for detecting C9orf72 repeat expansions, but notes that interpretation of PCR results can be challenging due to indels in the flanking regions of the repeat. This suggests that RP-PCR may not be as effective at detecting long repeat expansions as algorithms that can analyze whole-genome sequence data, such as ExpansionHunter.\nDocument 5 mentions that bioinformatic methods have identified new repeat expansions in humans, but requires alignment information to identify them. This suggests that ExpansionHunter or other algorithms that can analyze whole-genome sequence data may be useful for identifying new repeat expansions.\nDocument 6 mentions that alternative repeat motifs are found in some disorders associated with tandem repeat expansions, which complicates identification. However, a recently developed algorithm can now detect them in whole-genome sequence data, which is consistent with the approach used by ExpansionHunter.\nDocument 7 mentions that whole genome STR analysis can be used to detect long repeat expansions, but does not provide specific information about the algorithm used.\nDocument 8 mentions that repeat-primed PCR (RP-PCR) is a widely used method for detecting C9orf72 repeat expansions, but notes that interpretation of PCR results can be challenging due to indels in the flanking regions of the",
    "llama-2-7b-chat-hf_fact_raw": "1. ExpansionHunter is an algorithm used for the detection of long repeat expansions.\n2. ExpansionHunter was used to analyze WGS data from 3001 ALS patients and correctly classified all expanded samples.\n3. Many algorithms, including ExpansionHunter, use depth of coverage to detect long repeat expansions.\n4. Repeat-primed PCR (RP-PCR) is a method for detecting C9orf72 repeat expansions, but its interpretation can be challenging due to indels in the flanking regions.\n5. Bioinformatic methods, potentially including ExpansionHunter, are capable of identifying new repeat expansions in human whole-genome sequence data.",
    "llama-2-7b-chat-hf_fact": [
      "ExpansionHunter is an algorithm used for the detection of long repeat expansions.",
      "ExpansionHunter was used to analyze WGS data from 3001 ALS patients and correctly classified all expanded samples.",
      "Many algorithms, including ExpansionHunter, use depth of coverage to detect long repeat expansions.",
      "Repeat-primed PCR (RP-PCR) is a method for detecting C9orf72 repeat expansions, but its interpretation can be challenging due to indels in the flanking regions.",
      "Bioinformatic methods, potentially including ExpansionHunter, are capable of identifying new repeat expansions in human whole-genome sequence data."
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, neuroligin-3 promotes the growth and proliferation of high-grade gliomas (HGGs), which are a type of brain tumor. The documents suggest that neuroligin-3 is an activity-regulated secreted glioma mitogen that induces the PI3K-mTOR signaling pathway in HGG cells, leading to their proliferation and growth. The expression of neuroligin-3 is also inversely correlated with survival in human HGG.\nThe documents provide evidence that neuroligin-3 is involved in the pathogenesis of HGGs, and that it plays a critical role in promoting their growth and proliferation. The mechanisms by which neuroligin-3 promotes HGG growth involve its secretion from active neurons in the tumor microenvironment, which induces the PI3K-mTOR signaling pathway and feedforward expression of neuroligin-3 in glioma cells.\nIn summary, the information provided in the documents suggests that neuroligin-3 promotes the growth and proliferation of high-grade gliomas by inducing the PI3K-mTOR signaling pathway and feedforward expression of neuroligin-3 in glioma cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. Neuroligin-3 promotes the growth and proliferation of high-grade gliomas (HGGs), a type of brain tumor.\n2. Neuroligin-3 induces the PI3K-mTOR signaling pathway in HGG cells.\n3. The expression of neuroligin-3 is inversely correlated with survival in human HGG.\n4. Neuroligin-3 is secreted from active neurons in the tumor microenvironment of HGGs.\n5. Neuroligin-3's promotion of HGG growth involves feedforward expression of neuroligin-3 in glioma cells.",
    "llama-2-7b-chat-hf_fact": [
      "Neuroligin-3 promotes the growth and proliferation of high-grade gliomas (HGGs), a type of brain tumor.",
      "Neuroligin-3 induces the PI3K-mTOR signaling pathway in HGG cells.",
      "The expression of neuroligin-3 is inversely correlated with survival in human HGG.",
      "Neuroligin-3 is secreted from active neurons in the tumor microenvironment of HGGs.",
      "Neuroligin-3's promotion of HGG growth involves feedforward expression of neuroligin-3 in glioma cells."
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the approximate size of gas vesicles can be estimated to be:\n* Length: 0.1-2 μm (Document 0)\n* Width: 45-200 nm (Document 1)\n* Diameter: 0.2-1.5 μm (Document 5)\nIt is important to note that the size of gas vesicles can vary in different organisms and under different conditions. Additionally, the size of gas vesicles can be affected by factors such as the presence of other proteins and the degree of gas filling.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gas vesicles have an estimated length of 0.1-2 μm.\n2. Gas vesicles have an estimated width of 45-200 nm.\n3. Gas vesicles have an estimated diameter of 0.2-1.5 μm.\n4. The size of gas vesicles can vary in different organisms.\n5. The size of gas vesicles can be affected by factors such as the presence of other proteins and the degree of gas filling.",
    "llama-2-7b-chat-hf_fact": [
      "Gas vesicles have an estimated length of 0.1-2 μm.",
      "Gas vesicles have an estimated width of 45-200 nm.",
      "Gas vesicles have an estimated diameter of 0.2-1.5 μm.",
      "The size of gas vesicles can vary in different organisms.",
      "The size of gas vesicles can be affected by factors such as the presence of other proteins and the degree of gas filling."
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-2-7b-chat-hf_response": "Based on the provided documents, here are the BET proteins listed:\n1. BRD2\n2. BRD3\n3. BRD4\n4. BRDT\nThese proteins are members of the BET protein family, which are characterized by the presence of two N-terminal bromodomains (BD1 and BD2) and an extraterminal domain (ET). They are epigenetic readers that regulate gene transcription by binding to acetylated histones and master transcriptional factors. The BET family consists of four conserved members in mammals (BRD2, BRD3, BRD4, and BRDT) that regulate numerous cancer-related and immunity-associated genes.",
    "llama-2-7b-chat-hf_fact_raw": "1. BRD2 is a member of the BET protein family.\n2. BRD3 is a member of the BET protein family.\n3. BRD4 is a member of the BET protein family.\n4. BRDT is a member of the BET protein family.\n5. The BET protein family is characterized by having two N-terminal bromodomains and an extraterminal domain.",
    "llama-2-7b-chat-hf_fact": [
      "BRD2 is a member of the BET protein family.",
      "BRD3 is a member of the BET protein family.",
      "BRD4 is a member of the BET protein family.",
      "BRDT is a member of the BET protein family.",
      "The BET protein family is characterized by having two N-terminal bromodomains and an extraterminal domain."
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the algorithm that has been developed for prediction of protein subcellular localization using deep learning is DeepLoc. This algorithm was proposed in 2017 and uses a deep learning model to predict the subcellular localization of proteins. The paper describing the algorithm can be found in Bioinformatics, volume 33, issue 21, in 2017.\nDeepLoc uses a deep neural network to predict the subcellular localization of proteins based on their sequence information. The network consists of multiple layers of artificial neurons that learn to extract features from the protein sequence, followed by a classification layer that predicts the subcellular localization of the protein. The authors of the paper evaluated the performance of DeepLoc on a dataset of 1000 proteins and achieved an accuracy of 85.6%.\nOther algorithms that have been proposed for protein subcellular localization prediction using deep learning include DeepPSL, which uses a stacked autoencoder network to predict protein subcellular localization [1], and HCPL, which uses a hybrid deep-learning architecture to improve single-cell classification for protein localization [2].\nIt is worth noting that the accuracy of protein subcellular localization prediction can be improved by incorporating additional features, such as protein-protein interaction information [3, 4, 5]. However, the use of deep learning algorithms has shown promising results in this task, and can potentially provide more accurate predictions than traditional machine learning methods.",
    "llama-2-7b-chat-hf_fact_raw": "1. The DeepLoc algorithm was developed for prediction of protein subcellular localization using deep learning.\n2. DeepLoc was proposed in 2017.\n3. The paper describing DeepLoc was published in Bioinformatics, volume 33, issue 21, in 2017.\n4. DeepLoc uses a deep neural network to predict the subcellular localization of proteins from their sequence information.\n5. The authors of the DeepLoc paper reported an accuracy of 85.6% on a dataset of 1000 proteins.",
    "llama-2-7b-chat-hf_fact": [
      "The DeepLoc algorithm was developed for prediction of protein subcellular localization using deep learning.",
      "DeepLoc was proposed in 2017.",
      "The paper describing DeepLoc was published in Bioinformatics, volume 33, issue 21, in 2017.",
      "DeepLoc uses a deep neural network to predict the subcellular localization of proteins from their sequence information.",
      "The authors of the DeepLoc paper reported an accuracy of 85.6% on a dataset of 1000 proteins."
    ]
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, MULTOVL is a software application suite that detects and statistically analyzes multiple overlaps of genomic regions in a fast and efficient manner. It supports the detection of multiple region intersections, unions, and solitary genomic regions, and estimates the significance of actually observed overlaps by comparing them with empirical null distributions generated by random shuffling of the intervals throughout the genome.\nMULTOVL was developed by András Aszódi and is available as a pre-compiled binary package for some popular architectures, or as source code that can be built from scratch. The package provides a detailed documentation and installation instructions, including a guide for building the software from source code.\nMULTOVL has been used in various applications, including combining technical replicate tracks of ChIP-chip enrichment regions [1], and testing for significance of overlaps in a genomic region [2].\nIn summary, MULTOVL is a powerful tool for detecting and analyzing multiple overlaps of genomic regions, and can be used for a variety of applications in bioinformatics and genomics research.",
    "llama-2-7b-chat-hf_fact_raw": "1. MULTOVL is a software application suite designed for detecting and statistically analyzing multiple overlaps of genomic regions.\n2. The software supports the detection of multiple region intersections, unions, and solitary genomic regions.\n3. MULTOVL estimates the significance of observed overlaps by comparing them with empirical null distributions generated by random shuffling of intervals throughout the genome.\n4. András Aszódi developed MULTOVL.\n5. MULTOVL is available as a pre-compiled binary package for some popular architectures, and also as source code.",
    "llama-2-7b-chat-hf_fact": [
      "MULTOVL is a software application suite designed for detecting and statistically analyzing multiple overlaps of genomic regions.",
      "The software supports the detection of multiple region intersections, unions, and solitary genomic regions.",
      "MULTOVL estimates the significance of observed overlaps by comparing them with empirical null distributions generated by random shuffling of intervals throughout the genome.",
      "András Aszódi developed MULTOVL.",
      "MULTOVL is available as a pre-compiled binary package for some popular architectures, and also as source code."
    ]
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it is possible that GDF15 could be used as a biomarker for metformin treatment.\nDocument 1 suggests that there is evidence to suggest that GDF15 may be involved in the weight-lowering effects of metformin. Document 2 also suggests that GDF15 levels have been revealed as a robust biomarker for metformin use. Document 3 mentions that GDF15 was newly discovered to be a promising target of metformin, and Document 4 suggests that metformin activates GDF15 expression, which reduces appetite and induces weight loss.\nHowever, it is important to note that not all of the documents provide conclusive evidence for the use of GDF15 as a biomarker for metformin treatment. For example, Document 5 suggests that the GDF15-GFRAL pathway is dispensable for the effects of metformin on energy balance, and Document 6 mentions that GDF-15 has been widely explored as a biomarker for disease prognosis.\nOverall, while there is some evidence to suggest that GDF15 may be a biomarker for metformin treatment, further research is needed to confirm this association.",
    "llama-2-7b-chat-hf_fact_raw": "1. GDF15 may be involved in the weight-lowering effects of metformin, as suggested by Document 1.\n2. GDF15 levels have been identified as a potential biomarker for metformin use, according to Document 2.\n3. Document 3 indicates that GDF15 is a newly discovered promising target of metformin.\n4. Metformin activates GDF15 expression, which is associated with reduced appetite and induced weight loss, as mentioned in Document 4.\n5. The GDF15-GFRAL pathway may not be essential for the effects of metformin on energy balance, as suggested by Document 5.",
    "llama-2-7b-chat-hf_fact": [
      "GDF15 may be involved in the weight-lowering effects of metformin, as suggested by Document 1.",
      "GDF15 levels have been identified as a potential biomarker for metformin use, according to Document 2.",
      "Document 3 indicates that GDF15 is a newly discovered promising target of metformin.",
      "Metformin activates GDF15 expression, which is associated with reduced appetite and induced weight loss, as mentioned in Document 4.",
      "The GDF15-GFRAL pathway may not be essential for the effects of metformin on energy balance, as suggested by Document 5."
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it is more common for recursive splicing to occur in short introns.\nDocument 0 mentions that \"recursive splicing,\" which involves non-canonical splicing elements positioned deep within introns, often occurs in short introns. Similarly, Document 1 states that intronic sequences, which are mostly non-protein-coding, have evolved over time in eukaryotic genomes, and Document 2 mentions that many long Drosophila introns are processed by an unusual recursive strategy involving ratchet points (RPs).\nIn contrast, Documents 4, 6, and 7 suggest that recursive splicing is more common in short introns. Document 4 states that an intricate recursive RNA splicing mechanism that removes especially long introns (non-coding sequences) from genes has been found to be evolutionarily conserved and more prevalent in short introns. Document 6 mentions that recursive splicing, a process by which a single intron is removed from pre-mRNA transcripts in multiple distinct segments, has been observed in a small subset of Drosophila melanogaster introns, but only in short introns. Document 7 clarifies that intronic ratchet points (RPs) require a cryptic exon at the RP (an RS-exon), which is subsequently always skipped and thus absent from mRNA, indicating that recursive splicing is more common in short introns.\nDocument 8 provides further evidence for the prevalence of recursive splicing in short introns, stating that the recursively spliced introns range in size from 11,341 bp to 132,736 bp, with an average size of 45,164 bp, and that recursive-splice-site-containing introns are enriched in large introns (97% of all ...).\nIn summary, while the information provided in the documents does not definitively answer the user's question, the available evidence suggests that recursive splicing is more common in short introns than in long introns.",
    "llama-2-7b-chat-hf_fact_raw": "1. Recursive splicing often occurs in short introns according to Document 0.\n2. Document 4 indicates that an intricate recursive RNA splicing mechanism is more prevalent in short introns.\n3. Document 6 observes recursive splicing in a small subset of Drosophila melanogaster introns, specifically in short introns.\n4. Document 7 states that intronic ratchet points (RPs) require a cryptic exon at the RP, which is always skipped in mRNA, suggesting recursive splicing is more common in short introns.\n5. Document 8 notes that recursively spliced introns range in size from 11,341 bp to 132,736 bp, with an average size of 45,164 bp.",
    "llama-2-7b-chat-hf_fact": [
      "Recursive splicing often occurs in short introns according to Document 0.",
      "Document 4 indicates that an intricate recursive RNA splicing mechanism is more prevalent in short introns.",
      "Document 6 observes recursive splicing in a small subset of Drosophila melanogaster introns, specifically in short introns.",
      "Document 7 states that intronic ratchet points (RPs) require a cryptic exon at the RP, which is always skipped in mRNA, suggesting recursive splicing is more common in short introns.",
      "Document 8 notes that recursively spliced introns range in size from 11,341 bp to 132,736 bp, with an average size of 45,164 bp."
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the TALE-iD method appears to be a genome editing technology used for modifying essentially any sequence of interest in living cells or organisms. The method involves the use of TALE nucleases, activators, transposases, recombinases, epigenomic modifiers, and base editors to make targeted changes to the genome. The TALE-iD method is considered a broadly applicable approach for genome editing and has been used in various applications, including agricultural and medical research.\nThe documents provided provide additional information on the TALE-iD method, including its history, design guidelines, and applications. For example, Document 1 provides an overview of the TALEN technology, which is a type of TALE-iD method, and its achievements in agricultural and medical research. Document 2 provides information on the Cys 2-His 2 zinc-finger protein domain, which is a common DNA-binding motif found in eukaryotes and is used in the TALE-iD method. Document 3 highlights the main applications of targeted genome editing, including basic research, biotechnology, and medicine.\nOverall, the TALE-iD method appears to be a powerful tool for genome editing with a wide range of applications in various fields.",
    "llama-2-7b-chat-hf_fact_raw": "1. The TALE-iD method is used for genome editing.\n2. It allows for modifying any sequence of interest in living cells or organisms.\n3. The method uses TALE nucleases, activators, transposases, recombinases, epigenomic modifiers, and base editors.\n4. The TALE-iD method has applications in agricultural and medical research.\n5. The Cys 2-His 2 zinc-finger protein domain is used in the TALE-iD method and is a common DNA-binding motif in eukaryotes.",
    "llama-2-7b-chat-hf_fact": [
      "The TALE-iD method is used for genome editing.",
      "It allows for modifying any sequence of interest in living cells or organisms.",
      "The method uses TALE nucleases, activators, transposases, recombinases, epigenomic modifiers, and base editors.",
      "The TALE-iD method has applications in agricultural and medical research.",
      "The Cys 2-His 2 zinc-finger protein domain is used in the TALE-iD method and is a common DNA-binding motif in eukaryotes."
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the Lisp framework that has been developed for image processing is FunImageJ. Documents 1, 3, and 7 mention FunImageJ as a Lisp framework for scientific image processing, and Document 6 mentions that the image-processing framework described in the chapter utilizes modern 3D graphics hardware for 2D image-processing tasks. Document 8 also mentions image processing as manipulation of an image that has been digitized and uploaded into a computer, which aligns with FunImageJ's focus on scientific image processing.",
    "llama-2-7b-chat-hf_fact_raw": "1. FunImageJ is a Lisp framework developed for image processing.\n2. Documents 1, 3, and 7 mention FunImageJ in the context of scientific image processing.\n3. Document 6 describes a Lisp image-processing framework that utilizes modern 3D graphics hardware for 2D image-processing tasks.\n4. Document 8 relates image processing to the manipulation of digitized images uploaded into a computer.",
    "llama-2-7b-chat-hf_fact": [
      "FunImageJ is a Lisp framework developed for image processing.",
      "Documents 1, 3, and 7 mention FunImageJ in the context of scientific image processing.",
      "Document 6 describes a Lisp image-processing framework that utilizes modern 3D graphics hardware for 2D image-processing tasks.",
      "Document 8 relates image processing to the manipulation of digitized images uploaded into a computer."
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it is estimated that around 1,000 genes in Saccharomyces cerevisiae (baker's yeast) are the result of an ancient whole genome duplication. This estimate is based on the following information:\n1. Many duplicate genes have been found in S. cerevisiae, and these often seem to be phenotypically redundant (Documents 0, 3, 5, 7).\n2. A total of 1,625,809 high-quality reference-based SNPs were detected across 1,011 genomes of S. cerevisiae, indicating a high degree of genetic variation within the species (Document 1).\n3. A total of 457 duplicated gene pairs were identified in S. cerevisiae, with 145 paired regions covering 88% of the genome (Document 2).\n4. Genome duplication is a major evolutionary process that has shaped the genomes of several eukaryotic lineages, including fungi, and S. cerevisiae is a key model organism in this field (Documents 4, 7).\n5. The sequencing of the S. cerevisiae genome in the 1990s revealed the presence of conserved blocks of duplicated genes, indicating an ancestral duplication of the entire genome (Document 4).\nBased on these findings, it is estimated that around 1,000 genes in S. cerevisiae are the result of an ancient whole genome duplication. However, it is important to note that this estimate is based on a limited sample of the genome and may not be representative of the entire genome. Further research is needed to provide a more accurate estimate of the number of genes that have resulted from this ancient event.",
    "llama-2-7b-chat-hf_fact_raw": "1. It is estimated that around 1,000 genes in Saccharomyces cerevisiae are the result of an ancient whole genome duplication.\n2. A total of 1,625,809 high-quality reference-based SNPs were detected across 1,011 genomes of Saccharomyces cerevisiae.\n3. A total of 457 duplicated gene pairs were identified in Saccharomyces cerevisiae.\n4. Genome duplication is a major evolutionary process that has shaped the genomes of several eukaryotic lineages, including fungi.\n5. The sequencing of the Saccharomyces cerevisiae genome in the 1990s revealed the presence of conserved blocks of duplicated genes.",
    "llama-2-7b-chat-hf_fact": [
      "It is estimated that around 1,000 genes in Saccharomyces cerevisiae are the result of an ancient whole genome duplication.",
      "A total of 1,625,809 high-quality reference-based SNPs were detected across 1,011 genomes of Saccharomyces cerevisiae.",
      "A total of 457 duplicated gene pairs were identified in Saccharomyces cerevisiae.",
      "Genome duplication is a major evolutionary process that has shaped the genomes of several eukaryotic lineages, including fungi.",
      "The sequencing of the Saccharomyces cerevisiae genome in the 1990s revealed the presence of conserved blocks of duplicated genes."
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the complex that is bound by estrogen-related receptor β (Esrrb) is likely to be a complex of Esrrb with other transcription factors and coactivators.\nDocument 2 mentions that Esrrb activity at crucial regulatory elements of the pluripotency network, coupled with its role as a mitotic bookmarking factor and the ability to reset cellular metabolism, might explain its potent functions in ensuring the stability of pluripotency and driving the late stages of reprogramming. This suggests that Esrrb is involved in regulating the expression of genes involved in pluripotency and reprogramming, which is consistent with the idea that it forms a complex with other transcription factors and coactivators.\nDocument 5 mentions that Estrogen-related receptor gamma (Esrrg) regulates mitochondrial and synaptic genes and modulates vulnerability to synucleinopathy. Since Esrrb is a member of the same family as Esrrg, it is likely that Esrrb also regulates mitochondrial and synaptic genes, and may have similar functions as Esrrg.\nDocument 7 mentions that Estrogen-related receptors (ERRα, β and γ) are orphan nuclear receptors that control the transcription of genes involved in the production of cellular energy in response to developmental and hormonal signals. This suggests that Esrrb may be involved in regulating the expression of genes involved in cellular energy metabolism, which is consistent with the idea that it forms a complex with other transcription factors and coactivators.\nDocument 8 mentions that the structure of estrogen-related receptors (ERRs) is similar to that of estrogen receptors (ERα and ERβ), but they are incapable of being bound by estrogen. This suggests that Esrrb may have a similar structure to ERα and ERβ, but may not be directly activated by estrogen.\nBased on these findings, it is likely that Esrrb forms a complex with other transcription factors and coactivators to regulate the expression of genes involved in pluripotency, reprogramming, mitochondrial and synapt",
    "llama-2-7b-chat-hf_fact_raw": "1. Estrogen-related receptor β (Esrrb) is likely to form a complex with other transcription factors and coactivators.\n2. Esrrb is involved in regulating the expression of genes involved in pluripotency and reprogramming.\n3. Esrrb may regulate mitochondrial and synaptic genes and have functions similar to Estrogen-related receptor gamma (Esrrg).\n4. Estrogen-related receptors, including ERRα, β, and γ, control the transcription of genes involved in the production of cellular energy.\n5. The structure of estrogen-related receptors (ERRs) is similar to that of estrogen receptors (ERα and ERβ), but they are not bound by estrogen.",
    "llama-2-7b-chat-hf_fact": [
      "Estrogen-related receptor β (Esrrb) is likely to form a complex with other transcription factors and coactivators.",
      "Esrrb is involved in regulating the expression of genes involved in pluripotency and reprogramming.",
      "Esrrb may regulate mitochondrial and synaptic genes and have functions similar to Estrogen-related receptor gamma (Esrrg).",
      "Estrogen-related receptors, including ERRα, β, and γ, control the transcription of genes involved in the production of cellular energy.",
      "The structure of estrogen-related receptors (ERRs) is similar to that of estrogen receptors (ERα and ERβ), but they are not bound by estrogen."
    ]
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, ZCCHC17 appears to play a role in regulating gene expression, particularly in the context of Alzheimer's disease (AD).\nDocument 3 suggests that ZCCHC17 is a putative master regulator of synaptic gene dysfunction in AD, and that its dysfunction is predicted to cause impaired expression of synaptic genes. Document 4 further investigates the function of ZCCHC17 and its role in AD pathogenesis, finding that ZCCHC17 protein declines early in AD brain tissue, before significant gliosis or neuronal loss.\nDocument 5 provides evidence that ZCCHC17 modulates neuronal RNA splicing and supports cognitive resilience in AD. The study finds that ZCCHC17 is downregulated in the brains of AD patients, leading to impaired splicing of synaptic genes and cognitive decline.\nDocument 7 suggests that the ZCCHC genes play a regulatory role in the development and progression of solid tumors, including hepatocellular carcinoma (HCC). However, the information provided in the other documents does not mention ZCCHC17's role in HCC.\nIn summary, based on the information provided in the documents, ZCCHC17 appears to be involved in regulating gene expression, particularly in the context of AD, and may play a role in modulating neuronal RNA splicing and cognitive resilience. However, its role in HCC is not mentioned in the provided documents.",
    "llama-2-7b-chat-hf_fact_raw": "1. ZCCHC17 is implicated in regulating gene expression, especially in relation to Alzheimer's disease (AD).\n2. Document 3 suggests that ZCCHC17 is a putative master regulator of synaptic gene dysfunction in AD.\n3. Document 4 indicates that ZCCHC17 protein levels decline early in AD brain tissue, before significant gliosis or neuronal loss occurs.\n4. Document 5 provides evidence that ZCCHC17 modulates neuronal RNA splicing and supports cognitive resilience in AD.\n5. Document 7 suggests that ZCCHC genes are involved in the development and progression of solid tumors, including hepatocellular carcinoma (HCC).",
    "llama-2-7b-chat-hf_fact": [
      "ZCCHC17 is implicated in regulating gene expression, especially in relation to Alzheimer's disease (AD).",
      "Document 3 suggests that ZCCHC17 is a putative master regulator of synaptic gene dysfunction in AD.",
      "Document 4 indicates that ZCCHC17 protein levels decline early in AD brain tissue, before significant gliosis or neuronal loss occurs.",
      "Document 5 provides evidence that ZCCHC17 modulates neuronal RNA splicing and supports cognitive resilience in AD.",
      "Document 7 suggests that ZCCHC genes are involved in the development and progression of solid tumors, including hepatocellular carcinoma (HCC)."
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the proteins that form the nuclear pore basket in human cells are:\n1. Nucleoporins (Nups): According to Document 4, approximately two-thirds of the proteins that make up the nuclear pore complex (NPC) are classified as structural or scaffold Nups, which form the predominant physical structure of the pore.\n2. Inner pore ring: Document 9 mentions that the nuclear basket is anchored by the inner pore ring, which is one of the structural components of the NPC.\n3. Cytoplasmic filaments: Document 9 also mentions that the cytoplasmic filaments are peripheral elements emanating from the nuclear and cytoplasmic rings, which suggest that these filaments are part of the NPC structure.\nTherefore, the proteins that form the nuclear pore basket in human cells are:\n* Nucleoporins (Nups)\n* Inner pore ring\n* Cytoplasmic filaments\nIt's worth noting that the exact composition of the nuclear pore basket may vary depending on the specific cell type and the stage of the cell cycle. However, the proteins listed above are the main components of the NPC structure in human cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. Nucleoporins (Nups) make up approximately two-thirds of the proteins in the nuclear pore complex (NPC) in human cells.\n2. Structural or scaffold Nucleoporins (Nups) form the predominant physical structure of the nuclear pore.\n3. The nuclear basket is anchored by the inner pore ring, which is a structural component of the NPC.\n4. Cytoplasmic filaments are peripheral elements of the NPC structure in human cells.\n5. The exact composition of the nuclear pore basket may vary depending on the cell type and the stage of the cell cycle.",
    "llama-2-7b-chat-hf_fact": [
      "Nucleoporins (Nups) make up approximately two-thirds of the proteins in the nuclear pore complex (NPC) in human cells.",
      "Structural or scaffold Nucleoporins (Nups) form the predominant physical structure of the nuclear pore.",
      "The nuclear basket is anchored by the inner pore ring, which is a structural component of the NPC.",
      "Cytoplasmic filaments are peripheral elements of the NPC structure in human cells.",
      "The exact composition of the nuclear pore basket may vary depending on the cell type and the stage of the cell cycle."
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it can be concluded that gepotidacin is a type II topoisomerase inhibitor. This is supported by Document 2, which states that gepotidacin is a triazaacenaphthylene that strongly inhibits the growth of Neisseria gonorrhoeae and other conventional pathogens at low microgram concentrations, and Document 9, which mentions that gepotidacin is a first-in-class triazaacenaphthylene novel bacterial topoisomerase inhibitor (NBTI). Topoisomerase inhibitors are a class of antibiotics that work by interfering with the ability of bacteria to divide and replicate their DNA, and they are often used to treat bacterial infections.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gepotidacin is a type II topoisomerase inhibitor.\n2. Gepotidacin inhibits the growth of Neisseria gonorrhoeae and other conventional pathogens at low microgram concentrations.\n3. Gepotidacin is classified as a triazaacenaphthylene.\n4. Gepotidacin is a novel bacterial topoisomerase inhibitor (NBTI).\n5. Topoisomerase inhibitors interfere with the ability of bacteria to divide and replicate their DNA.",
    "llama-2-7b-chat-hf_fact": [
      "Gepotidacin is a type II topoisomerase inhibitor.",
      "Gepotidacin inhibits the growth of Neisseria gonorrhoeae and other conventional pathogens at low microgram concentrations.",
      "Gepotidacin is classified as a triazaacenaphthylene.",
      "Gepotidacin is a novel bacterial topoisomerase inhibitor (NBTI).",
      "Topoisomerase inhibitors interfere with the ability of bacteria to divide and replicate their DNA."
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-2-7b-chat-hf_response": "Canvas SPW is a tool for identifying inherited and de novo copy number variants (CNVs) from pedigree sequencing data. It supports a number of family structures and provides a wide range of scoring and filtering options to automate and streamline the identification of de novo CNVs. Canvas SPW is available for download from GitHub and can be run on Windows, Linux, or macOS.\nThe tool uses a combination of algorithms to identify CNVs, including a hidden Markov model (HMM) for detecting germline CNVs and a Bayesian framework for detecting de novo CNVs. Canvas SPW also infers genome-wide parameters such as cancer ploidy, purity, and heterogeneity from the sequencing data.\nCanvas SPW is designed to be user-friendly and can be used for a variety of applications, including identifying inherited CNVs in families, detecting de novo CNVs in tumors, and studying the genetic architecture of complex diseases. The tool can also be used to identify CNVs in small pedigrees, even for a single sample analysis.\nThe software is written in C# and can be run under a recent version of Mono, .NET 4.5.1, or .NET Core 1.1. The software is licensed under the MIT License, which allows for free use, modification, and distribution of the software.\nIn addition to Canvas SPW, there are other tools available for CNV calling, such as TrioCNV, MDTS, and PennCNV. These tools have different algorithms and features, and may be better suited for specific types of data or analysis.\nOverall, Canvas SPW is a powerful tool for identifying CNVs in pedigree sequencing data, and can be a valuable addition to the toolkit of any researcher or clinician working in the field of genomics.",
    "llama-2-7b-chat-hf_fact_raw": "1. Canvas SPW is a tool used for identifying inherited and de novo copy number variants (CNVs) from pedigree sequencing data.\n2. The tool supports various family structures and offers scoring and filtering options to identify de novo CNVs.\n3. Canvas SPW is compatible with Windows, Linux, and macOS operating systems.\n4. The software is written in C# and can be run using Mono, .NET 4.5.1, or .NET Core 1.1.\n5. Canvas SPW is licensed under the MIT License, which permits free use, modification, and distribution of the software.",
    "llama-2-7b-chat-hf_fact": [
      "Canvas SPW is a tool used for identifying inherited and de novo copy number variants (CNVs) from pedigree sequencing data.",
      "The tool supports various family structures and offers scoring and filtering options to identify de novo CNVs.",
      "Canvas SPW is compatible with Windows, Linux, and macOS operating systems.",
      "The software is written in C# and can be run using Mono, .NET 4.5.1, or .NET Core 1.1.",
      "Canvas SPW is licensed under the MIT License, which permits free use, modification, and distribution of the software."
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-2-7b-chat-hf_response": "Based on the provided documents, here are some STING agonists that have been identified:\n1. SHR1032: A novel STING agonist that stimulates anti-tumor immunity and directly induces apoptosis in acute myeloid leukemia (AML) cells. (Document 1)\n2. cGAMP interactor 1 (STING1): An endoplasmic reticulum-sessile protein that serves as a signaling hub, receiving input from several pattern recognition receptors and sensing ectopic DNA species in the cytosol. (Documents 2, 4, and 5)\n3. STING agonists: Are being developed as a novel cancer therapeutic, and early phase clinical trials of intratumoral STING agonists are already showing promise, alone and in combination with checkpoint blockade. (Document 6)\n4. Glyco-STING: A novel STING agonist that is being developed to target the tumor microenvironment and enhance the immune response. (Document 7)\nIt is important to note that these are some of the STING agonists that have been identified in the provided documents, and there may be other STING agonists that have been studied or are being developed. Additionally, the development of more potent and selective STING agonists as well as novel delivery systems that would allow for sustained inflammation in the tumor microenvironment could potentially augment response rates to current immunotherapy approaches and overcome acquired resistance. (Document 8)",
    "llama-2-7b-chat-hf_fact_raw": "1. SHR1032 is identified as a novel STING agonist that stimulates anti-tumor immunity and induces apoptosis in acute myeloid leukemia cells.\n2. cGAMP interactor 1 (STING1) is an endoplasmic reticulum-sessile protein that acts as a signaling hub and senses ectopic DNA species in the cytosol.\n3. STING agonists are being developed as a novel cancer therapeutic, and early phase clinical trials are showing promise.\n4. Glyco-STING is a novel STING agonist being developed to target the tumor microenvironment and enhance the immune response.\n5. Development of more potent and selective STING agonists and novel delivery systems is suggested to potentially augment response rates to current immunotherapy approaches and overcome acquired resistance.",
    "llama-2-7b-chat-hf_fact": [
      "SHR1032 is identified as a novel STING agonist that stimulates anti-tumor immunity and induces apoptosis in acute myeloid leukemia cells.",
      "cGAMP interactor 1 (STING1) is an endoplasmic reticulum-sessile protein that acts as a signaling hub and senses ectopic DNA species in the cytosol.",
      "STING agonists are being developed as a novel cancer therapeutic, and early phase clinical trials are showing promise.",
      "Glyco-STING is a novel STING agonist being developed to target the tumor microenvironment and enhance the immune response.",
      "Development of more potent and selective STING agonists and novel delivery systems is suggested to potentially augment response rates to current immunotherapy approaches and overcome acquired resistance."
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, SLIC-CAGE is a method for capturing the 5' ends of RNA polymerase II transcripts from as little as 5-10 ng of total RNA. This approach uses specially designed, selectively degradable carrier RNA to achieve a dramatic increase in sensitivity compared to existing CAGE methods. The ability of SLIC-CAGE to generate data for genome-wide promoterome with 1000-fold less material than required by existing CAGE methods is demonstrated by generating a complex, high-quality library from mouse embryonic day 11.5 primordial germ cells.\nIn more detail, SLIC-CAGE involves the following steps:\n1. Sample preparation: Total RNA is isolated from the sample of interest, typically in the range of 5-10 ng.\n2. Carrier RNA design: A specially designed, selectively degradable carrier RNA is synthesized to capture the 5' ends of RNA polymerase II transcripts.\n3. Library preparation: The carrier RNA is hybridized to the total RNA sample, and the complex is then captured using oligonucleotide probes.\n4. Sequencing: The captured library is then sequenced using Next-Generation Sequencing (NGS) technologies.\nThe advantages of SLIC-CAGE over existing CAGE methods include:\n1. Sensitivity: SLIC-CAGE is able to capture 5' ends of RNA polymerase II transcripts from as little as 5-10 ng of total RNA, which is a 1000-fold increase in sensitivity compared to existing CAGE methods.\n2. Low input requirements: The ability to generate data for genome-wide promoterome with 1000-fold less material than required by existing CAGE methods makes SLIC-CAGE a valuable tool for studies with limited sample availability.\n3. High-resolution transcription start site mapping: SLIC-CAGE allows for high-resolution transcription start site mapping using nanogram-levels of total RNA, which is a significant improvement over existing CAGE methods.\nIn summary, SLIC-CAGE is a powerful tool for",
    "llama-2-7b-chat-hf_fact_raw": "1. SLIC-CAGE is a method used for capturing the 5' ends of RNA polymerase II transcripts from as little as 5-10 ng of total RNA.\n2. The method uses selectively degradable carrier RNA to increase sensitivity compared to existing CAGE methods.\n3. SLIC-CAGE can generate a high-quality library from mouse embryonic day 11.5 primordial germ cells.\n4. SLIC-CAGE involves isolating total RNA, synthesizing carrier RNA, preparing a library, and sequencing using Next-Generation Sequencing technologies.\n5. SLIC-CAGE offers a 1000-fold increase in sensitivity for capturing 5' ends of RNA polymerase II transcripts compared to existing CAGE methods.",
    "llama-2-7b-chat-hf_fact": [
      "SLIC-CAGE is a method used for capturing the 5' ends of RNA polymerase II transcripts from as little as 5-10 ng of total RNA.",
      "The method uses selectively degradable carrier RNA to increase sensitivity compared to existing CAGE methods.",
      "SLIC-CAGE can generate a high-quality library from mouse embryonic day 11.5 primordial germ cells.",
      "SLIC-CAGE involves isolating total RNA, synthesizing carrier RNA, preparing a library, and sequencing using Next-Generation Sequencing technologies.",
      "SLIC-CAGE offers a 1000-fold increase in sensitivity for capturing 5' ends of RNA polymerase II transcripts compared to existing CAGE methods."
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, LEM-3 appears to play a crucial role in various cellular processes, including:\n1. Chromatin processing: LEM-3 is involved in the processing of chromatin bridges that arise from incomplete DNA replication, unresolved recombination intermediates, or the perturbance of chromosome structure. (Document 0)\n2. Meiotic recombination repair: The conserved LEM-3/Ankle1 nuclease is involved in the combinatorial regulation of meiotic recombination repair and chromosome segregation in Caenorhabditis elegans. (Document 1)\n3. Nuclear organization: Transcriptionally repressed chromatin localizes to specific areas within the eukaryotic nucleus and is often found at the nuclear periphery, which is thought to provide a specialized compartment for gene silencing. However, the molecular mechanisms that establish this spatial chromatin organization are still poorly understood. (Document 4)\n4. DNA repair: LEM-3, along with other proteins, contributes to the reorganization of chromatin during DNA repair. (Document 8)\n5. Cellular development: Emerin, a conserved LEM-domain protein, is involved in the regulation of cellular development and has been implicated in various human diseases. (Document 9)\nIn summary, LEM-3 appears to play a crucial role in various cellular processes, including chromatin processing, meiotic recombination repair, nuclear organization, DNA repair, and cellular development.",
    "llama-2-7b-chat-hf_fact_raw": "1. LEM-3 is involved in the processing of chromatin bridges that arise from incomplete DNA replication, unresolved recombination intermediates, or the perturbance of chromosome structure.\n2. The LEM-3/Ankle1 nuclease is involved in the regulation of meiotic recombination repair and chromosome segregation in Caenorhabditis elegans.\n3. LEM-3 contributes to the reorganization of chromatin during DNA repair.\n4. Emerin, a conserved LEM-domain protein, is involved in the regulation of cellular development.\n5. Emerin has been implicated in various human diseases.",
    "llama-2-7b-chat-hf_fact": [
      "LEM-3 is involved in the processing of chromatin bridges that arise from incomplete DNA replication, unresolved recombination intermediates, or the perturbance of chromosome structure.",
      "The LEM-3/Ankle1 nuclease is involved in the regulation of meiotic recombination repair and chromosome segregation in Caenorhabditis elegans.",
      "LEM-3 contributes to the reorganization of chromatin during DNA repair.",
      "Emerin, a conserved LEM-domain protein, is involved in the regulation of cellular development.",
      "Emerin has been implicated in various human diseases."
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the releases of tmVar are:\n1. tmVar 2.0: The Java code of tmVar 2.0 is publicly available, and it is also a part of PubTator Central, a web-based system that provides automatic annotation of biomedical concepts in PubMed and PMC articles.\n2. tmVar 3.0: This is the latest release of tmVar, which provides advanced variant normalization options such as allele-specific identifiers from the ClinGen Allele Registry. It exhibits state-of-the-art performance with over 90% in F-measure for variant recognition and normalization, when evaluated on three independent benchmarking datasets.\nTherefore, the releases of tmVar are tmVar 2.0 and tmVar 3.0.",
    "llama-2-7b-chat-hf_fact_raw": "1. tmVar 2.0's Java code is publicly available.\n2. tmVar 2.0 is part of PubTator Central, which provides automatic annotation of biomedical concepts in PubMed and PMC articles.\n3. tmVar 3.0 is the latest release of tmVar.\n4. tmVar 3.0 provides advanced variant normalization options, including allele-specific identifiers from the ClinGen Allele Registry.\n5. tmVar 3.0 has demonstrated over 90% in F-measure for variant recognition and normalization on three independent benchmarking datasets.",
    "llama-2-7b-chat-hf_fact": [
      "tmVar 2.0's Java code is publicly available.",
      "tmVar 2.0 is part of PubTator Central, which provides automatic annotation of biomedical concepts in PubMed and PMC articles.",
      "tmVar 3.0 is the latest release of tmVar.",
      "tmVar 3.0 provides advanced variant normalization options, including allele-specific identifiers from the ClinGen Allele Registry.",
      "tmVar 3.0 has demonstrated over 90% in F-measure for variant recognition and normalization on three independent benchmarking datasets."
    ]
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the database of somatic mutations in normal cells is DSMNC (Document 0, 1, 2, 5, and 6). DSMNC is a timely and valuable collection of somatic mutations in individual normal cells, which allows for the analysis of the burdens and signatures of somatic mutations in various types of heterogeneous normal cells. The database contains mutation profiles of over 1,000 cell lines used in cancer research (Document 4).\nIt is important to note that the somatic mutations in normal cells are ultra-low frequency and hidden in the genetic background of heterogeneous cells (Document 6). Therefore, identifying expressed somatic mutations from single-cell RNA sequencing data de novo is challenging but highly valuable (Document 7).\nThe VAF (variants allele frequency) of a somatic mutation depends on the prevalence of the mutation, which is largely driven by how early the mutation occurs in development, and the heterogeneity of the tissue selected for sequencing (Document 8).\nIn summary, DSMNC is the database of somatic mutations in normal cells, and it is a valuable resource for analyzing the burdens and signatures of somatic mutations in various types of heterogeneous normal cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. DSMNC is the database of somatic mutations in normal cells.\n2. The DSMNC database contains mutation profiles of over 1,000 cell lines used in cancer research.\n3. Somatic mutations in normal cells are ultra-low frequency.\n4. Identifying expressed somatic mutations from single-cell RNA sequencing data de novo is challenging.\n5. The variant allele frequency (VAF) of a somatic mutation is influenced by the timing of the mutation's occurrence in development and the heterogeneity of the tissue selected for sequencing.",
    "llama-2-7b-chat-hf_fact": [
      "DSMNC is the database of somatic mutations in normal cells.",
      "The DSMNC database contains mutation profiles of over 1,000 cell lines used in cancer research.",
      "Somatic mutations in normal cells are ultra-low frequency.",
      "Identifying expressed somatic mutations from single-cell RNA sequencing data de novo is challenging.",
      "The variant allele frequency (VAF) of a somatic mutation is influenced by the timing of the mutation's occurrence in development and the heterogeneity of the tissue selected for sequencing."
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-2-7b-chat-hf_response": "Yes, there are several graph kernel libraries available implemented in Java. Here are some of them:\n1. GraphKernels: This is a Java library for computing graph kernels, including baseline kernels such as label histogram based kernels, classic graph kernels such as random walk based kernels, and state-of-the-art kernels such as the Weisfeiler-Lehman kernel. The library is implemented in C++ for efficiency and provides a Java interface for ease of use.\n2. GraKeL: This is a library that provides implementations of several well-established graph kernels, as well as a unified framework for working with these kernels. GraKeL also provides implementations of some frameworks that work on top of graph kernels. The library is written in C++ and provides a Java interface.\n3. SVM Light: This is an implementation of Support Vector Machines (SVMs) in C, which can be used for graph classification. The library provides a fast optimization algorithm, working set selection based on steepest feasible descent, and caching of kernel evaluations.\n4. Dijkstra's Algorithm: This is a library for finding the least expensive path in a weighted graph between a starting node and a destination node. The library provides a fast and efficient algorithm for computing the shortest path in a graph.\n5. TensorFlow Geometric: This is a library for building Graph Neural Networks (GNNs) in TensorFlow. The library provides kernel libraries for computing graph kernels and implements popular GNNs such as Graph Convolutional Networks (GCNs) and Graph Attention Networks (GATs).\nAll of these libraries are compatible with Java and can be used for graph kernel computations in Java programs.",
    "llama-2-7b-chat-hf_fact_raw": "1. GraphKernels is a Java library that computes various graph kernels, including label histogram based kernels and the Weisfeiler-Lehman kernel.\n2. GraKeL provides implementations of several graph kernels and a unified framework for working with these kernels.\n3. SVM Light is an implementation of Support Vector Machines that can be used for graph classification.\n4. Dijkstra's Algorithm library is used for finding the least expensive path in a weighted graph.\n5. TensorFlow Geometric is a library for building Graph Neural Networks and provides kernel libraries for computing graph kernels.",
    "llama-2-7b-chat-hf_fact": [
      "GraphKernels is a Java library that computes various graph kernels, including label histogram based kernels and the Weisfeiler-Lehman kernel.",
      "GraKeL provides implementations of several graph kernels and a unified framework for working with these kernels.",
      "SVM Light is an implementation of Support Vector Machines that can be used for graph classification.",
      "Dijkstra's Algorithm library is used for finding the least expensive path in a weighted graph.",
      "TensorFlow Geometric is a library for building Graph Neural Networks and provides kernel libraries for computing graph kernels."
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 1-9, the four advances integrated into the SHERLOCKv2 platform are:\n1. 4-channel single reaction multiplexing using orthogonal CRISPR enzymes.\n2. Quantitative measurement of input down to 2 aM (attomolar).\n3. 3.5-fold increase in signal sensitivity by combining Cas13 with Csm6, an auxiliary CRISPR enzyme.\n4. Detection of four nucleic acid sequences in a single reaction using a combination of four different Cas13 and Cas12 enzymes.",
    "llama-2-7b-chat-hf_fact_raw": "1. SHERLOCKv2 platform integrates 4-channel single reaction multiplexing using orthogonal CRISPR enzymes.\n2. SHERLOCKv2 platform can quantitatively measure input down to 2 attomolar (aM).\n3. The platform achieves a 3.5-fold increase in signal sensitivity by combining Cas13 with Csm6, an auxiliary CRISPR enzyme.\n4. SHERLOCKv2 can detect four nucleic acid sequences in a single reaction using a combination of four different Cas13 and Cas12 enzymes.",
    "llama-2-7b-chat-hf_fact": [
      "SHERLOCKv2 platform integrates 4-channel single reaction multiplexing using orthogonal CRISPR enzymes.",
      "SHERLOCKv2 platform can quantitatively measure input down to 2 attomolar (aM).",
      "The platform achieves a 3.5-fold increase in signal sensitivity by combining Cas13 with Csm6, an auxiliary CRISPR enzyme.",
      "SHERLOCKv2 can detect four nucleic acid sequences in a single reaction using a combination of four different Cas13 and Cas12 enzymes."
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the Bartender algorithm is a clustering algorithm used to count high-complexity deeply sequenced barcode reads. It is considered the most accurate algorithm for this task, with a comparable speed to other existing algorithms. The algorithm uses a new statistical test schema that combines both nucleotide sequence and cluster size information to prevent over- or under-estimation of the number of clusters.\nAn algorithm is a well-defined sequential computational technique that accepts input and produces output to solve a problem. In other words, an algorithm is said to be accurate if it produces the proper output for each input instance.\nMachine learning algorithms, including the Bartender algorithm, are a part of artificial intelligence and use a combination of accurate, probabilistic, and upgraded techniques to enable computers to learn from past data and recognize complex patterns in large, noisy, or complex datasets.\nAn algorithm can be expressed in pseudocode, which is a language-independent way to represent an algorithm, allowing programmers from different languages to understand and translate it.\nBRILLO is an AI-powered bartending robot that can engage in complex dialogue with customers, demonstrating the potential of algorithms in robotics.\nReal-time perception-driven feedback control, which can be achieved through the use of algorithms, can greatly benefit industrial robots and robot bartenders like BRILLO.\nAlgorithms are an important aspect of computer science, and understanding them can help you solve problems more efficiently in various fields, including robotics, machine learning, and more.\nIn summary, the Bartender algorithm is a clustering algorithm used to count high-complexity deeply sequenced barcode reads, and it is considered the most accurate algorithm for this task. Algorithms are well-defined sequential computational techniques that can be used to solve a wide range of problems, and they are an important aspect of computer science.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Bartender algorithm is a clustering algorithm used to count high-complexity deeply sequenced barcode reads.\n2. It is considered the most accurate algorithm for counting high-complexity deeply sequenced barcode reads.\n3. The Bartender algorithm uses a new statistical test schema that combines nucleotide sequence and cluster size information.\n4. The Bartender algorithm has a comparable speed to other existing algorithms for the same task.\n5. BRILLO is an AI-powered bartending robot that can engage in complex dialogue with customers.",
    "llama-2-7b-chat-hf_fact": [
      "The Bartender algorithm is a clustering algorithm used to count high-complexity deeply sequenced barcode reads.",
      "It is considered the most accurate algorithm for counting high-complexity deeply sequenced barcode reads.",
      "The Bartender algorithm uses a new statistical test schema that combines nucleotide sequence and cluster size information.",
      "The Bartender algorithm has a comparable speed to other existing algorithms for the same task.",
      "BRILLO is an AI-powered bartending robot that can engage in complex dialogue with customers."
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, there are several web-based pedigree editors available:\n1. Pedigreejs: This is an interactive graphical pedigree editor written in JavaScript that uses standard SVG format to produce images. It is lightweight and can be easily configured and incorporated into web applications.\n2. Ped_draw: This is a free online tool for creating pedigrees that is geared towards clinical applications. It has limited support for complex pedigrees commonly seen in areas like forensic genetics and animal breeding.\n3. HaploForge: This is another free online tool for creating pedigrees that is geared towards clinical applications. It allows users to create and edit pedigrees, and also provides tools for visualizing and analyzing the data.\n4. Progeny: This is a web-based tool for creating and managing pedigrees. It is designed for clinical genetics centers and provides features such as automatic generation of pedigree diagrams, data validation, and data export.\n5. GenoDraw: This is a web tool that provides clinical practitioners with the ability to create, maintain, and visualize patients' and their families' information in the form of pedigree diagrams. It implements a graph-based three-step process for generating diagrams according to a de facto standard in the area and clinical settings.\nIt's worth noting that these web-based pedigree editors are designed for different purposes and have varying levels of complexity and functionality, so it's important to evaluate each one based on your specific needs and requirements.",
    "llama-2-7b-chat-hf_fact_raw": "1. Pedigreejs is an interactive graphical pedigree editor that uses SVG format for images.\n2. Ped_draw is a free online tool for creating pedigrees with limited support for complex pedigrees.\n3. HaploForge is a free online tool that allows users to create, edit, and analyze pedigrees.\n4. Progeny is a web-based tool designed for clinical genetics centers with features like automatic pedigree diagram generation.\n5. GenoDraw is a web tool that helps clinical practitioners create and visualize pedigree diagrams.",
    "llama-2-7b-chat-hf_fact": [
      "Pedigreejs is an interactive graphical pedigree editor that uses SVG format for images.",
      "Ped_draw is a free online tool for creating pedigrees with limited support for complex pedigrees.",
      "HaploForge is a free online tool that allows users to create, edit, and analyze pedigrees.",
      "Progeny is a web-based tool designed for clinical genetics centers with features like automatic pedigree diagram generation.",
      "GenoDraw is a web tool that helps clinical practitioners create and visualize pedigree diagrams."
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, there are several curated databases available for spider-venom toxins:\n1. ArachnoServer: This is a manually curated database that provides detailed information on the sequence, structure, and biological activity of protein toxins from spider venoms. It includes a new molecular target ontology designed especially for venom toxins, the most up-to-date taxonomic information available, and a powerful advanced search interface.\n2. VenomDB: This is a comprehensive database of venom peptides and proteins from various animal species, including spiders. It provides information on the sequence, structure, function, and pharmacology of these toxins, as well as their evolutionary relationships.\n3. ToxinDB: This is a database of toxins from various sources, including spider venoms. It provides information on the sequence, structure, function, and pharmacology of these toxins, as well as their potential applications in medicine and other fields.\n4. Natural Products Database (NPDB): This is a database of natural products, including venom peptides and proteins from spiders. It provides information on the chemical structure, biological activity, and pharmacological properties of these compounds, as well as their sources and isolation methods.\nThese databases can be useful for researchers interested in studying the sequence, structure, function, and pharmacology of spider-venom toxins, as well as their potential applications in medicine and other fields.",
    "llama-2-7b-chat-hf_fact_raw": "1. ArachnoServer is a manually curated database that provides information on protein toxins from spider venoms.\n2. VenomDB is a comprehensive database that includes venom peptides and proteins from various animal species, including spiders.\n3. ToxinDB is a database that contains information on toxins from various sources, including spider venoms.\n4. The Natural Products Database (NPDB) includes information on venom peptides and proteins from spiders.\n5. ArachnoServer features a new molecular target ontology designed specifically for venom toxins.",
    "llama-2-7b-chat-hf_fact": [
      "ArachnoServer is a manually curated database that provides information on protein toxins from spider venoms.",
      "VenomDB is a comprehensive database that includes venom peptides and proteins from various animal species, including spiders.",
      "ToxinDB is a database that contains information on toxins from various sources, including spider venoms.",
      "The Natural Products Database (NPDB) includes information on venom peptides and proteins from spiders.",
      "ArachnoServer features a new molecular target ontology designed specifically for venom toxins."
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there is limited evidence to suggest that Axitinib prolongs survival of Pancreatic Cancer (PC) patients.\nDocument 2 shows that the overall 5-year survival for pancreatic cancer has increased from 0.9% in 1975 to 4.2% in 2011 in patients of all stages, but there is no specific information on Axitinib's impact on survival. Document 4 mentions that the combined five-year survival rate for pancreatic cancer is very low at just 5-10%, which suggests that even with treatment, the prognosis for PC patients is poor.\nDocument 5 shows that in a clinical trial comparing gemcitabine plus Axitinib to gemcitabine alone in patients with unresectable, locally advanced, or metastatic pancreatic cancer, there was no significant improvement in overall survival with the addition of Axitinib.\nDocument 6 mentions that the primary endpoint of the trial was overall survival, but the results showed that Axitinib did not significantly improve overall survival in PC patients.\nDocument 7 highlights the poor prognosis for PC patients, with a 5-year survival rate of only 2-9%. There is no information in the provided documents to suggest that Axitinib improves survival in PC patients.\nIn conclusion, while there is some evidence to suggest that Axitinib may have some benefits in the treatment of advanced HCC, there is limited evidence to support its use in prolonging survival of PC patients. The poor prognosis for PC patients and the lack of significant improvement in overall survival with Axitinib suggest that other treatments may be more effective in improving survival outcomes for these patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. The overall 5-year survival for pancreatic cancer increased from 0.9% in 1975 to 4.2% in 2011.\n2. The combined five-year survival rate for pancreatic cancer is between 5-10%.\n3. In a clinical trial, the addition of Axitinib to gemcitabine did not show a significant improvement in overall survival for patients with unresectable, locally advanced, or metastatic pancreatic cancer.\n4. The primary endpoint of the trial mentioned in Document 6 was overall survival.\n5. The 5-year survival rate for pancreatic cancer patients is only 2-9%.",
    "llama-2-7b-chat-hf_fact": [
      "The overall 5-year survival for pancreatic cancer increased from 0.9% in 1975 to 4.2% in 2011.",
      "The combined five-year survival rate for pancreatic cancer is between 5-10%.",
      "In a clinical trial, the addition of Axitinib to gemcitabine did not show a significant improvement in overall survival for patients with unresectable, locally advanced, or metastatic pancreatic cancer.",
      "The primary endpoint of the trial mentioned in Document 6 was overall survival.",
      "The 5-year survival rate for pancreatic cancer patients is only 2-9%."
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, MLP regulates F-actin dynamics through its interaction with the Arp2/3 complex.\nDocument 8 explains that the WRC (WASP regulatory complex) interacts with the Arp2/3 complex through its CA motif, and with F-actin through its W motif. The WRC is depicted in the open (active) conformation, indicating that it is capable of interacting with both the Arp2/3 complex and F-actin.\nDocument 9 provides additional information on the regulation of actin assembly by RhoA. RhoA promotes actin assembly through its effectors mDIA and ROCK, which initiate actin filament assembly.\nTaken together, these documents suggest that MLP regulates F-actin dynamics through its interaction with the Arp2/3 complex, which is a key regulator of actin assembly and dynamics. The WRC, which is composed of MLP and other proteins, interacts with the Arp2/3 complex and F-actin to regulate actin dynamics and promote actin filament assembly.",
    "llama-2-7b-chat-hf_fact_raw": "1. MLP regulates F-actin dynamics through its interaction with the Arp2/3 complex.\n2. The WRC interacts with the Arp2/3 complex through its CA motif.\n3. The WRC interacts with F-actin through its W motif.\n4. RhoA promotes actin assembly through its effectors mDIA and ROCK.\n5. The WRC is composed of MLP and other proteins.",
    "llama-2-7b-chat-hf_fact": [
      "MLP regulates F-actin dynamics through its interaction with the Arp2/3 complex.",
      "The WRC interacts with the Arp2/3 complex through its CA motif.",
      "The WRC interacts with F-actin through its W motif.",
      "RhoA promotes actin assembly through its effectors mDIA and ROCK.",
      "The WRC is composed of MLP and other proteins."
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, there are approximately 50 pseudokinases in the human kinome. This number is mentioned in Documents 2, 4, 6, 7, and 9.\nPseudokinases are protein kinases that lack sequence similarity to the eukaryotic protein kinase (ePK) domain, which is a common feature of most protein kinases. Despite their lack of sequence similarity, pseudokinases share some regulatory mechanisms with canonical kinases, such as allostery and conformational disruption.\nThe human kinome contains over 500 protein kinases, excluding pseudokinases, and these enzymes play a crucial role in cell signaling and regulation. However, the exact number of pseudokinases in the human kinome is not provided in the documents.\nIt is worth noting that the definition of a pseudokinase can vary depending on the source, and some studies may use different criteria to define these proteins. Additionally, the functional significance of pseudokinases is still not fully understood, and further research is needed to determine their role in cell signaling and disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are approximately 50 pseudokinases in the human kinome according to Documents 2, 4, 6, 7, and 9.\n2. Pseudokinases lack sequence similarity to the eukaryotic protein kinase (ePK) domain.\n3. The human kinome contains over 500 protein kinases, excluding pseudokinases.\n4. Pseudokinases share some regulatory mechanisms with canonical kinases.\n5. The functional significance of pseudokinases is not fully understood.",
    "llama-2-7b-chat-hf_fact": [
      "There are approximately 50 pseudokinases in the human kinome according to Documents 2, 4, 6, 7, and 9.",
      "Pseudokinases lack sequence similarity to the eukaryotic protein kinase (ePK) domain.",
      "The human kinome contains over 500 protein kinases, excluding pseudokinases.",
      "Pseudokinases share some regulatory mechanisms with canonical kinases.",
      "The functional significance of pseudokinases is not fully understood."
    ]
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, here are 3 apoE mimetics:\n1. Ac-hE18A-NH(2) - This is a peptide mimetic of the receptor-binding region of apoE, which has been shown to have anti-inflammatory effects.\n2. ApoEp - This is a peptide mimetic of the LDL receptor-binding domain of apoE, which has been shown to have anti-inflammatory effects.\n3. 6KApoEp - This is a peptide mimetic of the LDL receptor-binding domain of apoE with 6 lysines added to the N-terminus, which has been shown to have anti-inflammatory effects.\nIt is important to note that these are just a few examples of apoE mimetics that have been studied, and there may be other mimetics that have been developed or are in the process of being developed.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ac-hE18A-NH(2) is a peptide mimetic of the receptor-binding region of apoE.\n2. ApoEp is a peptide mimetic of the LDL receptor-binding domain of apoE.\n3. 6KApoEp is a peptide mimetic of the LDL receptor-binding domain of apoE with 6 lysines added to the N-terminus.",
    "llama-2-7b-chat-hf_fact": [
      "Ac-hE18A-NH(2) is a peptide mimetic of the receptor-binding region of apoE.",
      "ApoEp is a peptide mimetic of the LDL receptor-binding domain of apoE.",
      "6KApoEp is a peptide mimetic of the LDL receptor-binding domain of apoE with 6 lysines added to the N-terminus."
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-2-7b-chat-hf_response": "Based on the provided documents, there are sex differences in SAMHD1 activity in primary macrophages. Specifically, the documents show that:\n1. Female macrophages have higher SAMHD1 activity compared to male macrophages, which correlates with lower HIV-1 infectivity in female-derived macrophages. (Documents 0 and 1)\n2. Depletion of SAMHD1 abrogates the sex-dependent differences in viral restriction, indicating that SAMHD1 is an essential modulator of infectivity in a sex-dependent manner in macrophages. (Documents 2 and 4)\n3. The differential expression levels and activation states of SAMHD1 in various cell types contribute to unique dNTP pools that either aid or restrict viral replication, depending on the cell type. (Document 5)\n4. SAMHD1 has a larger impact on nelarabine/AraG than on cytarabine in ALL cells, with opposite effects observed in acute myeloid leukaemia cells, indicating entity-specific differences. (Document 7)\nOverall, these findings suggest that SAMHD1 activity is a key factor in determining the susceptibility of macrophages to HIV-1 infection, and that there are sex-dependent differences in SAMHD1 activity that play a role in the regulation of HIV-1 infection.",
    "llama-2-7b-chat-hf_fact_raw": "1. Female macrophages have higher SAMHD1 activity compared to male macrophages.\n2. Higher SAMHD1 activity in female macrophages correlates with lower HIV-1 infectivity in female-derived macrophages.\n3. Depletion of SAMHD1 removes the sex-dependent differences in viral restriction in macrophages.\n4. SAMHD1 is an essential modulator of infectivity in a sex-dependent manner in macrophages.\n5. The differential expression levels and activation states of SAMHD1 contribute to unique dNTP pools that affect viral replication.",
    "llama-2-7b-chat-hf_fact": [
      "Female macrophages have higher SAMHD1 activity compared to male macrophages.",
      "Higher SAMHD1 activity in female macrophages correlates with lower HIV-1 infectivity in female-derived macrophages.",
      "Depletion of SAMHD1 removes the sex-dependent differences in viral restriction in macrophages.",
      "SAMHD1 is an essential modulator of infectivity in a sex-dependent manner in macrophages.",
      "The differential expression levels and activation states of SAMHD1 contribute to unique dNTP pools that affect viral replication."
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it can be concluded that RUNX2 does not inhibit astrocyte differentiation. In fact, RUNX2 promotes astrocyte maturation.\nDocument 0 suggests that NFIA and ATF3 are drivers of astrocyte differentiation, while RUNX2 promotes astrocyte maturation. This implies that RUNX2 plays a role in the later stages of astrocyte differentiation, after the initial stages have been set by NFIA and ATF3.\nDocument 1 and Document 2 provide evidence that RUNX2 is involved in the regulation of osteoblast differentiation, but do not mention anything about astrocyte differentiation.\nDocument 3 suggests that RUNX2 is involved in the development of osteosarcoma, but does not provide any information about its role in astrocyte differentiation.\nDocument 4 shows that overexpression of RUNX2 in mNSCs induces astrocyte differentiation, which is consistent with the idea that RUNX2 promotes astrocyte maturation.\nDocument 5 provides evidence that in vitro-differentiated astrocytes lack expression of many mature astrocyte-specific genes, including genes for the transcription factors NFIA and ATF3. This suggests that these genes are important for the initial stages of astrocyte differentiation, but that RUNX2 is involved in the later stages of maturation.\nDocument 7 suggests that introduction of Runx2 proteins into breast cancer cells attenuates their ability to inhibit in vitro osteogenic differentiation of mouse marrow stromal cells and their ability in vivo to generate osteolytic lesions in bone. This implies that RUNX2 has a role in regulating cellular differentiation, including astrocyte differentiation.\nDocument 8 provides an overview of the current model of astrocyte differentiation in mice, which includes the generation of immature astrocytes from neural stem cells, followed by their maturation through the expression of genes such as NFIA and ATF3.\nDocument 9 highlights the importance of further research into the epigenomic changes that occur during astrocy",
    "llama-2-7b-chat-hf_fact_raw": "1. RUNX2 promotes astrocyte maturation.\n2. NFIA and ATF3 are drivers of astrocyte differentiation.\n3. RUNX2 is involved in the regulation of osteoblast differentiation.\n4. Overexpression of RUNX2 in mNSCs induces astrocyte differentiation.\n5. Introduction of Runx2 proteins into breast cancer cells attenuates their ability to inhibit in vitro osteogenic differentiation of mouse marrow stromal cells.",
    "llama-2-7b-chat-hf_fact": [
      "RUNX2 promotes astrocyte maturation.",
      "NFIA and ATF3 are drivers of astrocyte differentiation.",
      "RUNX2 is involved in the regulation of osteoblast differentiation.",
      "Overexpression of RUNX2 in mNSCs induces astrocyte differentiation.",
      "Introduction of Runx2 proteins into breast cancer cells attenuates their ability to inhibit in vitro osteogenic differentiation of mouse marrow stromal cells."
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the Cobb-Stainsby excision arthroplasty would typically be performed in the forefoot, specifically at the metatarsophalangeal joint. This is because the procedure involves excision of part of the proximal phalanx, reduction of the plantar plate, and Kirschner wire fixation, all of which are performed at the metatarsophalangeal joint. The procedure is used to treat claw and hammer toes, which are common deformities of the forefoot that can cause pain and disability. The Cobb-Stainsby excision arthroplasty is a variant of an excision arthroplasty that combines the Stainsby procedure with extensor tendon transfer to the metatarsal head.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is typically performed in the forefoot.\n2. The procedure involves excision of part of the proximal phalanx.\n3. The Cobb-Stainsby excision arthroplasty includes reduction of the plantar plate.\n4. Kirschner wire fixation is a part of the Cobb-Stainsby excision arthroplasty.\n5. The procedure is used to treat claw and hammer toes.",
    "llama-2-7b-chat-hf_fact": [
      "The Cobb-Stainsby excision arthroplasty is typically performed in the forefoot.",
      "The procedure involves excision of part of the proximal phalanx.",
      "The Cobb-Stainsby excision arthroplasty includes reduction of the plantar plate.",
      "Kirschner wire fixation is a part of the Cobb-Stainsby excision arthroplasty.",
      "The procedure is used to treat claw and hammer toes."
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it can be concluded that GRHL2 over-expression does lead to EMT.\nIn Document 1, it is mentioned that GRHL2 suppresses EMT, which is required for the migration and invasion of carcinoma. However, in Document 2, it is shown that high GRHL2 expression is highly correlated with worse relapse-free survival in all four subtypes of breast cancer, indicating that excess GRHL2 can lead to EMT.\nSimilarly, in Document 4, it is stated that GRHL2 has dual roles in cancer, supporting tumor growth while suppressing EMT. Additionally, Document 7 shows that GRHL2 regulates the expression of target genes in embryonic and adult murine tissue, including genes involved in epithelial differentiation and barrier formation.\nFurthermore, Document 8 suggests that the gradual loss of GRHL2 expression along the EMT spectrum of ovarian cancer cell lines might lead to epithelial dedifferentiation, which is a hallmark of EMT.\nFinally, in Document 9, it is shown that overexpression of GRHL2 in BC cells with a mesenchymal phenotype results in a hybrid epithelial/mesenchymal phenotype, which is more strongly correlated with tumor aggressiveness than a pure mesenchymal phenotype.\nIn conclusion, based on the information provided in the documents, it can be inferred that GRHL2 over-expression leads to EMT in various types of cancer, including breast cancer and ovarian cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. GRHL2 over-expression is correlated with worse relapse-free survival in all four subtypes of breast cancer.\n2. GRHL2 has dual roles in cancer, supporting tumor growth while suppressing EMT.\n3. GRHL2 regulates the expression of target genes involved in epithelial differentiation and barrier formation in embryonic and adult murine tissue.\n4. The loss of GRHL2 expression along the EMT spectrum of ovarian cancer cell lines might lead to epithelial dedifferentiation.\n5. Overexpression of GRHL2 in breast cancer cells with a mesenchymal phenotype results in a hybrid epithelial/mesenchymal phenotype associated with increased tumor aggressiveness.",
    "llama-2-7b-chat-hf_fact": [
      "GRHL2 over-expression is correlated with worse relapse-free survival in all four subtypes of breast cancer.",
      "GRHL2 has dual roles in cancer, supporting tumor growth while suppressing EMT.",
      "GRHL2 regulates the expression of target genes involved in epithelial differentiation and barrier formation in embryonic and adult murine tissue.",
      "The loss of GRHL2 expression along the EMT spectrum of ovarian cancer cell lines might lead to epithelial dedifferentiation.",
      "Overexpression of GRHL2 in breast cancer cells with a mesenchymal phenotype results in a hybrid epithelial/mesenchymal phenotype associated with increased tumor aggressiveness."
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it appears that several T-UCRs have been implicated in lung cancer. These include:\n1. uc.339: Document 1 mentions that uc.339 is an oncogene in lung cancer.\n2. Uc.283+A: Document 5 suggests that overexpression of Uc.283+A in a hypermethylated colon cancer cell line leads to increased cell death, suggesting that it may have tumor suppressive functions.\n3. Uc.157: Document 5 also mentions that T-UCRs are highly methylated in cancer cell lines, including Uc.157.\nIt is important to note that the functional characterization of T-UCRs is still in its early stages, and more research is needed to fully understand their role in cancer. However, the evidence suggests that T-UCRs may play a role in lung cancer and other types of cancer, and may serve as potential biomarkers or therapeutic targets.",
    "llama-2-7b-chat-hf_fact_raw": "1. T-UCR uc.339 has been implicated as an oncogene in lung cancer.\n2. T-UCR Uc.283+A may have tumor suppressive functions.\n3. T-UCR Uc.157 is highly methylated in cancer cell lines.\n4. T-UCRs may play a role in lung cancer and other types of cancer.\n5. T-UCRs may serve as potential biomarkers or therapeutic targets in cancer.",
    "llama-2-7b-chat-hf_fact": [
      "T-UCR uc.339 has been implicated as an oncogene in lung cancer.",
      "T-UCR Uc.283+A may have tumor suppressive functions.",
      "T-UCR Uc.157 is highly methylated in cancer cell lines.",
      "T-UCRs may play a role in lung cancer and other types of cancer.",
      "T-UCRs may serve as potential biomarkers or therapeutic targets in cancer."
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, here is what is known about the orphan receptor GPR151:\n1. GPR151 is an inhibitory G protein-coupled receptor that is highly enriched in receptor nuclei neurons and plays a role in regulating mood, stress, nicotine withdrawal, and preventing obesity. (Document 2)\n2. GPR151 is an orphan receptor belonging to the class A GPCR family, meaning it does not have a well-defined endogenous ligand or a clear physiological function. (Document 1)\n3. The expression of GPR151 is restricted to certain brain regions, including the habenula, a small brain region involved in aversion processing, addiction, and mood disorders. (Document 4)\n4. GPR151 is involved in the regulation of glucose metabolism and hepatic gluconeogenesis, and excessive signaling through the glucagon receptor, a G alpha subunit-coupled GCPR, contributes to pathologically elevated hepatic gluconeogenesis. (Document 5)\n5. GPR151 is highly enriched in the medial and lateral habenula of humans and rodents, and is expressed at presynaptic membranes and synaptic vesicles, associating with synaptic components controlling vesicle release and ion transport. (Document 7)\n6. A rare, putative loss-of-function mutation in GPR151 has been associated with lower odds ratio for type 2 diabetes, but the mechanism behind this association has remained elusive. (Document 8)\n7. GPR151 is an orphan member of the class A rhodopsin-like family of GPCRs, and is a member of the SOG subfamily that includes somatostatin, opioid, galanin, and kisspeptin receptors. (Document 9)\nOverall, GPR151 is a complex receptor with multiple functions in the brain and periphery, including the regulation of mood, stress, and glucose metabolism. Further research is needed to fully understand",
    "llama-2-7b-chat-hf_fact_raw": "1. GPR151 is an inhibitory G protein-coupled receptor that plays a role in regulating mood, stress, nicotine withdrawal, and preventing obesity.\n2. GPR151 belongs to the class A GPCR family and is considered an orphan receptor without a well-defined endogenous ligand or clear physiological function.\n3. The expression of GPR151 is restricted to certain brain regions, including the habenula.\n4. GPR151 is involved in the regulation of glucose metabolism and hepatic gluconeogenesis.\n5. A rare, putative loss-of-function mutation in GPR151 has been associated with lower odds ratio for type 2 diabetes.",
    "llama-2-7b-chat-hf_fact": [
      "GPR151 is an inhibitory G protein-coupled receptor that plays a role in regulating mood, stress, nicotine withdrawal, and preventing obesity.",
      "GPR151 belongs to the class A GPCR family and is considered an orphan receptor without a well-defined endogenous ligand or clear physiological function.",
      "The expression of GPR151 is restricted to certain brain regions, including the habenula.",
      "GPR151 is involved in the regulation of glucose metabolism and hepatic gluconeogenesis.",
      "A rare, putative loss-of-function mutation in GPR151 has been associated with lower odds ratio for type 2 diabetes."
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the attenuated live viruses contained in the Fluzone Intradermal Quadrivalent vaccine are:\n* A/H1N1\n* A/H3N2\n* B/Yamagata\n* B/Victoria\nThese viruses are contained in the vaccine as split-virion particles, which are designed to mimic the natural infection process and stimulate a stronger immune response.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": []
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the part of the TNFR2 gene that is genetically associated with Systemic Lupus Erythematosus is the juxtamembrane inversion in the TNFR2 gene resulting in a mutation from methionine (TNFR2(196MET)) to arginine (TNFR2(196ARG)). This mutation has been genetically associated with an increased risk for Systemic Lupus Erythematosus and familial rheumatoid arthritis.\nThe documents provide evidence that TNFR2 plays a role in the pathogenesis of Systemic Lupus Erythematosus, and that the TNFR2(196MET/ARG) polymorphism is associated with an increased risk of developing the disease. For example, Document 3 mentions that low copy number of the complement component C4 gene, which is located near the TNFR2 gene, is a risk factor for Systemic Lupus Erythematosus, while high copy number is associated with an increased risk of developing the disease. Document 5 also highlights the role of TNFR2 signaling in the proliferation and activation of regulatory T cells, which are involved in the immune system and can contribute to the development of autoimmune diseases such as Systemic Lupus Erythematosus.\nOverall, the documents suggest that the TNFR2 gene is a potential genetic target for the treatment of Systemic Lupus Erythematosus, and that the TNFR2(196MET/ARG) polymorphism may be a useful marker for identifying individuals at risk of developing the disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. The juxtamembrane inversion in the TNFR2 gene resulting in a mutation from methionine (TNFR2(196MET)) to arginine (TNFR2(196ARG)) is genetically associated with Systemic Lupus Erythematosus.\n2. The TNFR2(196MET/ARG) polymorphism is associated with an increased risk of developing Systemic Lupus Erythematosus and familial rheumatoid arthritis.\n3. Low copy number of the complement component C4 gene, located near the TNFR2 gene, is a risk factor for Systemic Lupus Erythematosus.\n4. High copy number of the complement component C4 gene is associated with an increased risk of developing Systemic Lupus Erythematosus.\n5. TNFR2 signaling plays a role in the proliferation and activation of regulatory T cells, which are involved in the immune system and can contribute to the development of autoimmune diseases such as Systemic Lupus Erythematosus.",
    "llama-2-7b-chat-hf_fact": [
      "The juxtamembrane inversion in the TNFR2 gene resulting in a mutation from methionine (TNFR2(196MET)) to arginine (TNFR2(196ARG)) is genetically associated with Systemic Lupus Erythematosus.",
      "The TNFR2(196MET/ARG) polymorphism is associated with an increased risk of developing Systemic Lupus Erythematosus and familial rheumatoid arthritis.",
      "Low copy number of the complement component C4 gene, located near the TNFR2 gene, is a risk factor for Systemic Lupus Erythematosus.",
      "High copy number of the complement component C4 gene is associated with an increased risk of developing Systemic Lupus Erythematosus.",
      "TNFR2 signaling plays a role in the proliferation and activation of regulatory T cells, which are involved in the immune system and can contribute to the development of autoimmune diseases such as Systemic Lupus Erythematosus."
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, there is currently no vaccine available for peanut allergy. However, there are ongoing clinical trials for a peanut allergy vaccine, including a phase 1/2 trial for a virus-like particle (VLP) peanut vaccine and a phase 2 trial for an oral immunotherapy drug, Peanut (Arachis hypogaea) Allergen Powder-dnfp (Palforzia). These trials are aimed at evaluating the safety and efficacy of these treatments in individuals with peanut allergy.\nIt is important to note that while these developments are promising, a vaccine for peanut allergy is still in the experimental stages and has not yet been approved for use in humans. If you have a peanut allergy, it is important to continue to avoid peanuts and seek medical attention if you experience an allergic reaction.\nIn summary, while there is currently no vaccine available for peanut allergy, ongoing clinical trials are exploring the safety and efficacy of potential treatments. If you have a peanut allergy, it is important to consult with a healthcare professional for proper diagnosis and treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is currently no vaccine available for peanut allergy.\n2. Clinical trials for a peanut allergy vaccine are ongoing, including a phase 1/2 trial for a virus-like particle (VLP) peanut vaccine.\n3. A phase 2 trial for an oral immunotherapy drug, Peanut (Arachis hypogaea) Allergen Powder-dnfp (Palforzia), is also in progress.\n4. The potential treatments for peanut allergy are still in the experimental stages.\n5. The vaccine for peanut allergy has not yet been approved for use in humans.",
    "llama-2-7b-chat-hf_fact": [
      "There is currently no vaccine available for peanut allergy.",
      "Clinical trials for a peanut allergy vaccine are ongoing, including a phase 1/2 trial for a virus-like particle (VLP) peanut vaccine.",
      "A phase 2 trial for an oral immunotherapy drug, Peanut (Arachis hypogaea) Allergen Powder-dnfp (Palforzia), is also in progress.",
      "The potential treatments for peanut allergy are still in the experimental stages.",
      "The vaccine for peanut allergy has not yet been approved for use in humans."
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the mouse Fxy gene is particular in its chromosomal position in that it spans the pseudoautosomal boundary (PAB) in C57BL/6 mice. The 5' end of the gene is X-unique, but the 3' end is present on both the X and Y chromosomes. This means that the gene is located in a region where the X and Y chromosomes are highly homologous and can recombine during meiosis, but the gene itself is not X-unique.\nIt is worth noting that the Fxy gene is not X-unique in humans and other mammals, as all of the gene is located on the X chromosome. The translocation of the Fxy gene into the high-recombining pseudoautosomal region in mice has resulted in a rapid increase in GC content, which may be due to the high gene density in this region. Additionally, the Fxy gene is one of the few genes that are located in a region of sequence identity between the X and Y chromosomes, known as the pseudoautosomal region (PAR).",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse Fxy gene spans the pseudoautosomal boundary (PAB) in C57BL/6 mice.\n2. The 5' end of the mouse Fxy gene is X-unique, while the 3' end is present on both the X and Y chromosomes.\n3. The Fxy gene is located in a region where the X and Y chromosomes can recombine during meiosis.\n4. In humans and other mammals, the Fxy gene is located only on the X chromosome, not on the Y chromosome.\n5. The translocation of the Fxy gene into the pseudoautosomal region in mice has led to an increase in GC content.",
    "llama-2-7b-chat-hf_fact": [
      "The mouse Fxy gene spans the pseudoautosomal boundary (PAB) in C57BL/6 mice.",
      "The 5' end of the mouse Fxy gene is X-unique, while the 3' end is present on both the X and Y chromosomes.",
      "The Fxy gene is located in a region where the X and Y chromosomes can recombine during meiosis.",
      "In humans and other mammals, the Fxy gene is located only on the X chromosome, not on the Y chromosome.",
      "The translocation of the Fxy gene into the pseudoautosomal region in mice has led to an increase in GC content."
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method is the use of a complex of methidiumpropyl-EDTA (MPE) and ferrous iron (Fe2+) to cleave the linker DNA between nucleosomes in the genome. This results in the generation of single- and double-stranded DNA breaks, which can be used for massively parallel sequencing to obtain a genome-wide characterization of chromatin structure.\nThe documents describe MPE-seq as a method that is similar to micrococcal nuclease (MNase) sequencing, but with some distinct advantages. Like MNase, MPE-Fe (II) preferentially cleaves the linker DNA between nucleosomes, but it does not have the same sequence bias as MNase. This allows for a more comprehensive analysis of chromatin structure and regulation. Additionally, MPE-seq can be combined with ChIP (chromatin immunoprecipitation) for histones and histone PTMs (post-translational modifications) to provide a detailed readout of chromatin structure and regulation.\nThe documents also mention that a method that relies on the chemical modification of engineered histone H4 has been developed to map nucleosomes in yeast, but this technique requires the genetic modification of histone H4. Another approach is to use MPE-seq in combination with MNase-seq to generate a detailed readout of chromatin structure and regulation.\nIn summary, the basis of the MPE-seq method is the use of a complex of MPE and Fe2+ to cleave the linker DNA between nucleosomes in the genome, resulting in the generation of single- and double-stranded DNA breaks that can be used for massively parallel sequencing to obtain a genome-wide characterization of chromatin structure.",
    "llama-2-7b-chat-hf_fact_raw": "1. The methidiumpropyl-EDTA sequencing (MPE-seq) method uses a complex of methidiumpropyl-EDTA (MPE) and ferrous iron (Fe2+) to cleave linker DNA between nucleosomes.\n2. MPE-seq results in the generation of single- and double-stranded DNA breaks for massively parallel sequencing.\n3. MPE-seq is similar to micrococcal nuclease (MNase) sequencing but does not have the same sequence bias as MNase.\n4. MPE-seq can be combined with chromatin immunoprecipitation (ChIP) to analyze chromatin structure and regulation.\n5. A method using chemical modification of engineered histone H4 to map nucleosomes in yeast requires genetic modification of histone H4.",
    "llama-2-7b-chat-hf_fact": [
      "The methidiumpropyl-EDTA sequencing (MPE-seq) method uses a complex of methidiumpropyl-EDTA (MPE) and ferrous iron (Fe2+) to cleave linker DNA between nucleosomes.",
      "MPE-seq results in the generation of single- and double-stranded DNA breaks for massively parallel sequencing.",
      "MPE-seq is similar to micrococcal nuclease (MNase) sequencing but does not have the same sequence bias as MNase.",
      "MPE-seq can be combined with chromatin immunoprecipitation (ChIP) to analyze chromatin structure and regulation.",
      "A method using chemical modification of engineered histone H4 to map nucleosomes in yeast requires genetic modification of histone H4."
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the programming language used for implementing GWAR is Python. Document 1 mentions that Python is an object-oriented, high-level programming language that is ideal for rapid development, and Document 4 shows that Python is a popular framework for web and desktop development, with a high level of popularity among developers. Document 5 defines Python as a programming language for expressing detailed instructions for a digital computer, and Document 6 uses Python to build a decision model for programming language selection. While Document 2 mentions the use of assembly language in the Electronic Delay Storage Automatic Calculator (EDSAC) in 1949, and Document 3 discusses the design and implementation of one's own language, there is no direct mention of GWAR being implemented in any of these documents. Therefore, based on the information provided, Python is the most likely programming language used for implementing GWAR.",
    "llama-2-7b-chat-hf_fact_raw": "1. The programming language used for implementing GWAR is Python.\n2. Python is an object-oriented, high-level programming language.\n3. Python is suitable for rapid development.\n4. Python is popular for web and desktop development.\n5. Python is used to express detailed instructions for a digital computer.",
    "llama-2-7b-chat-hf_fact": [
      "The programming language used for implementing GWAR is Python.",
      "Python is an object-oriented, high-level programming language.",
      "Python is suitable for rapid development.",
      "Python is popular for web and desktop development.",
      "Python is used to express detailed instructions for a digital computer."
    ]
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, there is limited evidence to suggest that xaliproden improves the prognosis of amyotrophic lateral sclerosis (ALS). While some documents mention the potential for improved prognosis through the use of survival models and novel staging and scoring systems, there is no specific mention of xaliproden as a prognostic factor.\nDocument 0 mentions that improved prognosis can inform the patient and their family about the disease course and improve end-of-life planning, but does not specifically mention xaliproden as a factor in this process. Similarly, Document 1 and Document 2 provide information on the degenerative nature of ALS and the median survival time of approximately 3-5 years, but do not mention xaliproden as a prognostic factor.\nDocument 3 mentions that the disease is relentlessly progressive in most patients, with a median survival of about 3 years after symptom onset, and that death is mostly attributed to respiratory failure. This information suggests that the prognosis for ALS patients is generally poor, and that xaliproden may not have a significant impact on this prognosis.\nDocument 4 mentions that the survival time of ALS is greatly variable and that protective or risk effects of potential survival predictors are controversial. This suggests that there is still much to be learned about the factors that influence the prognosis of ALS, and that xaliproden may not be a significant factor in this process.\nDocument 5 provides an overview of the latest advances in ALS research, including the genetic architecture and pathophysiology of the disease. While this document mentions the potential for genetic testing to become standard practice in the future, it does not specifically mention xaliproden as a prognostic factor.\nDocument 7 provides a summary of the critical discoveries and advances in disease characterization, diagnosis, imaging, and biomarkers for ALS. While this document mentions the potential for new diagnostic criteria and genetic risk factors to expedite the diagnostic process, it does not specifically mention xaliproden as a prognostic factor.\nDocument 8 provides an overview of the multisystem nature of ALS, including",
    "llama-2-7b-chat-hf_fact_raw": "1. There is limited evidence to suggest that xaliproden improves the prognosis of amyotrophic lateral sclerosis (ALS).\n2. The median survival time for ALS patients is approximately 3-5 years.\n3. ALS is described as relentlessly progressive in most patients, with a median survival of about 3 years after symptom onset.\n4. Death in ALS patients is mostly attributed to respiratory failure.\n5. The survival time of ALS is greatly variable, and the effects of potential survival predictors are controversial.",
    "llama-2-7b-chat-hf_fact": [
      "There is limited evidence to suggest that xaliproden improves the prognosis of amyotrophic lateral sclerosis (ALS).",
      "The median survival time for ALS patients is approximately 3-5 years.",
      "ALS is described as relentlessly progressive in most patients, with a median survival of about 3 years after symptom onset.",
      "Death in ALS patients is mostly attributed to respiratory failure.",
      "The survival time of ALS is greatly variable, and the effects of potential survival predictors are controversial."
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the LiPS-A3S line has the transgene inserted in chromosome 15. Specifically, the integration event occurred within the 3' UTR region of the gene.",
    "llama-2-7b-chat-hf_fact_raw": "1. The transgene in the LiPS-A3S line is inserted in chromosome 15.\n2. The integration of the transgene occurred within the 3' UTR region of a gene.",
    "llama-2-7b-chat-hf_fact": [
      "The transgene in the LiPS-A3S line is inserted in chromosome 15.",
      "The integration of the transgene occurred within the 3' UTR region of a gene."
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are several deep learning tools available for predicting drug synergy:\n1. DeepSynergy: This tool combines chemical information of drugs and genomic features of cancer cells to predict drug pairs with synergistic effects. It is available for implementation at <https://www.bioinf.jku.at/software/DeepSynergy>. Contact: klambauer@bioinf.jku.at.\n2. Dual Feature Fusion Network for Drug–Drug Synergy prediction (DFFNDDS): This deep learning model utilizes a fine-tuned pretrained model to predict drug combinations with synergistic effects.\n3. TranSynergy: This tool is a mechanism-driven and self-attention boosted deep learning model for predicting drug synergy. It is available for implementation at <https://www.bioinformatics.org/documents/9>.\nThese tools use various deep learning algorithms, such as graph neural networks, tensor factorization, and fine-tuned pretrained models, to predict drug synergy based on chemical information and genomic features of cancer cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepSynergy is a tool that predicts drug pairs with synergistic effects using chemical information of drugs and genomic features of cancer cells.\n2. DeepSynergy is available for implementation at <https://www.bioinf.jku.at/software/DeepSynergy>.\n3. The Dual Feature Fusion Network for Drug–Drug Synergy prediction (DFFNDDS) is a deep learning model that predicts drug combinations with synergistic effects.\n4. TranSynergy is a deep learning model for predicting drug synergy that uses self-attention mechanisms.\n5. TranSynergy is available for implementation at <https://www.bioinformatics.org/documents/9>.",
    "llama-2-7b-chat-hf_fact": [
      "DeepSynergy is a tool that predicts drug pairs with synergistic effects using chemical information of drugs and genomic features of cancer cells.",
      "DeepSynergy is available for implementation at <https://www.bioinf.jku.at/software/DeepSynergy>.",
      "The Dual Feature Fusion Network for Drug–Drug Synergy prediction (DFFNDDS) is a deep learning model that predicts drug combinations with synergistic effects.",
      "TranSynergy is a deep learning model for predicting drug synergy that uses self-attention mechanisms.",
      "TranSynergy is available for implementation at <https://www.bioinformatics.org/documents/9>."
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the cloud-based platform that has been developed for comparing GWAS is easyGWAS. Document 1 clearly states that easyGWAS is a cloud-based platform for comparing the results of genome-wide association studies. Additionally, Document 4 mentions that the platform has been extended to include a new phenotype semantic data layer, which enhances the existing visualizations, data reports, and outputs, and provides new interfaces for harmonized phenotype searches across GWAS-related databases. This suggests that easyGWAS is a comprehensive platform for comparing GWAS results and facilitating the search and analysis of GWAS data.",
    "llama-2-7b-chat-hf_fact_raw": "1. easyGWAS is a cloud-based platform developed for comparing genome-wide association studies (GWAS).\n2. easyGWAS includes a new phenotype semantic data layer.\n3. The phenotype semantic data layer in easyGWAS enhances visualizations, data reports, and outputs.\n4. easyGWAS provides interfaces for harmonized phenotype searches across GWAS-related databases.",
    "llama-2-7b-chat-hf_fact": [
      "easyGWAS is a cloud-based platform developed for comparing genome-wide association studies (GWAS).",
      "easyGWAS includes a new phenotype semantic data layer.",
      "The phenotype semantic data layer in easyGWAS enhances visualizations, data reports, and outputs.",
      "easyGWAS provides interfaces for harmonized phenotype searches across GWAS-related databases."
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that CMB305 may be effective in treating sarcomas, including synovial sarcoma and myxoid liposarcoma. Document 1 reports the results of a clinical trial evaluating the efficacy of CMB305 in combination with atezolizumab in patients with NY-ESO-1-expressing synovial or myxoid round cell liposarcoma. The trial showed that the combination of CMB305 and atezolizumab resulted in a disease control rate of 61.9% and observed anti-NY-ESO-1 antibody and T-cell responses in 62.9 and 47.4% of cases, respectively.\nDocument 5 also reports on a phase Ib trial of CMB305 in patients with sarcomas, which found a disease control rate of 61.9% and observed anti-NY-ESO-1 antibody and T-cell responses in 62.9 and 47.4% of cases, respectively.\nDocument 7 reports on an open-label randomized phase II trial evaluating the efficacy and safety of adding the CMB305 regimen to atezolizumab in patients with synovial sarcoma or myxoid liposarcoma. The trial found that the addition of CMB305 to atezolizumab resulted in a higher overall response rate compared to atezolizumab alone.\nBased on these findings, it appears that CMB305 may be a promising therapeutic option for patients with sarcomas, including synovial sarcoma and myxoid liposarcoma. However, it is important to note that these findings are based on early-stage clinical trials, and further research is needed to confirm these results and establish the long-term safety and efficacy of CMB305 in clinical practice.",
    "llama-2-7b-chat-hf_fact_raw": "1. CMB305 may be effective in treating sarcomas, including synovial sarcoma and myxoid liposarcoma.\n2. A clinical trial reported a disease control rate of 61.9% when using CMB305 in combination with atezolizumab for patients with NY-ESO-1-expressing synovial or myxoid round cell liposarcoma.\n3. The same clinical trial observed anti-NY-ESO-1 antibody responses in 62.9% of cases and T-cell responses in 47.4% of cases when using CMB305 with atezolizumab.\n4. A phase Ib trial of CMB305 in patients with sarcomas found similar disease control rates and immune responses as the previously mentioned clinical trial.\n5. An open-label randomized phase II trial found that adding CMB305 to atezolizumab resulted in a higher overall response rate compared to atezolizumab alone in patients with synovial sarcoma or myxoid liposarcoma.",
    "llama-2-7b-chat-hf_fact": [
      "CMB305 may be effective in treating sarcomas, including synovial sarcoma and myxoid liposarcoma.",
      "A clinical trial reported a disease control rate of 61.9% when using CMB305 in combination with atezolizumab for patients with NY-ESO-1-expressing synovial or myxoid round cell liposarcoma.",
      "The same clinical trial observed anti-NY-ESO-1 antibody responses in 62.9% of cases and T-cell responses in 47.4% of cases when using CMB305 with atezolizumab.",
      "A phase Ib trial of CMB305 in patients with sarcomas found similar disease control rates and immune responses as the previously mentioned clinical trial.",
      "An open-label randomized phase II trial found that adding CMB305 to atezolizumab resulted in a higher overall response rate compared to atezolizumab alone in patients with synovial sarcoma or myxoid liposarcoma."
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, Saint's Triad refers to the association of three conditions: hiatal hernia, gallbladder disease, and diverticulosis. These conditions are often seen together in patients with atypical abdominal symptoms, and were first identified by British surgeon Professor Charles Frederick Morris Saint in the 1940s. The triad is also known as Morris's Triad or Saint's Syndrome.\nThe three conditions that make up Saint's Triad are:\n1. Hiatal hernia: a protrusion of the stomach through the diaphragm into the chest cavity.\n2. Gallbladder disease: inflammation or obstruction of the gallbladder, which can cause abdominal pain and other symptoms.\n3. Diverticulosis: the presence of small pouches or sacs in the wall of the colon, which can also cause abdominal pain and other symptoms.\nIt is important to consider the possibility of Saint's Triad in patients with atypical abdominal symptoms, as the conditions that make up the triad can have similar symptoms and may be difficult to diagnose separately.",
    "llama-2-7b-chat-hf_fact_raw": "1. Saint's Triad consists of hiatal hernia, gallbladder disease, and diverticulosis.\n2. These conditions are often seen together in patients with atypical abdominal symptoms.\n3. Saint's Triad was first identified by British surgeon Professor Charles Frederick Morris Saint in the 1940s.\n4. Saint's Triad is also known as Morris's Triad or Saint's Syndrome.\n5. Hiatal hernia involves the protrusion of the stomach through the diaphragm into the chest cavity.",
    "llama-2-7b-chat-hf_fact": [
      "Saint's Triad consists of hiatal hernia, gallbladder disease, and diverticulosis.",
      "These conditions are often seen together in patients with atypical abdominal symptoms.",
      "Saint's Triad was first identified by British surgeon Professor Charles Frederick Morris Saint in the 1940s.",
      "Saint's Triad is also known as Morris's Triad or Saint's Syndrome.",
      "Hiatal hernia involves the protrusion of the stomach through the diaphragm into the chest cavity."
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, there is no clear association between overexpression of LY6K and better prognosis for non-small cell lung cancer patients. In fact, Document 0 suggests that high expression of LY6K is associated with poor prognosis in patients, while Document 1 and 7 mention that the prognosis of non-small cell lung cancer patients is still poor despite advances in conventional treatments.\nDocument 2 mentions that human LY6 genes are novel biomarkers for poor cancer prognosis, and Document 6 highlights that lung cancer is one of the leading causes of cancer-related mortality worldwide, including in China. Document 8 suggests that immunotherapy is not practical for non-small cell lung cancer (NSCLC) patients, which further underscores the poor prognosis of these patients.\nTherefore, based on the information provided, it appears that overexpression of LY6K is not associated with better prognosis for non-small cell lung cancer patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. Overexpression of LY6K is associated with poor prognosis in non-small cell lung cancer patients according to Document 0.\n2. The prognosis of non-small cell lung cancer patients remains poor despite advances in conventional treatments as mentioned in Document 1 and 7.\n3. Human LY6 genes are considered novel biomarkers for poor cancer prognosis as per Document 2.\n4. Lung cancer is one of the leading causes of cancer-related mortality worldwide, including in China, as highlighted in Document 6.\n5. Immunotherapy is suggested to be not practical for non-small cell lung cancer patients by Document 8.",
    "llama-2-7b-chat-hf_fact": [
      "Overexpression of LY6K is associated with poor prognosis in non-small cell lung cancer patients according to Document 0.",
      "The prognosis of non-small cell lung cancer patients remains poor despite advances in conventional treatments as mentioned in Document 1 and 7.",
      "Human LY6 genes are considered novel biomarkers for poor cancer prognosis as per Document 2.",
      "Lung cancer is one of the leading causes of cancer-related mortality worldwide, including in China, as highlighted in Document 6.",
      "Immunotherapy is suggested to be not practical for non-small cell lung cancer patients by Document 8."
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-2-7b-chat-hf_response": "Based on the provided documents, the following CDK targets are dephosphorylated during cytokinesis:\n1. Sld2\n2. Sld3\n3. Ask1\n4. Fin1\n5. Sli15\nThese substrates are dephosphorylated by the Cdc14 phosphatase, which is activated during mitotic exit. The gradual change in the Cdk/Cdc14 ratio instructs sequential dephosphorylation of these substrates, with early targets being dephosphorylated by a small amount of Cdc14 even in the presence of persisting Cdk activity, and later targets requiring the Cdk-Cdc14 balance to shift farther toward Cdc14.\nIt is worth noting that the documents do not provide a comprehensive list of all CDK targets that are dephosphorylated during cytokinesis, and further research may identify additional targets. However, the documents provide evidence that Sld2, Sld3, Ask1, Fin1, and Sli15 are dephosphorylated during cytokinesis, and these substrates are likely to play important roles in the process.",
    "llama-2-7b-chat-hf_fact_raw": "1. Sld2 is dephosphorylated during cytokinesis.\n2. Sld3 is dephosphorylated during cytokinesis.\n3. Ask1 is dephosphorylated during cytokinesis.\n4. Fin1 is dephosphorylated during cytokinesis.\n5. Sli15 is dephosphorylated during cytokinesis.",
    "llama-2-7b-chat-hf_fact": [
      "Sld2 is dephosphorylated during cytokinesis.",
      "Sld3 is dephosphorylated during cytokinesis.",
      "Ask1 is dephosphorylated during cytokinesis.",
      "Fin1 is dephosphorylated during cytokinesis.",
      "Sli15 is dephosphorylated during cytokinesis."
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Xanamem is an investigational drug that works by inhibiting the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) in the brain. This enzyme converts the inactive steroid cortisone to the active steroid cortisol, which is involved in the body's stress response. Elevated levels of cortisol in the brain have been linked to cognitive decline and Alzheimer's disease. Xanamem is designed to cross the blood-brain barrier and block the activity of 11β-HSD1, reducing the production of cortisol in the brain and potentially improving cognitive function.\nActinogen Medical, a biotech company, is developing Xanamem as a potential treatment for Alzheimer's disease. The company has conducted several clinical trials with Xanamem, including a phase 2 trial that failed to establish a drug-placebo difference. However, the company continues to develop Xanamem as a potential treatment for cognitive impairment in Alzheimer's disease.\nIt is important to note that Xanamem is an investigational product and has not been approved for use outside of a clinical trial by the FDA or any global regulatory authority. More research is needed to determine the safety and efficacy of Xanamem for the treatment of Alzheimer's disease or other cognitive disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xanamem is an investigational drug that inhibits the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) in the brain.\n2. The enzyme 11β-HSD1 converts cortisone to cortisol, which is involved in the body's stress response.\n3. Elevated levels of cortisol in the brain have been linked to cognitive decline and Alzheimer's disease.\n4. Actinogen Medical is developing Xanamem as a potential treatment for Alzheimer's disease.\n5. Xanamem has not been approved for use outside of a clinical trial by the FDA or any global regulatory authority.",
    "llama-2-7b-chat-hf_fact": [
      "Xanamem is an investigational drug that inhibits the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) in the brain.",
      "The enzyme 11β-HSD1 converts cortisone to cortisol, which is involved in the body's stress response.",
      "Elevated levels of cortisol in the brain have been linked to cognitive decline and Alzheimer's disease.",
      "Actinogen Medical is developing Xanamem as a potential treatment for Alzheimer's disease.",
      "Xanamem has not been approved for use outside of a clinical trial by the FDA or any global regulatory authority."
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-2-7b-chat-hf_response": "Based on the provided documents, it appears that the Hof1-Cyk3 interaction plays a crucial role in the process of cytokinesis in yeast. Specifically, the interaction is involved in the formation of the cleavage furrow and the separation of the daughter cells during cytokinesis.\nAccording to Document 1, the Hof1-Cyk3 interaction is necessary for the proper formation of the cleavage furrow and the subsequent separation of the daughter cells. The interaction is mediated by a direct binding of the Hof1 SH3 domain to a proline-rich motif in Cyk3, and occurs specifically at the time of cytokinesis.\nDocument 2 provides additional evidence for the importance of the Hof1-Cyk3 interaction in yeast cytokinesis. The authors found that hof1Δ cyk3Δ double mutants are nearly dead, indicating that the interaction is essential for cell viability.\nDocument 3 further supports the idea that the Hof1-Cyk3 interaction is involved in cytokinesis. The authors found that the interaction is mediated by a direct binding of the Hof1 SH3 domain to a proline-rich motif in Cyk3, and occurs specifically at the time of cytokinesis.\nDocument 4 provides additional context for the role of Hof1 in yeast cytokinesis. The authors found that Hof1 is orthologous to fission yeast Cdc15, and that the Hof1 network bears striking resemblance to the fission yeast Cdc15 network that is targeted by polarity kinases.\nDocument 5 provides additional evidence for the importance of the Hof1-Cyk3 interaction in yeast cytokinesis. The authors found that depletion of Iqg1 activity in budding yeast results in chains of cells that have failed to undergo cytokinesis and lyse after several rounds of nuclear division.\nDocument 6 provides additional context for the role of Cyk3 in yeast cytokinesis. The authors found that fission yeast rng2 mutants, which are also defective in cytokinetic actin ring formation, fail to form a septum, become multinucleate and die.\nDocument 7 summarizes the recent progresses in our understanding of how budding yeast cells orchest",
    "llama-2-7b-chat-hf_fact_raw": "1. The Hof1-Cyk3 interaction is involved in the formation of the cleavage furrow during cytokinesis in yeast.\n2. The Hof1-Cyk3 interaction is necessary for the proper separation of daughter cells during cytokinesis.\n3. The interaction between Hof1 and Cyk3 is mediated by the direct binding of the Hof1 SH3 domain to a proline-rich motif in Cyk3.\n4. Hof1Δ cyk3Δ double mutants in yeast are nearly dead, indicating that the interaction is essential for cell viability.\n5. Depletion of Iqg1 activity in budding yeast results in chains of cells that fail to undergo cytokinesis and lyse after several rounds of nuclear division.",
    "llama-2-7b-chat-hf_fact": [
      "The Hof1-Cyk3 interaction is involved in the formation of the cleavage furrow during cytokinesis in yeast.",
      "The Hof1-Cyk3 interaction is necessary for the proper separation of daughter cells during cytokinesis.",
      "The interaction between Hof1 and Cyk3 is mediated by the direct binding of the Hof1 SH3 domain to a proline-rich motif in Cyk3.",
      "Hof1Δ cyk3Δ double mutants in yeast are nearly dead, indicating that the interaction is essential for cell viability.",
      "Depletion of Iqg1 activity in budding yeast results in chains of cells that fail to undergo cytokinesis and lyse after several rounds of nuclear division."
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, T-UCRs that have been implicated in gastric cancer are:\n1. Uc.160: Down-regulated in gastric adenoma and gastric cancer tissues (Honma et al., 2017).\n2. miR-592: Overexpression has been identified in gastric cancer cells and may regulate MAPKs like ERK1/2 and JNK, modulating proliferation, survival, and metastasis (Document 7).\nIt is important to note that these findings are based on a limited number of studies and more research is needed to fully understand the role of T-UCRs in gastric cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. Uc.160 is down-regulated in gastric adenoma and gastric cancer tissues according to Honma et al., 2017.\n2. miR-592 overexpression has been identified in gastric cancer cells.\n3. miR-592 may regulate MAPKs such as ERK1/2 and JNK.\n4. miR-592 is implicated in modulating proliferation, survival, and metastasis in gastric cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Uc.160 is down-regulated in gastric adenoma and gastric cancer tissues according to Honma et al., 2017.",
      "miR-592 overexpression has been identified in gastric cancer cells.",
      "miR-592 may regulate MAPKs such as ERK1/2 and JNK.",
      "miR-592 is implicated in modulating proliferation, survival, and metastasis in gastric cancer."
    ]
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE) in patients. The LSI is derived from the American College of Rheumatology (ACR) classification criteria and is calculated based on the number and type of organs involved, the intensity of inflammation, and the use of immunosuppressive drugs.\nThe LSI ranges from 0 to 10, with higher scores indicating greater severity of disease. The index has been found to be strongly correlated with previous severity scores for lupus and has been used as a predictor variable in statistical analyses.\nThe LSI has been used in various studies to assess the severity of SLE and to identify factors associated with disease severity. For example, one study found that patients with higher LSI scores had higher pass rates on a licensing examination, while another study found that LSI was associated with kidney involvement in SLE patients.\nOverall, the Lupus Severity Index is a useful tool for assessing the severity of SLE and for identifying factors that are associated with disease severity.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE) in patients.\n2. The LSI is derived from the American College of Rheumatology (ACR) classification criteria.\n3. The LSI score ranges from 0 to 10, with higher scores indicating greater severity of the disease.\n4. The LSI has been found to be strongly correlated with previous severity scores for lupus.\n5. The LSI has been used as a predictor variable in statistical analyses related to SLE.",
    "llama-2-7b-chat-hf_fact": [
      "The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE) in patients.",
      "The LSI is derived from the American College of Rheumatology (ACR) classification criteria.",
      "The LSI score ranges from 0 to 10, with higher scores indicating greater severity of the disease.",
      "The LSI has been found to be strongly correlated with previous severity scores for lupus.",
      "The LSI has been used as a predictor variable in statistical analyses related to SLE."
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it appears that de novo mutations in the ZSWIM6 gene can cause several disorders, including:\n1. Acromelic frontonasal dysostosis (AFND): This is an autosomal-dominant severe frontonasal and limb malformation syndrome associated with neurocognitive and motor delay. A recurrent de novo missense variant within the C-terminal Sin3-like domain of ZSWIM6 has been identified as the cause of this disorder.\n2. Schizophrenia: Clinical studies have linked ZSWIM6 mutations to developmental and neurological diseases, including schizophrenia. While the function of ZSWIM6 remains largely unknown, it is important to understand its role in the development of this neuropsychiatric disorder.\n3. Neurodevelopmental disorder with movement abnormalities, abnormal gait, and autistic features: ZSWIM6 mutations have been identified in individuals with this rare disorder, which is characterized by movement abnormalities, abnormal gait, and autistic features.\nIt is important to note that these disorders are rare and the prevalence of ZSWIM6 mutations in these conditions is not well established. Further research is needed to fully understand the relationship between ZSWIM6 mutations and these disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. De novo mutations in the ZSWIM6 gene can cause Acromelic frontonasal dysostosis (AFND).\n2. A recurrent de novo missense variant within the C-terminal Sin3-like domain of ZSWIM6 has been identified as the cause of Acromelic frontonasal dysostosis (AFND).\n3. Clinical studies have linked ZSWIM6 mutations to schizophrenia.\n4. ZSWIM6 mutations have been identified in individuals with a neurodevelopmental disorder characterized by movement abnormalities, abnormal gait, and autistic features.\n5. The function of ZSWIM6 in relation to neuropsychiatric disorders like schizophrenia remains largely unknown.",
    "llama-2-7b-chat-hf_fact": [
      "De novo mutations in the ZSWIM6 gene can cause Acromelic frontonasal dysostosis (AFND).",
      "A recurrent de novo missense variant within the C-terminal Sin3-like domain of ZSWIM6 has been identified as the cause of Acromelic frontonasal dysostosis (AFND).",
      "Clinical studies have linked ZSWIM6 mutations to schizophrenia.",
      "ZSWIM6 mutations have been identified in individuals with a neurodevelopmental disorder characterized by movement abnormalities, abnormal gait, and autistic features.",
      "The function of ZSWIM6 in relation to neuropsychiatric disorders like schizophrenia remains largely unknown."
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the disease that can be classified using the Koos Classification is vestibular schwannoma (VS). The Koos grading scale is a classification system used to characterize the tumor and its effects on adjacent brain structures, and it is often used to determine treatment plans. The classification captures many of the characteristics of treatment decisions and is used by experts to evaluate the tumor size and anatomical relationship.\nThe documents mention that VS is a benign, slow-growing tumor arising from the Schwann cells surrounding the vestibulocochlear nerve, and that the Koos grading scale is a frequently used classification system for VS that accounts for extrameatal tumor dimension and compression of the brain stem. The documents also mention that the Koos classification captures many of the characteristics of treatment decisions and is often used to determine treatment plans.\nTherefore, based on the information provided in the documents, the disease that can be classified using the Koos Classification is vestibular schwannoma (VS).",
    "llama-2-7b-chat-hf_fact_raw": "1. The Koos Classification is used to classify vestibular schwannoma (VS).\n2. The Koos grading scale characterizes the tumor and its effects on adjacent brain structures.\n3. The Koos grading scale is used to determine treatment plans for vestibular schwannoma.\n4. Vestibular schwannoma is a benign, slow-growing tumor that arises from the Schwann cells.\n5. The Koos grading scale accounts for extrameatal tumor dimension and compression of the brain stem.",
    "llama-2-7b-chat-hf_fact": [
      "The Koos Classification is used to classify vestibular schwannoma (VS).",
      "The Koos grading scale characterizes the tumor and its effects on adjacent brain structures.",
      "The Koos grading scale is used to determine treatment plans for vestibular schwannoma.",
      "Vestibular schwannoma is a benign, slow-growing tumor that arises from the Schwann cells.",
      "The Koos grading scale accounts for extrameatal tumor dimension and compression of the brain stem."
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, AZD8601 has the following in vivo effects:\n1. Improves vascularization and tissue oxygenation of the wound bed: Documents 0 and 5 show that AZD8601 improves vascularization and tissue oxygenation of the wound bed, leading to accelerated re-epithelialization during the early phase of diabetic wound healing.\n2. Enhances VEGF-A expression: Documents 1, 2, and 3 show that AZD8601 is a mRNA-based therapy that encodes for VEGF-A, which is responsible for carrying genetic instructions transcribed from DNA, and leads to sustained transient expression of functional VEGF-A protein in the skin, heart, and skeletal muscle in animal models.\n3. Accelerates wound healing: Documents 0, 5, and 9 show that AZD8601 accelerates wound healing, with a sustained acceleration of wound healing depending on the accumulated dose.\n4. Minimizes innate immune responses: Document 2 shows that AZD8601 is formulated in a biocompatible citrate-buffered saline and optimized for high-efficiency VEGF-A expression with minimal innate immune response.\n5. Safety and tolerability: Document 4 shows that the safety and tolerability of AZD8601 are evaluated in patients undergoing surgical revascularization, and Document 8 shows that AZD8601 is safe and well-tolerated in patients with moderately decreased left ventricular function.\nIn summary, AZD8601 has been shown to improve vascularization and tissue oxygenation of the wound bed, enhance VEGF-A expression, accelerate wound healing, minimize innate immune responses, and demonstrate safety and tolerability in various animal models and clinical trials.",
    "llama-2-7b-chat-hf_fact_raw": "1. AZD8601 improves vascularization and tissue oxygenation of the wound bed, which leads to accelerated re-epithelialization during the early phase of diabetic wound healing.\n2. AZD8601 is a mRNA-based therapy that encodes for VEGF-A, leading to sustained transient expression of functional VEGF-A protein in the skin, heart, and skeletal muscle in animal models.\n3. AZD8601 accelerates wound healing, with a sustained acceleration of wound healing depending on the accumulated dose.\n4. AZD8601 is formulated in a biocompatible citrate-buffered saline and optimized for high-efficiency VEGF-A expression with minimal innate immune response.\n5. The safety and tolerability of AZD8601 have been evaluated in patients undergoing surgical revascularization, and it is safe and well-tolerated in patients with moderately decreased left ventricular function.",
    "llama-2-7b-chat-hf_fact": [
      "AZD8601 improves vascularization and tissue oxygenation of the wound bed, which leads to accelerated re-epithelialization during the early phase of diabetic wound healing.",
      "AZD8601 is a mRNA-based therapy that encodes for VEGF-A, leading to sustained transient expression of functional VEGF-A protein in the skin, heart, and skeletal muscle in animal models.",
      "AZD8601 accelerates wound healing, with a sustained acceleration of wound healing depending on the accumulated dose.",
      "AZD8601 is formulated in a biocompatible citrate-buffered saline and optimized for high-efficiency VEGF-A expression with minimal innate immune response.",
      "The safety and tolerability of AZD8601 have been evaluated in patients undergoing surgical revascularization, and it is safe and well-tolerated in patients with moderately decreased left ventricular function."
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, SAHFS (Senescence Associated Heterochromatic Foci) are created through a complex process involving the repositioning of the genome. This process is thought to occur according to certain chromatin features, such as histone H3 trimethylated on lysine 9 (H3K9me3) and H3K27me3, and involves the formation of multi-layered structures centered on a condensed heterochromatic core. The exact mechanisms by which this occurs are not fully understood, but it is thought to involve the dysregulation of chromatin organization with age.\nIt is important to note that senescence is a heterogeneous phenotype, and the creation of SAHFS is just one aspect of this process. Other factors, such as the age-related dysregulation of chromatin organization, can also contribute to the formation of SAHFS. Additionally, the creation of SAHFS is not the only mechanism by which cellular senescence can be induced, and other factors, such as DNA damage and telomere erosion, can also lead to senescence.\nIn summary, SAHFS are created through a complex process involving the repositioning of the genome, and this process is thought to involve the dysregulation of chromatin organization with age. However, the exact mechanisms by which this occurs are not fully understood, and further research is needed to fully elucidate the process of SAHFS formation.",
    "llama-2-7b-chat-hf_fact_raw": "1. SAHFS (Senescence Associated Heterochromatic Foci) are created through a process involving the repositioning of the genome.\n2. The formation of SAHFS involves chromatin features such as histone H3 trimethylated on lysine 9 (H3K9me3) and H3K27me3.\n3. The creation of SAHFS involves the formation of multi-layered structures centered on a condensed heterochromatic core.\n4. The dysregulation of chromatin organization with age is thought to contribute to the formation of SAHFS.\n5. Cellular senescence can also be induced by other factors, such as DNA damage and telomere erosion, not just the creation of SAHFS.",
    "llama-2-7b-chat-hf_fact": [
      "SAHFS (Senescence Associated Heterochromatic Foci) are created through a process involving the repositioning of the genome.",
      "The formation of SAHFS involves chromatin features such as histone H3 trimethylated on lysine 9 (H3K9me3) and H3K27me3.",
      "The creation of SAHFS involves the formation of multi-layered structures centered on a condensed heterochromatic core.",
      "The dysregulation of chromatin organization with age is thought to contribute to the formation of SAHFS.",
      "Cellular senescence can also be induced by other factors, such as DNA damage and telomere erosion, not just the creation of SAHFS."
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the function of the PDZ domain in SATB1 is to mediate interactions with several chromatin proteins. The PDZ domain is a putative region for interactions with other proteins and is also involved in the formation of SATB1 homodimers, which are essential for its DNA binding activity. Additionally, the PDZ domain may play a role in regulating the function of SATB1 at the protein level through post-translational modifications.\nThe documents mention that the PDZ domain of SATB1 is involved in the recruitment of chromatin proteins, but do not provide specific information on which chromatin proteins are interacted with by the PDZ domain. However, they do suggest that the PDZ domain is involved in the formation of SATB1 homodimers, which is essential for its DNA binding activity.\nIt is also mentioned that the function of SATB1 is regulated by post-translational modifications, but the documents do not provide specific information on how these modifications affect the function of the PDZ domain.\nIn summary, the function of the PDZ domain in SATB1 is to mediate interactions with several chromatin proteins and to play a role in the formation of SATB1 homodimers, which is essential for its DNA binding activity. However, the specific chromatin proteins interacted with by the PDZ domain and the exact mechanisms by which post-translational modifications regulate the function of the PDZ domain are not provided in the documents.",
    "llama-2-7b-chat-hf_fact_raw": "1. The PDZ domain in SATB1 mediates interactions with several chromatin proteins.\n2. The PDZ domain is involved in the formation of SATB1 homodimers.\n3. SATB1 homodimers are essential for its DNA binding activity.\n4. The function of SATB1 is regulated by post-translational modifications.\n5. The PDZ domain may play a role in regulating the function of SATB1 at the protein level through post-translational modifications.",
    "llama-2-7b-chat-hf_fact": [
      "The PDZ domain in SATB1 mediates interactions with several chromatin proteins.",
      "The PDZ domain is involved in the formation of SATB1 homodimers.",
      "SATB1 homodimers are essential for its DNA binding activity.",
      "The function of SATB1 is regulated by post-translational modifications.",
      "The PDZ domain may play a role in regulating the function of SATB1 at the protein level through post-translational modifications."
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the BLISS technique appears to be a meditation-based practice that aims to cultivate bliss and balance in the mind-body system. The technique involves adding a specific mantra to the end of every twice-daily meditation, as well as practicing detachment and deep meditation to support the wisdom sheath and the bliss body.\nAccording to Document 5, the BLISS technique is based on the idea that the body is a living, dynamic field of energy and intelligence, and that bliss is a fundamental aspect of this energy. The technique aims to help practitioners access and cultivate this bliss, leading to a state of non-duality and oneness with the world around them.\nDocument 7 provides more details on the BLISS technique, stating that it is an advanced set of techniques that is taught in two parts during one session. In the first part, practitioners receive a technique to add to the end of their meditation practice, which enhances bliss in the mind-body system. In the second part, practitioners receive an additional practice with a specific Sanskrit mantra for adding into their meditation practice.\nOverall, the BLISS technique appears to be a holistic practice that aims to cultivate bliss, balance, and non-duality in the mind-body system through meditation and other techniques.",
    "llama-2-7b-chat-hf_fact_raw": "1. The BLISS technique is a meditation-based practice.\n2. It involves adding a specific mantra to the end of every twice-daily meditation.\n3. The BLISS technique includes practicing detachment and deep meditation to support the wisdom sheath and the bliss body.\n4. The technique is based on the idea that bliss is a fundamental aspect of the body's energy.\n5. The BLISS technique is taught in two parts during one session.",
    "llama-2-7b-chat-hf_fact": [
      "The BLISS technique is a meditation-based practice.",
      "It involves adding a specific mantra to the end of every twice-daily meditation.",
      "The BLISS technique includes practicing detachment and deep meditation to support the wisdom sheath and the bliss body.",
      "The technique is based on the idea that bliss is a fundamental aspect of the body's energy.",
      "The BLISS technique is taught in two parts during one session."
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, here are 3 NK3R antagonists that have been studied for the treatment of menopausal vasomotor symptoms:\n1. Fezolinetant: This is the first NK3R antagonist to be approved by the FDA for the treatment of moderate to severe hot flushes in menopause.\n2. Talnetant: This NK3R antagonist has been studied in several clinical trials for the treatment of hot flushes, and has been shown to be effective in reducing the frequency and severity of hot flushes.\n3. Osanetant: This NK3R antagonist has also been studied in clinical trials for the treatment of hot flushes, and has been shown to be effective in improving hot flush frequency, severity, and quality of life.\nIt is important to note that these are just a few examples of NK3R antagonists that have been studied for the treatment of menopausal vasomotor symptoms, and there may be other compounds in development that have similar efficacy and safety profiles.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fezolinetant is an NK3R antagonist approved by the FDA for the treatment of moderate to severe hot flushes in menopause.\n2. Talnetant has been studied in clinical trials for the treatment of hot flushes.\n3. Osanetant has been studied in clinical trials for the treatment of hot flushes and has shown effectiveness in improving hot flush frequency, severity, and quality of life.",
    "llama-2-7b-chat-hf_fact": [
      "Fezolinetant is an NK3R antagonist approved by the FDA for the treatment of moderate to severe hot flushes in menopause.",
      "Talnetant has been studied in clinical trials for the treatment of hot flushes.",
      "Osanetant has been studied in clinical trials for the treatment of hot flushes and has shown effectiveness in improving hot flush frequency, severity, and quality of life."
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is PF-05190457. This is mentioned in Documents 1, 5, and 9.",
    "llama-2-7b-chat-hf_fact_raw": "1. PF-05190457 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
    "llama-2-7b-chat-hf_fact": [
      "PF-05190457 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects."
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the protective efficacy of Vaxchora against moderate to severe cholera is not explicitly stated in any of the documents. However, we can make an educated estimate based on the information provided.\nDocument 7 mentions that Vaxchora is effective for protecting vaccinated individuals against moderate and severe cholera disease. Additionally, Document 8 highlights the potential advantage of a single-dose cholera vaccine in rapidly protecting short-notice travelers to high-risk areas and controlling explosive outbreaks where logistics render 2-dose immunization regimens impractical.\nUsing the formula provided in Document 2, we can estimate the percentage vaccine efficacy/effectiveness of Vaxchora against moderate to severe cholera. Assuming a relative risk reduction of 50% (which is a reasonable estimate based on the available data), we can calculate the percentage vaccine efficacy/effectiveness as follows:\nPercentage vaccine efficacy/effectiveness = (1 - 0.5) × 100 = 50%\nTherefore, based on the information provided, Vaxchora appears to be effective in protecting against moderate to severe cholera, with an estimated efficacy of 50%. However, it is important to note that this estimate is based on limited data and may not reflect the full range of cholera severity or the vaccine's effectiveness in different populations or settings. Further research and clinical trials are needed to fully assess the protective efficacy of Vaxchora against moderate to severe cholera.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vaxchora is a vaccine intended to protect against moderate and severe cholera disease.\n2. Document 8 suggests that Vaxchora could be particularly beneficial for short-notice travelers to high-risk areas and for controlling explosive outbreaks.\n3. A single-dose cholera vaccine like Vaxchora offers a potential advantage in situations where a 2-dose immunization regimen is impractical.\n4. An estimated vaccine efficacy of Vaxchora against moderate to severe cholera is 50%, based on an assumed relative risk reduction of 50%.\n5. The estimate of Vaxchora's efficacy is based on limited data and may not reflect its effectiveness in different populations or settings.",
    "llama-2-7b-chat-hf_fact": [
      "Vaxchora is a vaccine intended to protect against moderate and severe cholera disease.",
      "Document 8 suggests that Vaxchora could be particularly beneficial for short-notice travelers to high-risk areas and for controlling explosive outbreaks.",
      "A single-dose cholera vaccine like Vaxchora offers a potential advantage in situations where a 2-dose immunization regimen is impractical.",
      "An estimated vaccine efficacy of Vaxchora against moderate to severe cholera is 50%, based on an assumed relative risk reduction of 50%.",
      "The estimate of Vaxchora's efficacy is based on limited data and may not reflect its effectiveness in different populations or settings."
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the first cholera vaccine approved in the US is Vaxchora, which was approved by the Food and Drug Administration (FDA) in 2016.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vaxchora is the first cholera vaccine approved in the US.\n2. The FDA approved Vaxchora in 2016.",
    "llama-2-7b-chat-hf_fact": [
      "Vaxchora is the first cholera vaccine approved in the US.",
      "The FDA approved Vaxchora in 2016."
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is loss-of-function variants in the nuclear factor κB subunit 1 (NFKB1) gene. This is supported by multiple studies, including Documents 1, 3, 4, 6, and 8, which indicate that NFKB1 variants are the most common monogenic cause of CVID in Europeans, accounting for 4% of cases in a cohort of 390 unrelated individuals.",
    "llama-2-7b-chat-hf_fact_raw": "1. The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is loss-of-function variants in the NFKB1 gene.\n2. Multiple studies, including Documents 1, 3, 4, 6, and 8, support the finding that NFKB1 variants are the most common monogenic cause of CVID in Europeans.\n3. NFKB1 variants account for 4% of cases in a cohort of 390 unrelated individuals with CVID.",
    "llama-2-7b-chat-hf_fact": [
      "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is loss-of-function variants in the NFKB1 gene.",
      "Multiple studies, including Documents 1, 3, 4, 6, and 8, support the finding that NFKB1 variants are the most common monogenic cause of CVID in Europeans.",
      "NFKB1 variants account for 4% of cases in a cohort of 390 unrelated individuals with CVID."
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-2-7b-chat-hf_response": "Based on the provided documents, the IFIT1 gene plays a crucial role in the pathogenesis of Systemic Lupus Erythematosus (SLE). Here are some key points that can be inferred from the documents:\n1. IFIT1 is an interferon-induced protein with tetratricopeptide repeats (IFIT) family member that is upregulated in SLE patients. (Documents 2, 4, and 7)\n2. The upregulation of IFIT1 has been associated with the development of SLE. (Documents 2, 4, and 7)\n3. IFIT1 plays a crucial role in the regulation of inflammation and immune responses. (Documents 1 and 3)\n4. IFIT1 is involved in the regulation of signaling pathways that are important in the pathogenesis of SLE. (Document 3)\n5. The dysregulation of IFIT1 has been implicated in the development of autoimmune diseases, including SLE. (Document 7)\nBased on these findings, it can be concluded that the IFIT1 gene plays a significant role in the pathogenesis of SLE, and its dysregulation may contribute to the development of the disease. Further research is needed to fully understand the mechanisms by which IFIT1 contributes to SLE and to identify potential therapeutic targets for the treatment of the disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. IFIT1 is an interferon-induced protein with tetratricopeptide repeats (IFIT) family member that is upregulated in SLE patients.\n2. The upregulation of IFIT1 has been associated with the development of Systemic Lupus Erythematosus (SLE).\n3. IFIT1 plays a role in the regulation of inflammation and immune responses.\n4. IFIT1 is involved in the regulation of signaling pathways important in the pathogenesis of SLE.\n5. The dysregulation of IFIT1 has been implicated in the development of autoimmune diseases, including SLE.",
    "llama-2-7b-chat-hf_fact": [
      "IFIT1 is an interferon-induced protein with tetratricopeptide repeats (IFIT) family member that is upregulated in SLE patients.",
      "The upregulation of IFIT1 has been associated with the development of Systemic Lupus Erythematosus (SLE).",
      "IFIT1 plays a role in the regulation of inflammation and immune responses.",
      "IFIT1 is involved in the regulation of signaling pathways important in the pathogenesis of SLE.",
      "The dysregulation of IFIT1 has been implicated in the development of autoimmune diseases, including SLE."
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the Liverpool Elbow Score (LES) is a valid and reliable elbow-specific scoring system that assesses both subjective and objective parameters of elbow function. It consists of a 15-item tool with a scale ranging from 0 to 10 points, with higher scores indicating better function. The LES is completed by both the clinician and patient, and has been validated in patients with various elbow pathologies.\nThe LES was developed to address the limitations of existing elbow scoring systems, which often lacked validity and reliability. The developers of the LES conducted a validation study to demonstrate its validity, reliability, and responsiveness to change in clinical condition. The study showed that the LES is a valid and reliable measure of elbow function, with acceptable internal consistency and test-retest reliability.\nThe LES has been used in various clinical settings, including the assessment of elbow function after total elbow arthroplasty. It has also been used in patients with different elbow pathologies, such as elbow stiffness and elbow osteoarthritis.\nIn summary, the Liverpool Elbow Score is a valid and reliable elbow-specific scoring system that provides a comprehensive assessment of elbow function. It is completed by both the clinician and patient, and has been validated in patients with various elbow pathologies.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Liverpool Elbow Score (LES) is an elbow-specific scoring system used to assess elbow function.\n2. The LES consists of a 15-item tool with a scale ranging from 0 to 10 points.\n3. Higher scores on the LES indicate better elbow function.\n4. The LES has been validated in patients with various elbow pathologies.\n5. The LES is used in clinical settings, including the assessment of elbow function after total elbow arthroplasty.",
    "llama-2-7b-chat-hf_fact": [
      "The Liverpool Elbow Score (LES) is an elbow-specific scoring system used to assess elbow function.",
      "The LES consists of a 15-item tool with a scale ranging from 0 to 10 points.",
      "Higher scores on the LES indicate better elbow function.",
      "The LES has been validated in patients with various elbow pathologies.",
      "The LES is used in clinical settings, including the assessment of elbow function after total elbow arthroplasty."
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the 100,000 Genomes Project has made significant efforts in understanding and treating sarcoma. Here are some key findings and efforts:\n1. Sarcoma ranked third overall among the number of patients' samples sent for sequencing in the 100,000 Genomes Project (Document 4).\n2. The project aims to establish a genomic medicine service for the NHS, provide clinical diagnosis with new personalized treatment options, and enable scientific discovery (Document 1).\n3. The project has identified gene fusions that are likely to be driving tumor growth in some cases of sarcoma (Document 8).\n4. The project has also re-evaluated prognosis and identified new treatment options for patients with sarcoma (Document 7).\n5. The project is in the process of investigating the role of genome sequencing in patients with undiagnosed rare diseases, including sarcoma, after usual care and the alignment of this research with health care implementation in the U.K. National Health Service (Document 5).\n6. The project has used data provided by patients and collected by the National Health Service as part of their care and has been funded by the National Institute for Health Research, NHS England, the Wellcome Trust, Cancer Research UK, and the Medical Research Council (Document 7).\nOverall, the 100,000 Genomes Project has made significant efforts in understanding and treating sarcoma through whole genome sequencing, and has identified new potential targets for treatment. These findings have the potential to improve diagnosis and treatment for patients with sarcoma in the future.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 100,000 Genomes Project ranked sarcoma third overall among the number of patients' samples sent for sequencing.\n2. The project aims to establish a genomic medicine service for the NHS and provide clinical diagnosis with personalized treatment options.\n3. The project has identified gene fusions likely driving tumor growth in some sarcoma cases.\n4. The project has re-evaluated prognosis and identified new treatment options for patients with sarcoma.\n5. The project is investigating the role of genome sequencing in patients with undiagnosed rare diseases, including sarcoma, in relation to health care implementation in the U.K. National Health Service.",
    "llama-2-7b-chat-hf_fact": [
      "The 100,000 Genomes Project ranked sarcoma third overall among the number of patients' samples sent for sequencing.",
      "The project aims to establish a genomic medicine service for the NHS and provide clinical diagnosis with personalized treatment options.",
      "The project has identified gene fusions likely driving tumor growth in some sarcoma cases.",
      "The project has re-evaluated prognosis and identified new treatment options for patients with sarcoma.",
      "The project is investigating the role of genome sequencing in patients with undiagnosed rare diseases, including sarcoma, in relation to health care implementation in the U.K. National Health Service."
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it appears that ALEX1 does contain armadillo repeats. Specifically, ALEX1 contains two armadillo repeats, which is consistent with the information provided in Document 6.\nThe armadillo repeat motif is a 42-amino acid sequence that is found in many proteins involved in various cellular processes, including cell adhesion, signal transduction, and tumorigenesis. The presence of armadillo repeats in ALEX1 suggests that it may play a role in these processes, although the exact function of ALEX1 is not specified in the documents provided.\nIt is worth noting that ALEX1 is a novel member of the Armadillo family, as mentioned in Document 6, and it has two armadillo repeats as opposed to more than six repeats in the classical Armadillo family members. This suggests that ALEX1 may have a unique function or mechanism of action compared to other Armadillo family members.\nIn summary, based on the information provided in the documents, ALEX1 does contain armadillo repeats and may play a role in cellular processes related to armadillo repeat proteins. However, further research is needed to fully understand the function of ALEX1 and its role in these processes.",
    "llama-2-7b-chat-hf_fact_raw": "1. ALEX1 contains two armadillo repeats.\n2. The armadillo repeat motif is a 42-amino acid sequence.\n3. Proteins with armadillo repeats are involved in cellular processes such as cell adhesion, signal transduction, and tumorigenesis.\n4. ALEX1 is a novel member of the Armadillo family.\n5. Classical Armadillo family members typically have more than six armadillo repeats.",
    "llama-2-7b-chat-hf_fact": [
      "ALEX1 contains two armadillo repeats.",
      "The armadillo repeat motif is a 42-amino acid sequence.",
      "Proteins with armadillo repeats are involved in cellular processes such as cell adhesion, signal transduction, and tumorigenesis.",
      "ALEX1 is a novel member of the Armadillo family.",
      "Classical Armadillo family members typically have more than six armadillo repeats."
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-2-7b-chat-hf_response": "Based on the provided documents, there are several enzymes that remove histone modifications. Here are some of them:\n1. Histone deacetylases (HDACs): These enzymes remove acetyl groups from histone proteins, leading to a decrease in histone acetylation levels. HDACs are known to be involved in various cellular processes, including chromatin remodeling, transcriptional regulation, and cell cycle progression.\n2. Histone acetyltransferases (HATs): These enzymes add acetyl groups to histone proteins, leading to an increase in histone acetylation levels. HATs are involved in various cellular processes, including transcriptional activation, chromatin remodeling, and cell proliferation.\n3. Histone demethylases: These enzymes remove methyl groups from histone proteins, leading to a decrease in histone methylation levels. Histone demethylases are involved in various cellular processes, including chromatin remodeling, transcriptional regulation, and cellular differentiation.\n4. Lysine-specific demethylase 1 (LSD1): This enzyme is involved in the removal of methyl groups from histone H3 lysine 4 (H3K4) and histone H3 lysine 27 (H3K27). LSD1 is known to play a role in the regulation of gene expression, particularly in the context of stem cells and cancer.\n5. JMJD2A: This enzyme is involved in the removal of methyl groups from histone H3 lysine 9 (H3K9) and histone H3 lysine 27 (H3K27). JMJD2A is known to play a role in the regulation of gene expression, particularly in the context of stem cells and cancer.\n6. KDM5B: This enzyme is involved in the removal of methyl groups from histone H3 lysine 4 (H3K4) and histone H3 lysine 27 (H3K27). KDM5B is known to play a role in the regulation of gene expression, particularly in the context of stem cells and cancer",
    "llama-2-7b-chat-hf_fact_raw": "1. Histone deacetylases (HDACs) remove acetyl groups from histone proteins.\n2. Histone acetyltransferases (HATs) add acetyl groups to histone proteins.\n3. Histone demethylases remove methyl groups from histone proteins.\n4. Lysine-specific demethylase 1 (LSD1) is involved in the removal of methyl groups from histone H3 lysine 4 (H3K4) and histone H3 lysine 27 (H3K27).\n5. JMJD2A is involved in the removal of methyl groups from histone H3 lysine 9 (H3K9) and histone H3 lysine 27 (H3K27).",
    "llama-2-7b-chat-hf_fact": [
      "Histone deacetylases (HDACs) remove acetyl groups from histone proteins.",
      "Histone acetyltransferases (HATs) add acetyl groups to histone proteins.",
      "Histone demethylases remove methyl groups from histone proteins.",
      "Lysine-specific demethylase 1 (LSD1) is involved in the removal of methyl groups from histone H3 lysine 4 (H3K4) and histone H3 lysine 27 (H3K27).",
      "JMJD2A is involved in the removal of methyl groups from histone H3 lysine 9 (H3K9) and histone H3 lysine 27 (H3K27)."
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, there is evidence to suggest that head CT scans may increase the risk of brain tumors in children and adolescents. The documents report on several studies that have found an association between head CT scans and the risk of brain tumors, with the risk increasing with the number of scans performed.\nOne study found that the estimated excess risk of brain tumors among patients 0 to 20 years of age at exposure was 0.32 cases per 10,000 exposed children, with the estimated risk in the 10 years following exposure being 1 brain tumor per 10,000 patients exposed to a 10 mGy scan at less than 10 years of age.\nAnother study found that patients who received high doses of radiation on the head in childhood have high risks of brain tumors, and that CT scans do produce more radiation exposure than other imaging techniques, with a radiation dose in the range of 5–50 mGY.\nA retrospective cohort study also found that excess relative risk of new brain tumor averaged 1.29 (95% confidence interval, 0.66-1.93) for pediatric patients exposed to one or more head CTs, with tumor incidence increasing with number of pediatric head CTs in a dose-dependent manner, with measurable excess incidence even after a single scan.\nIt is important to note that the risk of brain tumors associated with head CT scans is still relatively low, and the benefits of using CT scans for medical imaging in children and adolescents outweigh the risks. However, this information should be taken into consideration when deciding whether or not to perform a head CT scan on a child or adolescent.\nIn summary, the evidence suggests that head CT scans may increase the risk of brain tumors in children and adolescents, with the risk increasing with the number of scans performed. However, the risk is still relatively low, and the benefits of using CT scans for medical imaging in children and adolescents outweigh the risks.",
    "llama-2-7b-chat-hf_fact_raw": "1. Head CT scans may increase the risk of brain tumors in children and adolescents.\n2. One study estimated an excess risk of brain tumors at 0.32 cases per 10,000 exposed children aged 0 to 20 years.\n3. The estimated risk of developing a brain tumor within 10 years after exposure to a 10 mGy head CT scan before the age of 10 is 1 per 10,000 patients.\n4. Patients who received high doses of radiation on the head in childhood have high risks of brain tumors, and CT scans produce more radiation exposure than other imaging techniques, with doses ranging from 5–50 mGy.\n5. A retrospective cohort study found an excess relative risk of new brain tumor at 1.29 (95% confidence interval, 0.66-1.93) for pediatric patients exposed to one or more head CTs.",
    "llama-2-7b-chat-hf_fact": [
      "Head CT scans may increase the risk of brain tumors in children and adolescents.",
      "One study estimated an excess risk of brain tumors at 0.32 cases per 10,000 exposed children aged 0 to 20 years.",
      "The estimated risk of developing a brain tumor within 10 years after exposure to a 10 mGy head CT scan before the age of 10 is 1 per 10,000 patients.",
      "Patients who received high doses of radiation on the head in childhood have high risks of brain tumors, and CT scans produce more radiation exposure than other imaging techniques, with doses ranging from 5–50 mGy.",
      "A retrospective cohort study found an excess relative risk of new brain tumor at 1.29 (95% confidence interval, 0.66-1.93) for pediatric patients exposed to one or more head CTs."
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, Otx2 is associated with primed pluripotency.\nDocument 1 explains that Otx2 drives enhancer activation through affecting chromatin marks and the activity of associated genes. This suggests that Otx2 plays a role in regulating the expression of genes involved in pluripotency, which is a characteristic of primed pluripotency.\nDocument 2 also mentions that naive and primed pluripotency share key transcriptional regulators, including Oct4, Sox2, and Nanog, but that primed pluripotency has distinct signaling requirements and developmental properties. This suggests that while Oct4, Sox2, and Nanog are important for both naive and primed pluripotency, the latter has additional regulatory mechanisms that distinguish it from the former.\nDocument 6 highlights the role of Otx2 in regulating pluripotency-associated genes and redirecting Oct4 to previously inaccessible enhancer sites. This suggests that Otx2 plays a key role in maintaining or initiating cellular differentiation processes in primed pluripotency.\nFinally, Document 8 shows that Otx2 and Oct4 drive early enhancer activation during embryonic stem cell transition from naive pluripotency. This suggests that Otx2 and Oct4 are involved in the regulation of pluripotency in both naive and primed states.\nBased on these findings, it can be concluded that Otx2 is associated with primed pluripotency, which is characterized by distinct signaling requirements, transcriptomes, and developmental properties compared to naive pluripotency.",
    "llama-2-7b-chat-hf_fact_raw": "1. Otx2 is associated with primed pluripotency.\n2. Otx2 affects chromatin marks and the activity of genes involved in pluripotency.\n3. Primed pluripotency has distinct signaling requirements and developmental properties compared to naive pluripotency.\n4. Key transcriptional regulators such as Oct4, Sox2, and Nanog are shared between naive and primed pluripotency.\n5. Otx2 plays a role in redirecting Oct4 to previously inaccessible enhancer sites.",
    "llama-2-7b-chat-hf_fact": [
      "Otx2 is associated with primed pluripotency.",
      "Otx2 affects chromatin marks and the activity of genes involved in pluripotency.",
      "Primed pluripotency has distinct signaling requirements and developmental properties compared to naive pluripotency.",
      "Key transcriptional regulators such as Oct4, Sox2, and Nanog are shared between naive and primed pluripotency.",
      "Otx2 plays a role in redirecting Oct4 to previously inaccessible enhancer sites."
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-2-7b-chat-hf_response": "Based on the provided documents, there are 5 DNase I hypersensitive sites (DHSs) marking the murine beta globin locus region:\n1. 5'HS1\n2. 5'HS2\n3. 5'HS3\n4. 5'HS4\n5. 5'HS5\nThese DHSs are located at the 5' end of the beta globin locus and are known as the locus control region (LCR). The LCR is a dominant regulator of the entire beta globin gene cluster and is responsible for the high-level expression of the genes in transgenic mice. The five DHSs in the LCR are physically defined by their ability to mediate the regulation of the beta globin genes.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are 5 DNase I hypersensitive sites marking the murine beta globin locus region.\n2. The DNase I hypersensitive sites are named 5'HS1, 5'HS2, 5'HS3, 5'HS4, and 5'HS5.\n3. These hypersensitive sites are located at the 5' end of the beta globin locus.\n4. The locus control region (LCR) is a dominant regulator of the entire beta globin gene cluster.\n5. The LCR is responsible for the high-level expression of the genes in transgenic mice.",
    "llama-2-7b-chat-hf_fact": [
      "There are 5 DNase I hypersensitive sites marking the murine beta globin locus region.",
      "The DNase I hypersensitive sites are named 5'HS1, 5'HS2, 5'HS3, 5'HS4, and 5'HS5.",
      "These hypersensitive sites are located at the 5' end of the beta globin locus.",
      "The locus control region (LCR) is a dominant regulator of the entire beta globin gene cluster.",
      "The LCR is responsible for the high-level expression of the genes in transgenic mice."
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-2-7b-chat-hf_response": "Based on the provided documents, here are some European influenza vaccines:\n1. Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) - GlaxoSmithKline Biologicals)\n2. Pandemic influenza vaccine H5N1 - Baxter AG\n3. Emergency procedure\n4. Seasonal influenza vaccines - AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune)\n5. Influenza vaccination coverage and effectiveness\n6. All vaccines type - Total size of safety population should consist of at least 3000 individuals (rare ADRs – 1 in 1000)\n7. Influenza vaccine effectiveness (IVE) assessment - stratified by vaccine type or brand\n8. INFLUENZA VACCINE DEVELOPMENT—A GLOBAL ACHIEVEMENT\n9. Influenza seasonal - Influenza is an acute viral infection that spreads easily from person to person in any age group and that can cause serious complications in certain risk groups.\nIt's worth noting that the documents do not provide a comprehensive list of all European influenza vaccines, but rather a selection of some of the vaccines that are commonly used in the European Union. Additionally, the documents do not provide information on the specific brands or types of vaccines available in each country within the EU.",
    "llama-2-7b-chat-hf_fact_raw": "1. Adjupanrix is a European influenza vaccine produced by GlaxoSmithKline Biologicals.\n2. Baxter AG produces a pandemic influenza vaccine H5N1.\n3. AstraZeneca produces seasonal influenza vaccines.\n4. Influenza is an acute viral infection that can cause serious complications in certain risk groups.\n5. The safety population for all vaccine types should consist of at least 3000 individuals to detect rare adverse drug reactions (ADRs) that occur at a frequency of 1 in 1000.",
    "llama-2-7b-chat-hf_fact": [
      "Adjupanrix is a European influenza vaccine produced by GlaxoSmithKline Biologicals.",
      "Baxter AG produces a pandemic influenza vaccine H5N1.",
      "AstraZeneca produces seasonal influenza vaccines.",
      "Influenza is an acute viral infection that can cause serious complications in certain risk groups.",
      "The safety population for all vaccine types should consist of at least 3000 individuals to detect rare adverse drug reactions (ADRs) that occur at a frequency of 1 in 1000."
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it is clear that the Paramyxovirus geneome is segmented, negative-sense RNA.\nDocument 1 states that the Paramyxovirus genome is a single-stranded, negative-sense RNA molecule, while Document 2 compares the structure of RNA polymerases from negative-sense RNA viruses with segmented and non-segmented genomes, including Paramyxoviruses. This suggests that Paramyxoviruses have a segmented genome.\nDocument 3 mentions that the Paramyxovirus genome is approximately 14-20 kilobases in length, which is consistent with a segmented genome. Additionally, Document 4 notes that Paramyxoviruses are enveloped, non-segmented, negative-sense RNA viruses, further supporting the idea that their genome is segmented.\nDocument 6 specifically mentions that the APMV genome consists of a single stranded, negative sense, non-segmented RNA, while Document 7 discusses the genome of NSVs, which are also single-stranded, negative-sense RNA viruses.\nFinally, Document 8 raises the question of how Paramyxoviruses, which only encode one polymerase, are able to replicate their segmented genome. This suggests that the genome is indeed segmented, and that the virus has evolved mechanisms to facilitate replication.\nIn conclusion, based on the information provided in the documents, it is clear that the Paramyxovirus geneome is segmented, negative-sense RNA.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Paramyxovirus genome is a single-stranded, negative-sense RNA molecule.\n2. Paramyxoviruses are compared with other negative-sense RNA viruses that have segmented and non-segmented genomes.\n3. The Paramyxovirus genome is approximately 14-20 kilobases in length.\n4. Paramyxoviruses are enveloped viruses.\n5. The APMV genome consists of a single-stranded, negative-sense, non-segmented RNA.",
    "llama-2-7b-chat-hf_fact": [
      "The Paramyxovirus genome is a single-stranded, negative-sense RNA molecule.",
      "Paramyxoviruses are compared with other negative-sense RNA viruses that have segmented and non-segmented genomes.",
      "The Paramyxovirus genome is approximately 14-20 kilobases in length.",
      "Paramyxoviruses are enveloped viruses.",
      "The APMV genome consists of a single-stranded, negative-sense, non-segmented RNA."
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Roflumilast Cream is effective for treating plaque psoriasis. The cream was approved by the FDA in 2022 for the treatment of plaque psoriasis in patients aged 12 years and older, and it has been shown to be safe and effective in all hard-to-treat areas, including the face, skin folds, and genitalia. The cream works by inhibiting phosphodiesterase-4 (PDE-4), an enzyme that mediates inflammatory responses and plays a role in several dermatologic diseases, including psoriasis. The approval of Roflumilast Cream is based on data from the pivotal DERMIS-1 and DERMIS-2 phase 3 studies, which demonstrated its safety and efficacy in treating plaque psoriasis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Roflumilast Cream is effective for treating plaque psoriasis.\n2. The FDA approved Roflumilast Cream in 2022 for the treatment of plaque psoriasis in patients aged 12 years and older.\n3. Roflumilast Cream has been shown to be safe and effective in treating hard-to-treat areas, including the face, skin folds, and genitalia.\n4. The cream works by inhibiting phosphodiesterase-4 (PDE-4), an enzyme that mediates inflammatory responses.\n5. The approval of Roflumilast Cream was based on data from the DERMIS-1 and DERMIS-2 phase 3 studies.",
    "llama-2-7b-chat-hf_fact": [
      "Roflumilast Cream is effective for treating plaque psoriasis.",
      "The FDA approved Roflumilast Cream in 2022 for the treatment of plaque psoriasis in patients aged 12 years and older.",
      "Roflumilast Cream has been shown to be safe and effective in treating hard-to-treat areas, including the face, skin folds, and genitalia.",
      "The cream works by inhibiting phosphodiesterase-4 (PDE-4), an enzyme that mediates inflammatory responses.",
      "The approval of Roflumilast Cream was based on data from the DERMIS-1 and DERMIS-2 phase 3 studies."
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, there are several tools that have been developed for identifying and visualizing non-coding RNA (ncRNA) promoters:\n1. ncPro-ML: This is an integrated computational tool for identifying ncRNA promoters in multiple species. It uses different kinds of sequence encoding schemes and has been shown to be effective in identifying promoters in human and mouse. (Document 5)\n2. R2DT: This is a framework for predicting and visualizing RNA secondary structure using templates. It has been used to study the structure of ncRNAs and their promoters. (Document 1)\n3. DeepLncPro: This is a convolutional neural network based model that was proposed to identify lncRNA promoters in human and mouse. It has been shown to be effective in identifying promoters in these species. (Document 8)\n4. Other deep learning methods: Several documents mention the use of deep learning methods for identifying ncRNA subtypes, including lncRNA, circRNA, and small ncRNA. These methods have been shown to be effective in identifying these subtypes. (Documents 2, 3, 7)\nIt is worth noting that while these tools have been developed to identify ncRNA promoters, the field is still in its early stages, and there is still much to be learned about the mechanisms of ncRNA transcription and regulation. Therefore, more research is needed to fully understand the role of ncRNA promoters in gene expression and their potential as therapeutic targets.",
    "llama-2-7b-chat-hf_fact_raw": "1. ncPro-ML is a computational tool designed for identifying ncRNA promoters in multiple species.\n2. R2DT is a framework used for predicting and visualizing RNA secondary structure, including ncRNA promoters.\n3. DeepLncPro is a convolutional neural network based model developed to identify lncRNA promoters in human and mouse.\n4. Deep learning methods have been applied to identify ncRNA subtypes such as lncRNA, circRNA, and small ncRNA.\n5. The field of ncRNA promoter identification and visualization is still in its early stages and requires further research.",
    "llama-2-7b-chat-hf_fact": [
      "ncPro-ML is a computational tool designed for identifying ncRNA promoters in multiple species.",
      "R2DT is a framework used for predicting and visualizing RNA secondary structure, including ncRNA promoters.",
      "DeepLncPro is a convolutional neural network based model developed to identify lncRNA promoters in human and mouse.",
      "Deep learning methods have been applied to identify ncRNA subtypes such as lncRNA, circRNA, and small ncRNA.",
      "The field of ncRNA promoter identification and visualization is still in its early stages and requires further research."
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-2-7b-chat-hf_response": "Based on the information provided, SWIM tool has identified 171 down-regulated genes in glioblastoma stem-like cells compared to conventional glioma cell lines. These genes include:\n1. CAV1 (caveolin 1)\n2. COL5A1 (collagen type V alpha 1 chain)\n3. COL6A3 (collagen type VI alpha 3 chain)\n4. FLNB (filamin B)\n5. HMMR (histone methyltransferase SETDB1)\n6. ITGA3 (integrin alpha 3)\n7. ITGA5 (integrin alpha 5)\n8. MET (met)\n9. SDC1 (spermidine/spermine-binding protein 1)\n10. THBS1 (thrombospondin 1)\n11. VEGFC (vascular endothelial growth factor C)\nThese genes are involved in various biological processes, including \"ECM-receptor interaction\" and \"focal adhesion\" pathways. The down-regulation of these genes in glioblastoma stem-like cells may contribute to the development and progression of this disease.\nIt is worth noting that SWIM tool is a powerful tool for identifying switch genes involved in drastic changes of cell phenotype, and it can be applied to public datasets of gene expression profiles from human glioblastoma cells to identify potential biomarkers for this disease. Additionally, gene network analysis using SWIM can reveal interplay between transcription factor-encoding genes and predict important genes involved in the development and progression of glioblastoma.",
    "llama-2-7b-chat-hf_fact_raw": "1. The SWIM tool has identified 171 down-regulated genes in glioblastoma stem-like cells.\n2. CAV1 (caveolin 1) is one of the genes identified by the SWIM tool as down-regulated in glioblastoma.\n3. COL5A1 (collagen type V alpha 1 chain) is another gene identified by the SWIM tool as down-regulated in glioblastoma.\n4. The down-regulated genes identified by the SWIM tool are involved in \"ECM-receptor interaction\" and \"focal adhesion\" pathways.\n5. The SWIM tool is used for identifying switch genes involved in changes of cell phenotype and can be applied to public datasets of gene expression profiles from human glioblastoma cells.",
    "llama-2-7b-chat-hf_fact": [
      "The SWIM tool has identified 171 down-regulated genes in glioblastoma stem-like cells.",
      "CAV1 (caveolin 1) is one of the genes identified by the SWIM tool as down-regulated in glioblastoma.",
      "COL5A1 (collagen type V alpha 1 chain) is another gene identified by the SWIM tool as down-regulated in glioblastoma.",
      "The down-regulated genes identified by the SWIM tool are involved in \"ECM-receptor interaction\" and \"focal adhesion\" pathways.",
      "The SWIM tool is used for identifying switch genes involved in changes of cell phenotype and can be applied to public datasets of gene expression profiles from human glioblastoma cells."
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, there are several R packages that have been developed for studying Topologically Associating Domains (TADs):\n1. TADsplimer: This is the first computational tool to systematically detect TAD splits and mergers across the genome between Hi-C samples. It was developed by Lili Zhang, John P. Cooke, Qi Cao, and Kaifu Chen.\n2. SpectralTAD: This package uses spectral clustering to define a hierarchy of TADs. It was developed by Kellen G. Cresswell, John C. Stansfield, and Mikhail G. Dozmorov.\n3. TAD features appear to be strongly conserved in mammals, and higher-resolution Hi-C maps have detected finer domains, also dubbed sub-TADs, with a median size of 185 kb, associated with enrichment of specific chromatin features.\n4. Eukaryotic genomes are compacted into loops and TADs, which contribute to transcription, recombination, and genomic stability.\n5. In mammals, a few single-cell 3D genome mapping techniques have been developed, and their application shows that many TADs are reorganized in different cells, whereas chromatin compartments and lamina-associated domains are usually relatively stable.\n6. The development of ultra-high resolution microscopy and computational methods has enabled the study of TADs at unprecedented resolution.\n7. The genome of a eukaryotic organism is comprised of a supra-molecular complex of chromatin fibers and intricately folded three-dimensional structures. Chromatin interactions and topological changes in response to developmental and/or environmental stimuli affect gene expression.\n8. TADs are separated by genetically defined boundary elements, but the precise mechanism of their formation is currently unknown.\n9. Strategies for anchoring diverse datasets have been developed, including the use of enhancer-promoter loops, which are more important than TADs for regulating gene expression.\nThese packages provide various tools and methods for studying TADs, including the detection of TAD splits and mergers, the definition of a hierarchy of TADs using spectral clustering, the",
    "llama-2-7b-chat-hf_fact_raw": "1. TADsplimer is a computational tool designed to detect TAD splits and mergers across the genome between Hi-C samples.\n2. SpectralTAD is an R package that uses spectral clustering to define a hierarchy of TADs.\n3. Higher-resolution Hi-C maps have detected sub-TADs with a median size of 185 kb in mammals.\n4. Single-cell 3D genome mapping techniques have been developed to study TAD reorganization in different cells of mammals.\n5. Ultra-high resolution microscopy and computational methods have been developed to study TADs at unprecedented resolution.",
    "llama-2-7b-chat-hf_fact": [
      "TADsplimer is a computational tool designed to detect TAD splits and mergers across the genome between Hi-C samples.",
      "SpectralTAD is an R package that uses spectral clustering to define a hierarchy of TADs.",
      "Higher-resolution Hi-C maps have detected sub-TADs with a median size of 185 kb in mammals.",
      "Single-cell 3D genome mapping techniques have been developed to study TAD reorganization in different cells of mammals.",
      "Ultra-high resolution microscopy and computational methods have been developed to study TADs at unprecedented resolution."
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the bioconductor tool that has been developed for accessing bacterial regulatory networks is RegulonDB. Document 0 mentions that RegulonDB has collected, harmonized, and centralized data from hundreds of experiments for nearly two decades, making it a point of reference for transcriptional regulation in Escherichia coli and other bacteria. Document 5 also highlights the importance of RegulonDB in the reconstruction of bacterial regulatory networks using available experimental data. Therefore, it can be inferred that RegulonDB is a useful tool for accessing bacterial regulatory networks.",
    "llama-2-7b-chat-hf_fact_raw": "1. RegulonDB is a bioconductor tool developed for accessing bacterial regulatory networks.\n2. RegulonDB has been collecting, harmonizing, and centralizing data from experiments for nearly two decades.\n3. RegulonDB is a point of reference for transcriptional regulation in Escherichia coli and other bacteria.\n4. RegulonDB is used in the reconstruction of bacterial regulatory networks using experimental data.",
    "llama-2-7b-chat-hf_fact": [
      "RegulonDB is a bioconductor tool developed for accessing bacterial regulatory networks.",
      "RegulonDB has been collecting, harmonizing, and centralizing data from experiments for nearly two decades.",
      "RegulonDB is a point of reference for transcriptional regulation in Escherichia coli and other bacteria.",
      "RegulonDB is used in the reconstruction of bacterial regulatory networks using experimental data."
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the end products of the shikimate pathway are:\n1. Chorismate: This is the final product of the shikimate pathway, which is converted into aromatic amino acids, such as phenylalanine, tyrosine, and tryptophan, through a series of enzymatic reactions.\n2. Aromatic amino acids: The shikimate pathway is the primary route for the synthesis of aromatic amino acids in living systems. These amino acids include phenylalanine, tyrosine, and tryptophan, which are essential for various physiological processes in the body.\n3. Secondary metabolites: The shikimate pathway also leads to the synthesis of many secondary metabolites in plants, which have diverse physiological roles. These metabolites include flavonoids, alkaloids, and terpenoids, among others.\nIn summary, the end products of the shikimate pathway are chorismate, aromatic amino acids, and secondary metabolites.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chorismate is the final product of the shikimate pathway.\n2. The shikimate pathway leads to the synthesis of aromatic amino acids such as phenylalanine, tyrosine, and tryptophan.\n3. Aromatic amino acids synthesized by the shikimate pathway are essential for various physiological processes in the body.\n4. The shikimate pathway is involved in the synthesis of secondary metabolites in plants.\n5. Secondary metabolites produced by the shikimate pathway include flavonoids, alkaloids, and terpenoids.",
    "llama-2-7b-chat-hf_fact": [
      "Chorismate is the final product of the shikimate pathway.",
      "The shikimate pathway leads to the synthesis of aromatic amino acids such as phenylalanine, tyrosine, and tryptophan.",
      "Aromatic amino acids synthesized by the shikimate pathway are essential for various physiological processes in the body.",
      "The shikimate pathway is involved in the synthesis of secondary metabolites in plants.",
      "Secondary metabolites produced by the shikimate pathway include flavonoids, alkaloids, and terpenoids."
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, cabergoline is not used for the treatment of Nelson's syndrome. While Nelson's syndrome is a rare disorder that can occur in some patients with Cushing's disease as a result of removing both adrenal glands, the primary treatment for this condition is not cabergoline, but rather surgery, radiotherapy, and established medical therapy.\nCabergoline is a dopamine agonist that has been used to treat hyperprolactinemia and Parkinson's disease, but there is limited evidence to suggest its efficacy in the treatment of Nelson's syndrome. In fact, one of the documents cited (Document 5) states that the usefulness of cabergoline in the treatment of Nelson's syndrome is inconclusive.\nTemozolomide, a chemotherapy drug, has been used in some cases of aggressive Nelson's syndrome, but it is not a standard treatment for this condition.\nIn summary, while cabergoline may be used in some cases of hyperprolactinemia or Parkinson's disease, it is not a recommended treatment for Nelson's syndrome. The primary treatment for this condition is surgery, radiotherapy, and established medical therapy, and cabergoline is not a substitute for these treatments.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cabergoline is not used for the treatment of Nelson's syndrome.\n2. Nelson's syndrome is a rare disorder that can occur in patients with Cushing's disease after removing both adrenal glands.\n3. The primary treatments for Nelson's syndrome are surgery, radiotherapy, and established medical therapy.\n4. Cabergoline is a dopamine agonist used to treat hyperprolactinemia and Parkinson's disease.\n5. Temozolomide has been used in some cases of aggressive Nelson's syndrome, but it is not a standard treatment.",
    "llama-2-7b-chat-hf_fact": [
      "Cabergoline is not used for the treatment of Nelson's syndrome.",
      "Nelson's syndrome is a rare disorder that can occur in patients with Cushing's disease after removing both adrenal glands.",
      "The primary treatments for Nelson's syndrome are surgery, radiotherapy, and established medical therapy.",
      "Cabergoline is a dopamine agonist used to treat hyperprolactinemia and Parkinson's disease.",
      "Temozolomide has been used in some cases of aggressive Nelson's syndrome, but it is not a standard treatment."
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the main manifestation of Liebenberg syndrome is the fusion of wrist bones with consequent radial deviation. This is a characteristic feature of the condition, as described in Documents 1, 2, 3, 4, 6, and 7. The fusion of wrist bones can result in a variety of arm malformations, including dysplastic elbow joints and hypoplasia of the fingernails and toenails. Additionally, the condition may also involve progressive restriction of the proximal interphalangeal joints and rarely of the distal interphalangeal joints, as described in Document 8.",
    "llama-2-7b-chat-hf_fact_raw": "1. The main manifestation of Liebenberg syndrome is the fusion of wrist bones with consequent radial deviation.\n2. Liebenberg syndrome can result in arm malformations, including dysplastic elbow joints.\n3. Hypoplasia of the fingernails and toenails is associated with Liebenberg syndrome.\n4. Liebenberg syndrome may involve progressive restriction of the proximal interphalangeal joints.\n5. The condition can rarely involve restriction of the distal interphalangeal joints.",
    "llama-2-7b-chat-hf_fact": [
      "The main manifestation of Liebenberg syndrome is the fusion of wrist bones with consequent radial deviation.",
      "Liebenberg syndrome can result in arm malformations, including dysplastic elbow joints.",
      "Hypoplasia of the fingernails and toenails is associated with Liebenberg syndrome.",
      "Liebenberg syndrome may involve progressive restriction of the proximal interphalangeal joints.",
      "The condition can rarely involve restriction of the distal interphalangeal joints."
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, here are some orally bioavailable MPS1 kinase inhibitors:\n1. MPI-0479605: As mentioned in Document 1, this compound has potent activity against MPS1 (IC50 = 0.004 μM) and good cytotoxicity in HCT-116 cells (IC50 = 0.1 μM).\n2. CCT271850: This compound is a potent, selective, and orally bioavailable MPS1 kinase inhibitor, as mentioned in Document 5. It has been shown to inhibit MPS1 activity in vivo and has potential as a tumor stasis or regression agent.\n3. 27f: As mentioned in Document 8, this compound is an extremely potent MPS1 inhibitor with activity over 192 kinases, including MPS1. It can be orally administered and is active in vivo.\n4. Reversine: As mentioned in Document 2, reversine is an MPS1, Aurora A, and Aurora B inhibitor that disrupts the spindle assembly checkpoint in a JNK-independent manner.\nIt is important to note that the information provided in the documents is based on in vitro and in vivo experiments, and the efficacy and safety of these compounds in humans have not been fully evaluated. Therefore, further research and clinical trials are needed to confirm their potential as MPS1 kinase inhibitors for cancer treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. MPI-0479605 is an orally bioavailable MPS1 kinase inhibitor with an IC50 value of 0.004 μM against MPS1.\n2. CCT271850 is described as a potent, selective, and orally bioavailable MPS1 kinase inhibitor that has shown activity in vivo.\n3. The compound 27f is an orally bioavailable MPS1 inhibitor with activity over 192 kinases, including MPS1, and is active in vivo.\n4. Reversine is an inhibitor of MPS1, Aurora A, and Aurora B, and it disrupts the spindle assembly checkpoint in a JNK-independent manner.\n5. The efficacy and safety of MPI-0479605, CCT271850, 27f, and reversine in humans have not been fully evaluated, indicating that they are still under research and not yet confirmed for clinical use.",
    "llama-2-7b-chat-hf_fact": [
      "MPI-0479605 is an orally bioavailable MPS1 kinase inhibitor with an IC50 value of 0.004 μM against MPS1.",
      "CCT271850 is described as a potent, selective, and orally bioavailable MPS1 kinase inhibitor that has shown activity in vivo.",
      "The compound 27f is an orally bioavailable MPS1 inhibitor with activity over 192 kinases, including MPS1, and is active in vivo.",
      "Reversine is an inhibitor of MPS1, Aurora A, and Aurora B, and it disrupts the spindle assembly checkpoint in a JNK-independent manner.",
      "The efficacy and safety of MPI-0479605, CCT271850, 27f, and reversine in humans have not been fully evaluated, indicating that they are still under research and not yet confirmed for clinical use."
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it appears that golimumab has been studied for the treatment of type 1 diabetes, specifically in children and young adults with newly diagnosed overt (stage 3) type 1 diabetes.\nDocument 3 mentions that golimumab has been approved for the treatment of several autoimmune conditions in adults and children, and Document 5 provides results from a phase 2 study (T1GER study) that evaluated the safety and efficacy of golimumab in children and young adults with newly diagnosed type 1 diabetes. The study found that golimumab preserved β-cell function and reduced insulin use and hypoglycemia compared to placebo.\nTherefore, based on the available information, it seems that golimumab has been tested for the treatment of type 1 diabetes in children and young adults, and the results suggest that it may be effective in preserving β-cell function and reducing the need for exogenous insulin. However, it is important to note that the study was conducted in a small sample size and further research is needed to confirm these findings and establish the long-term safety and efficacy of golimumab for this indication.",
    "llama-2-7b-chat-hf_fact_raw": "1. Golimumab has been studied for the treatment of type 1 diabetes in children and young adults.\n2. The T1GER study is a phase 2 study that evaluated the safety and efficacy of golimumab in children and young adults with newly diagnosed type 1 diabetes.\n3. The T1GER study found that golimumab preserved β-cell function in participants.\n4. The T1GER study found that golimumab reduced insulin use and hypoglycemia compared to placebo.\n5. Golimumab has been approved for the treatment of several autoimmune conditions in adults and children.",
    "llama-2-7b-chat-hf_fact": [
      "Golimumab has been studied for the treatment of type 1 diabetes in children and young adults.",
      "The T1GER study is a phase 2 study that evaluated the safety and efficacy of golimumab in children and young adults with newly diagnosed type 1 diabetes.",
      "The T1GER study found that golimumab preserved β-cell function in participants.",
      "The T1GER study found that golimumab reduced insulin use and hypoglycemia compared to placebo.",
      "Golimumab has been approved for the treatment of several autoimmune conditions in adults and children."
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it is likely that progeria is caused by an autosomal recessive gene.\nDocument 4 mentions that Hutchinson-Gilford progeria syndrome is caused by an autosomal dominant mutation in a gene known as Lamin A (LMNA) found on chromosome 1. However, Document 9 suggests that premature-ageing syndromes, including progeria, are a heterogeneous group of rare genetic disorders that are caused by different mutations, including autosomal recessive mutations.\nAdditionally, Document 7 mentions that there are two main types of progeria, one of which is diagnosed in infancy or early childhood and is characterized by rapid aging. This suggests that the gene mutation responsible for progeria may be inherited in an autosomal recessive manner, as this type of inheritance pattern is commonly associated with rare genetic disorders.\nOverall, while the exact mechanism of progeria is not fully understood, the available information suggests that an autosomal recessive gene mutation is the most likely cause of this rare genetic disorder.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hutchinson-Gilford progeria syndrome is caused by a mutation in the Lamin A (LMNA) gene.\n2. The Lamin A (LMNA) gene is located on chromosome 1.\n3. Progeria is a rare genetic disorder.\n4. There are two main types of progeria, one of which is diagnosed in infancy or early childhood.\n5. Progeria is characterized by rapid aging.",
    "llama-2-7b-chat-hf_fact": [
      "Hutchinson-Gilford progeria syndrome is caused by a mutation in the Lamin A (LMNA) gene.",
      "The Lamin A (LMNA) gene is located on chromosome 1.",
      "Progeria is a rare genetic disorder.",
      "There are two main types of progeria, one of which is diagnosed in infancy or early childhood.",
      "Progeria is characterized by rapid aging."
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, common variants at 12q14 and 12q24 are associated with hippocampal volume. Specifically, the ENIGMA Consortium & the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium found that variants at these loci are associated with reduced hippocampal volume in dementia-free individuals. This association was also observed in a genome-wide association study (GWAS) of dementia-free individuals, which identified 46 SNPs at four loci with P values of <4.0 × 10(-7). Additionally, other studies have replicated these findings and have shown that these variants are associated with hippocampal volume in both cross-sectional and longitudinal analyses.",
    "llama-2-7b-chat-hf_fact_raw": "1. Common variants at 12q14 and 12q24 are associated with hippocampal volume.\n2. The ENIGMA Consortium & the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium found an association between variants at 12q14 and 12q24 and reduced hippocampal volume in dementia-free individuals.\n3. A genome-wide association study (GWAS) identified 46 SNPs at four loci with P values of <4.0 × 10(-7) associated with hippocampal volume.\n4. The association between variants at 12q14 and 12q24 and hippocampal volume has been replicated in other studies.\n5. Studies have shown that the association with hippocampal volume is evident in both cross-sectional and longitudinal analyses.",
    "llama-2-7b-chat-hf_fact": [
      "Common variants at 12q14 and 12q24 are associated with hippocampal volume.",
      "The ENIGMA Consortium & the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium found an association between variants at 12q14 and 12q24 and reduced hippocampal volume in dementia-free individuals.",
      "A genome-wide association study (GWAS) identified 46 SNPs at four loci with P values of <4.0 × 10(-7) associated with hippocampal volume.",
      "The association between variants at 12q14 and 12q24 and hippocampal volume has been replicated in other studies.",
      "Studies have shown that the association with hippocampal volume is evident in both cross-sectional and longitudinal analyses."
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the ligands of the Roundabout (Robo) receptors are:\n1. Slit protein family (Documents 2, 4, 6, 8)\nThe Slit protein family is emanating from the midline and interacts with the Robo receptors to regulate axon guidance and cell migration. The first three Robo genes were discovered in Drosophila, and Slits are the main ligands of Roundabout (Robo) receptors (Document 7). Slit-Robo signaling has been shown to be involved in not only neurogenesis but also the development of other organs (Document 8).\nTherefore, the answer to the user's question is: Slit protein family.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Slit protein family interacts with the Roundabout (Robo) receptors.\n2. The Slit protein family regulates axon guidance and cell migration.\n3. The first three Robo genes were discovered in Drosophila.\n4. Slit-Robo signaling is involved in neurogenesis.\n5. Slit-Robo signaling plays a role in the development of other organs.",
    "llama-2-7b-chat-hf_fact": [
      "The Slit protein family interacts with the Roundabout (Robo) receptors.",
      "The Slit protein family regulates axon guidance and cell migration.",
      "The first three Robo genes were discovered in Drosophila.",
      "Slit-Robo signaling is involved in neurogenesis.",
      "Slit-Robo signaling plays a role in the development of other organs."
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, there is evidence to suggest that TFII-I plays a role in megakaryopoiesis. Documents 0, 1, and 2 provide information on the repressive role of TFII-I in β-globin gene transcription and its implication in the differentiation of erythro-megakaryocytic cells. Document 3 mentions the ETS variant 6 gene (ETV6), which is involved in megakaryopoiesis through transcriptional repression.\nTFII-I is a ubiquitously expressed transcription factor that positively or negatively regulates gene expression. It has been implicated in various diseases, including neuronal and immunologic diseases, as well as in thymic epithelial cancer. However, the available information suggests that TFII-I plays a role in megakaryopoiesis, specifically in the differentiation of erythro-megakaryocytic cells.\nTherefore, based on the information provided, the answer to the user's question is: Yes, TFII-I is involved in megakaryopoiesis.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFII-I is implicated in the differentiation of erythro-megakaryocytic cells.\n2. TFII-I has a repressive role in β-globin gene transcription.\n3. The ETS variant 6 gene (ETV6) is involved in megakaryopoiesis through transcriptional repression.\n4. TFII-I is a ubiquitously expressed transcription factor that can positively or negatively regulate gene expression.\n5. TFII-I has been implicated in various diseases, including neuronal and immunologic diseases, as well as in thymic epithelial cancer.",
    "llama-2-7b-chat-hf_fact": [
      "TFII-I is implicated in the differentiation of erythro-megakaryocytic cells.",
      "TFII-I has a repressive role in β-globin gene transcription.",
      "The ETS variant 6 gene (ETV6) is involved in megakaryopoiesis through transcriptional repression.",
      "TFII-I is a ubiquitously expressed transcription factor that can positively or negatively regulate gene expression.",
      "TFII-I has been implicated in various diseases, including neuronal and immunologic diseases, as well as in thymic epithelial cancer."
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it can be concluded that atenolol is metabolized by CYP2D6 to a limited extent, but the clinical significance of this metabolism is not clear. The documents state that atenolol is primarily metabolized by CYP3A4 to inactive metabolites, and that CYP2D6 metabolism is not clinically significant. However, the documents also mention that CYP2D6 is responsible for the metabolism of many commonly prescribed drugs, including beta-blockers, and that genetic variations in CYP2D6 can affect drug metabolism and response.\nTherefore, the answer to the user's question is: Atenolol is metabolized by CYP2D6 to a limited extent, but the clinical significance of this metabolism is not clear. However, CYP2D6 is an important enzyme involved in the metabolism of many drugs, including beta-blockers, and genetic variations in CYP2D6 can affect drug metabolism and response.",
    "llama-2-7b-chat-hf_fact_raw": "1. Atenolol is metabolized by CYP2D6 to a limited extent.\n2. Atenolol is primarily metabolized by CYP3A4 to inactive metabolites.\n3. The clinical significance of atenolol's metabolism by CYP2D6 is not clear.\n4. CYP2D6 is responsible for the metabolism of many commonly prescribed drugs, including beta-blockers.\n5. Genetic variations in CYP2D6 can affect drug metabolism and response.",
    "llama-2-7b-chat-hf_fact": [
      "Atenolol is metabolized by CYP2D6 to a limited extent.",
      "Atenolol is primarily metabolized by CYP3A4 to inactive metabolites.",
      "The clinical significance of atenolol's metabolism by CYP2D6 is not clear.",
      "CYP2D6 is responsible for the metabolism of many commonly prescribed drugs, including beta-blockers.",
      "Genetic variations in CYP2D6 can affect drug metabolism and response."
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, the following are the versions of ExpansionHunter:\n1. ExpansionHunter-v5.0.0 (Latest version) - This is the latest version of ExpansionHunter, which introduces substantial changes to accelerate the analysis of large genome-wide STR catalogs, including build system improvements, bug fixes, and catalog updates.\n2. ExpansionHunter-v4.0.0 - This version provides limited support for insertions, deletions, and substitutions, and is suitable for whole human genome samples in PCR-free libraries.\n3. ExpansionHunter-v3.0.0 - This version is compatible with DRAGEN DNAseq pipeline 3.7.5 or later, and includes the option to perform ExpansionHunter analysis.\n4. ExpansionHunter-v2.0.0 - This version is suitable for whole human genome samples in PCR-free libraries, and provides repeat expansion detection options.\n5. ExpansionHunter-v1.0.0 - This is the initial version of ExpansionHunter, which was released in 2017.\nIt is important to note that the latest version of ExpansionHunter (v5.0.0) is recommended for use, as it provides the most up-to-date features and improvements.",
    "llama-2-7b-chat-hf_fact_raw": "1. ExpansionHunter-v5.0.0 is the latest version of ExpansionHunter.\n2. ExpansionHunter-v4.0.0 provides limited support for insertions, deletions, and substitutions.\n3. ExpansionHunter-v3.0.0 is compatible with DRAGEN DNAseq pipeline 3.7.5 or later.\n4. ExpansionHunter-v2.0.0 is suitable for whole human genome samples in PCR-free libraries.\n5. ExpansionHunter-v1.0.0 was released in 2017.",
    "llama-2-7b-chat-hf_fact": [
      "ExpansionHunter-v5.0.0 is the latest version of ExpansionHunter.",
      "ExpansionHunter-v4.0.0 provides limited support for insertions, deletions, and substitutions.",
      "ExpansionHunter-v3.0.0 is compatible with DRAGEN DNAseq pipeline 3.7.5 or later.",
      "ExpansionHunter-v2.0.0 is suitable for whole human genome samples in PCR-free libraries.",
      "ExpansionHunter-v1.0.0 was released in 2017."
    ]
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, Adamts18 plays a role in hormone receptor signaling by remodeling the basement membrane and contributing to mammary epithelial stemness. The expression of Adamts18 is driven by the PR/Wnt4 axis, and it is induced by upstream estrogen-progesterone in myoepithelial cells, which remodels the basement membrane and contributes to mammary epithelial stemness. Additionally, Adamts18 is required for stem cell activation and has multiple binding partners in the basement membrane, including the basal membrane-specific proteoglycan, Col18a1. The authors suggest that Adamts18 links luminal hormone receptor signaling to basement membrane remodeling and stem cell activation.\nIn terms of its role in hormone receptor signaling, Adamts18 appears to be involved in the regulation of mammary epithelial stemness, which is a critical process in lactation and breast cancer. The basement membrane is a critical component of the stem cell niche, and Adamts18 plays a key role in remodeling this membrane and maintaining its integrity. The expression of Adamts18 is regulated by hormone receptor signaling, particularly by the PR/Wnt4 axis, which suggests that Adamts18 is an important downstream effector of hormone receptor signaling in the basement membrane.\nIn summary, Adamts18 plays a critical role in hormone receptor signaling by remodeling the basement membrane and contributing to mammary epithelial stemness. Its expression is regulated by hormone receptor signaling, particularly by the PR/Wnt4 axis, and it has multiple binding partners in the basement membrane, including Col18a1.",
    "llama-2-7b-chat-hf_fact_raw": "1. Adamts18 is involved in remodeling the basement membrane and contributing to mammary epithelial stemness.\n2. The expression of Adamts18 is driven by the PR/Wnt4 axis.\n3. Adamts18 is induced by upstream estrogen-progesterone in myoepithelial cells.\n4. Adamts18 is required for stem cell activation.\n5. Adamts18 has multiple binding partners in the basement membrane, including Col18a1.",
    "llama-2-7b-chat-hf_fact": [
      "Adamts18 is involved in remodeling the basement membrane and contributing to mammary epithelial stemness.",
      "The expression of Adamts18 is driven by the PR/Wnt4 axis.",
      "Adamts18 is induced by upstream estrogen-progesterone in myoepithelial cells.",
      "Adamts18 is required for stem cell activation.",
      "Adamts18 has multiple binding partners in the basement membrane, including Col18a1."
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, Thiazovivin's mode of action can be inferred to be an inhibition of Rho kinase (ROCK). This is supported by several documents, including Document 0, which mentions that Thiazovivin can be replaced by other ROCK inhibitors such as Y27632 and HA-1077, and Document 5, which states that Thiazovivin, a Rho kinase inhibitor, improves stemness maintenance of embryo-derived stem-like cells under chemically defined culture conditions in cattle.\nAdditionally, Document 3 mentions that Thiazovivin is a novel ROCK inhibitor with IC50 of 0.5 μM in a cell-free assay, which suggests that it is effective in inhibiting ROCK activity. Document 6 also mentions that both P50-Thiazovivin and P50-control viruses exhibited equal susceptibility to Thiazovivin, suggesting that Thiazovivin may have a direct effect on the virus.\nOverall, the information provided in the documents suggests that Thiazovivin's mode of action is likely an inhibition of Rho kinase (ROCK), which may have implications for its use in regenerative medicine and virus infection.",
    "llama-2-7b-chat-hf_fact_raw": "1. Thiazovivin's mode of action is the inhibition of Rho kinase (ROCK).\n2. Thiazovivin can be replaced by other ROCK inhibitors such as Y27632 and HA-1077.\n3. Thiazovivin improves stemness maintenance of embryo-derived stem-like cells under chemically defined culture conditions in cattle.\n4. Thiazovivin is a novel ROCK inhibitor with an IC50 of 0.5 μM in a cell-free assay.\n5. Both P50-Thiazovivin and P50-control viruses exhibited equal susceptibility to Thiazovivin.",
    "llama-2-7b-chat-hf_fact": [
      "Thiazovivin's mode of action is the inhibition of Rho kinase (ROCK).",
      "Thiazovivin can be replaced by other ROCK inhibitors such as Y27632 and HA-1077.",
      "Thiazovivin improves stemness maintenance of embryo-derived stem-like cells under chemically defined culture conditions in cattle.",
      "Thiazovivin is a novel ROCK inhibitor with an IC50 of 0.5 μM in a cell-free assay.",
      "Both P50-Thiazovivin and P50-control viruses exhibited equal susceptibility to Thiazovivin."
    ]
  }
]